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ABSTRACT
This dissertation describes the genetic effects of platinum DNA
adducts in Escherichia coli from two perspectives. First, the
genotoxicities and mutagenicities of the three major DNA adducts formed
by cis-diamminedichloroplatinum(II) (cis-DDP), cis-[Pt(NH3)2{d(GpG)}]
(G*G*), cis- [Pt(NH3)2{d(ApG) }] (A*G*), and cis- [Pt (NH3)2{d(GpNpG) } ]
(G*NG)*, were investigated. These studies were conducted by using viral
genomes in which specific nucleotides in the natural sequence were
replaced with the aforementioned DNA adducts. The results of the site
specific evaluation of these adducts suggested principles applicable to
the design and evaluation of novel anticancer platinum-based therapeutic
agents. Accordingly, the second aspect of this work was the genotoxic
and mutagenic evaluation of cis-
ammine(cylcohexylamine)dichloroplatinum(II) (ACDP), a metabolite of the
platinum(IV) compound, cis, trans, cis-ammine(cyclohexylamine)dibutyrato-
dichloroplatinum(IV) (ACDDP), now undergoing clinical trials to
determine its efficacy as an anticancer drug.
The first aspect of this work, the site specific evaluation of the
cis-DDP G*G*, A*G*, and G*TG* adducts, was done by incorporating
oligodeoxynucleotide 24-mers, containing these lesions, into M13mp7L2
derived ss genomes. Both the platinum modified and unmodified, ss
genomes were transfected into E. coli DL7 cells that had been, or had
not been, irradiated with ultraviolet light in order to induce the SOS
response. The genotoxicities of the adducts were determined by using
the M13 plaque forming assay. Genomes containing the cis-DDP G*G*,
A*G*, and G*TG* adducts had survival levels of 5.2 + 1.2%, 21.6 + 2.6%,
13.5 ± 2.5%, respectively, compared to unmodified control genomes. Upon
SOS induction of the host E. coli cells, the survival of genomes
containing the cis-DDP G*G* and A*G* adducts rose significantly to 30.8
+ 5.4% and 32.4 + 4.9%, respectively. By contrast, the survival of
genomes containing the cis-DDP G*TG* adduct did not increase upon SOS
induction, remaining at 14.4 + 3.7%.
Mutations attributable to cis-DDP were observed only for modified
genomes replicated in SOS induced E. coli DL7 cells. The cis-DDP G*G*
and A*G* adducts produced highly targeted mutations at the 5' modified
base, with the predominant mutation consisting of G T and A - T
transversions for the two adducts, respectively. A G transitions also
arose from the cis-DDP A*G* adduct as well as a low level of tandem
mutations from both adducts affecting the 5' modified base as well as
the adjacent 5' base. The cis-DDP A*G* adduct was considerably more
mutagenic than the G*G* adduct, with a mutation frequency of 6.0%
compared to 1.4% for the latter adduct. In accordance with the lack of
an SOS-dependent increase in survival, the cis-DDP G*TG* adduct also was
not mutagenic.
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A drawback of current platinum based chemotherapy is the potential
carcinogenicity of cis-DDP. The site specific results suggest a
strategy for reducing the mutagenicity, and hence the potential
carcinogenicity, of platinum compounds. The high mutagenicity of the
A*G* adduct suggests that, if a platinum compound directed against the
formation of this highly mutagenic DNA lesion, its overall mutagenicity
would be decreased. ACDP is a compound that meets this criterion; its
cyclohexyl ring causes an orientational isomerism which, upon binding to
DNA, reduces the number of A*G* adducts threefold as compared with cis-
DDP DNA binding. ACDP, therefore, was predicted to be less mutagenic
than cis-DDP. This hypothesis was tested by comparing the
genotoxicities and mutagenicities of cis-DDP and ACDP DNA adducts in E.
coli. Both compounds displayed similar levels of genotoxicity in a
bacteriophage M13mp18 plaque-forming assay, with survival for genomes
platinated by either drug increasing by threefold in cells pretreated
with uv irradiation to induce the SOS functions of the host. The
mutagenicity of ACDP was lower than that of cis-DDP in the lacZ' a-
complementation forward mutational assay and was also SOS-dependent.
The mutational spectra for both drugs were similar; G T transversions
at d(GpG) sites were the most common mutations while G A transitions
and A T transversions, many at d(ApG), d(GpNpG), and d(GpG) sites,
were also well represented. Adduct mapping experiments revealed
excellent correlation between the location of DNA lesions and the sites
of mutations, confirming that the induced mutations were a consequence
of the platinum adducts. Analysis of the distribution of mutations
suggested that there were no sequence-dependent mutation hotspots;
mutagenesis was random throughout the lacZ' region of the M13mp18
bacteriophage genome.
Thesis Supervisor: Dr. John M. Essigmann
Title: Professor of Chemistry and Toxicology
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I. INTRODUCTION
14
The genotoxic properties of chemicals that bind to DNA and
selectively kill rapidly dividing cells by inhibition of replication or
transcription are exploited in cancer chemotherapy. One of the most
effective anticancer drugs believed to act by this mechanism is cis-
diamminedichloroplatinum(II) (cis-DDP, Figure 1). cis-DDP cures over
95% of testicular cancer cases and is also used in the treatment of
cancers of the head, neck, lung, stomach, esophagus, and urogenital
tissues. Despite being one of the most widely used chemotherapeutic
agents of the last decade, cis-DDP has several significant liabilities.
Dose-limiting toxicity, acquired and intrinsic resistance, and
cumbersome intravenous administration decrease the clinical efficacy of
cis-DDP. In recent years intense effort has been devoted to the design
and development of platinum-based drugs that have diminished toxicity,
are effective against cis-DDP resistant tumors and can be administered
orally. Conversely, a drawback of platinum-based chemotherapy that has
not yet been addressed adequately is the suspected human carcinogenicity
of cis-DDP. Accordingly, this thesis explores what attributes of
platinum compounds contribute to their mutagenicity, and implied
carcinogenicity, with the goal of elucidating principles that will
facilitate the design and evaluation of less mutagenic, and therefore
potentially less carcinogenic, drugs.
cis-DDP is a proven carcinogen in the mouse and rat (Leopold et
al., 1979). As has been shown for many electrophilic carcinogens,
cis-DDP is also a mutagen in bacterial (Beck & Brubaker, 1975; Benedict
et al., 1977) and in mammalian (Johnson, N. P. et al., 1980) cell
systems. Mutation is believed to be one of the multiple steps that
results in neoplastic transformation of cells (Weinberg, 1989).
Therefore, the appearance of second malignancies in patients treated
with cis-DDP is not surprising (Johnson, D. C. et al, 1980; Stewart &
Wilkinson, 1981; Meadet et al., 1983; Redman et al., 1984; Redman et
15
al., 1985; Bassett and Weiss, 1986), fueling speculation that these
cancers may have resulted from cis-DDP treatment. The incidence of
second cancers is highly specific. Acute non-lymophocytic leukemia
(ANLL) occurred in 95% of cis-DDP treated patients suffering a second
cancer, at a 50 fold higher rate of incidence than expected (Ratain et
al., 1987; Nichols et al., 1990). It should be noted that, because cis-
DDP typically is administered in conjunction with a battery of other
chemotherapeutic agents, some of which are also suspected carcinogens,
its carcinogenity in humans is implied but not firmly established
(Greene, 1992).
Several key questions arise as to how cis-DDP induces the mutations
that presumably engender the cancer phenotype. Are all of its multiple
DNA adducts mutagenic or is the mutagenic activity of the drug
attributable only to one, or to a subset, of its adducts? Are the
lesions that kill cells different from those that cause mutations and,
if so, could this observation be exploited in the development of a safer
therapeutic regimen? In order to address these questions, methodologies
have been developed that enable one to situate a single DNA lesion at a
specific site within a viral or plasmid genome (Green et al., 1984).
The resulting singly modified genomes can be used to determine the
mutation frequency and specificity of each adduct, and to what extent
the adduct compromises the viability of the genome. By using these
techniques to determine the relative contributions of each cis-DDP
adduct to the total mutagenicity and genotoxicity of the compound, it
may be possible to identify those lesions that are principally genotoxic
and those that are primarily premutagenic. This information could then
be used for the design or evaluation of new platinum based drugs;
ideally a new drug would maximize the number of genotoxic lesions and
minimize the proportion of premutagenic lesions (Bradley, 1991).
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This dissertation reports studies of the effects on survival and
mutagenesis of the three major cis-DDP DNA adducts in Escherichia coli.
For this purpose, M13mp7L2 derived ss viral genomes, each containing a
single cis-DDP A*G*, G*G*, or G*TG* adduct at a unique site, were
constructed. This work affords significant insights into the
biochemical and molecular processing of platinum DNA adducts. In more
general terms, the extensive use of the lacZ' mutational assay also
elucidates the molecular mechanisms eliciting mutagenicity in E. coli.
As mentioned, a practical application of this work would be the
design or evaluation of new platinum based drugs. Therefore, in
conjunction with the site specific studies, the comparative DNA binding,
genotoxic, and mutagenic effects of cis-DDP and cis-ammine(cyclohexyl-
amine)dichloroplatinum(II) (ACDP, Figure 1) were determined by
replicating drug-modified M13mp18 RF genomes in E. coli.
ACDP is the major metabolite of cis,trans,cis-ammine(cyclo-
hexylamine)dibutryratodichloroplatinum(IV), (ACDDP, Figure 1) a
promising new platinum-based anticancer drug now in clinical trials.
ACDDP is an orally active platinum (IV) compound undergoing testing as a
less toxic analogue of cis-DDP that is chemotherapeutically active
against resistant tumors. Its inclusion in this study is motivated by
the prediction that this drug will be less mutagenic than cis-DDP. This
prediction is based on the DNA-binding spectrum of ACDP combined with
the results of previous site-specific studies on platinum DNA adducts.
Hartwig and Lippard (1992) showed that ACDP binds to DNA in a manner
similar to cis-DDP but with the notable difference that ACDP formed 3
fold fewer intrastrand crosslinks at d(ApG) sites. Considering that the
cis-DDP A*G* adduct was determined to be 4-5 fold more mutagenic than
either the G*G* or G*TG* adducts, ACDP is predicted to have an overall
mutagenicity lower than that of cis-DDP. This hypothesis was
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experimentally tested and confirmed by comparing the two drugs in the
lacZ' -galactosidase a-complementation forward mutational assay in E.
coli. Simultaneously, the genotoxicity of the various platinum DNA
adducts was studied to ensure that a diminution of mutagenicity was
achieved while retaining a level of lethality necessary to retain the
chemotherapeutic effectiveness of these compounds.
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Figure 1. Structures of platinum compounds discussed in this
dissertation.
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II. LITERATURE SURVEY
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This section' briefly reviews what is known about the formation and
structural effects of platinum DNA adducts and the subsequent mutagenic
and genotoxic effects of these adducts in a prokaryotic system.
Limitations of current platinum-based chemotherapy are outlined,
demonstrating the need for new drugs. Platinum(IV) ammine/amine
dicarboxylates, a class of promising new drugs, are described, followed
by a discussion of ACDP, the biologically active metabolite of ACDDP, a
platinum(IV) drug now undergoing evaulation in clinical trials.
A. Platinum-DNA Interactions
DNA is considered to be the principal target of cis-DDP in vivo.
When mammalian cells are treated with cis-DDP, inhibition of replication
occurs preferentially over inhibition of transcription and translation
(Harder & Rosenberg, 1970; Howle & Gale, 1970). Pascoe and Roberts
(1974) have shown that pharmacologically relevant doses of cis-DDP given
to HeLa cells result in more platinum bound per molecule of DNA than RNA
or protein. At the 37% survival level (i.e. the survival that
corresponds to one lethal event per cell), the DNA contained 22 adducts,
whereas only 1 in 8 mRNA, 1 in 30 rRNA, and 1 in 1500 tRNA or protein
molecules were modified. Similarly, Akaboshi et al. (1992) reported
platinum adduct levels of 1 per 3-10,000 protein molecules, and 1 per 10
- 1,000 RNA molecules, while each DNA molecule had more than 9 adducts
present for D values of 50% in HeLa S-3 cells. Considering that a
large excess of unmodified RNA and protein molecules remain in cells
undergoing cis-DDP induced mortality, it is reasonable that this drug
effects cytotoxicity through it interactions with DNA.
'Portions of the literature survey are adapted (with permission)
from Bradley (1991).
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1. Mode of Cytotoxicity Induced by cis-DDP Modified DNA
The type and distribution of cis-DDP adducts in mammalian cells
(Plooy et al., 1985a; Akaboshi et al., 1992; Kusumoto et al., 1993) and
in cancer patients receiving platinum therapy (Fichtinger-Schepman et
al., 1987; Fichtinger-Schepman et al., 1990) is similar to that
determined in vitro. The large size and complexity of the mammalian
genome, however, has hindered the study of the mechanisms of
cytotoxicity, as well as the mutagenicity and repair, of cis-DDP adducts
in these systems. Nevertheless, a variety of models has been proposed
to account for the chemotherapeutic effectiveness of cis-DDP. cis-DDP
has been proposed to kill cells by apoptosis, with sensitivity to this
drug only occurring at certain points in the cell cycle (Evans & Dive,
1993; Krishnaswawy & Dewey, 1993).
Many early studies focused on the levels of platinum interstrand
crosslinking of DNA as the factor responsible for the cytotoxicity of
cis-DDP (Connors et al., 1979; Zwelling & Kohn, 1979). Interstrand
crosslinks, however, are a minor component of the adduct spectrum of
cis-DDP, comprising <5% of the total binding in vitro and in vivo.
Moreover, there have been conflicting reports about the correlation
between the levels of interstrand crosslinks and biological response
(see Pinto & Lippard, 1985a, for a review). A significant piece of
evidence refuting the importance of interstrand crosslinks is the
chemotherapeutic ineffectiveness of trans-DDP, despite the fact that
this geometric isomer of cis-DDP forms twice as many interstrand
crosslinks (Brabec & Leng, 1993; Decoville et al., 1993). Intrastrand
crosslinks, however, that are formed by cis-DDP and related compounds
are strongly correlated with the effectiveness of certain platinum
drugs.
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Of note are the 1,2 intrastrand crosslinks formed by cis-DDP at
adjacent nucleotides that, due to steric constraints, are not formed by
the trans-DDP isomer, suggesting that 1,2 adducts may be responsible for
the chemotherapeutic effectiveness of the former compound. The
predominant 1,2 intrastrand crosslinks formed by cis-DDP are the G*G*
and A*G* adducts. A class of HMG-box containing proteins has been
reported that bind specifically to these two adducts (Toney et al.,
1989; Donahue et al., 1990; Pil & Lippard, 1992; Brown et al., 1993). A
potential consequence of the binding of these proteins to cis-DDP
adducts is that bound adducts are shielded from repair thereby allowing
them to persist in the genome to mediate their cytotoxicity. Indeed,
the cis-DDP G*G* adduct is not repaired in human cell extracts, implying
that it may be important in mediating the chemotherapeutic effects of
this drug (Szymkowski et al., 1992). Alternatively, these proteins,
which include important cellular regulatory proteins such as the rRNA
transcription factor hUBF, may bind to cis-DDP G*G* and A*G* adducts.
Once bound, the proteins are prevented from performing their normal
cellular functions ultimately leading to cell death (X. Zhai & D.
Treiber, personal communication). The importance of this group of
proteins in mediating the chemotherapeutic effects of cis-DDP remains
unclear, however, as a recent report shows no correlation between the
levels of such proteins and the in vitro sensitivity of tumor cells to
cis-DDP (Bissett et al., 1993). Notwithstanding the current lack of
mechanistic insight into how cis-DDP DNA adducts mediate their cytotoxic
effects, evidence remains strong that cis-DDP DNA adducts are in some
way responsible for the therapeutic activity of this drug. Accordingly,
platinum-DNA adducts will be discussed in detail below. An underlying
knowledge of platinum-DNA interactions is necessary to understand the
genotoxic and mutagenic effects of cis-DDP reported in this
dissertation.
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2. Platinum-DNA Adducts.
cis-DDP is a bifunctional electrophilic compound that reacts with
DNA to form a variety of intra- and interstrand crosslinks (reviewed in
Sherman & Lippard, 1987). The principal adducts are the
cis- [Pt (NH3)2{d(GpG) }] and cis- [Pt (NH3)2{d(ApG) }] intrastrand crosslinks
(referred to as G*G* and A*G*, respectively, Figure 2); minor adducts
include cis-[Pt(NH3)2{d(GpNpG)}] intrastrand crosslinks (G*NG*, where N
is any intervening nucleotide), interstrand crosslinks, and monoadducts
(G*). In each of these adducts, the N7 atoms of the purine bases have
replaced the chloride ligands in the cis-DDP square plane. The G*G*
intrastrand crosslink constitutes 50-65% of the cis-DDP adducts formed
in DNA in vitro, with the next most abundant adduct, A*G*, comprising
approximately 25% of the total (Eastman, 1983; Fichtinger-Schepman et
al., 1985b).
trans-Diamminedichloroplatinum(II) (trans-DDP) is the geometric
isomer of cis-DDP. It also binds to DNA to produce intra- and
interstrand crosslinks at the N7 positions of purine bases, although
these adducts have not been as well characterized as those of cis-DDP.
Binding studies with oligodeoxynucleotides have shown trans-DDP to form
principally 1,3-intrastrand adducts (Eastman et al., 1988). Because
this compound is clinically inactive, the formation and removal of its
DNA adducts have often been compared to those of cis-DDP with the goal
of explaining the potent biological activity of the latter agent.
Studies of structure-activity relationships among various platinum
compounds have presented a compelling case that the cis geometry of the
chloride ligands is a key feature for biological activity. For example,
the monofunctional platinum compound chlorodiethylenetriamine-
platinum(II) ([Pt(dien)Cl]+ ) (Figure 1), whose major adduct occurs at
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the N7 position of guanine (Johnson, N. P. et al., 1982), does not
exhibit antitumor activity. Clinically active platinum compounds
include cis-dichloroethylenediamine-platinum (II) ([Pt (en) Cl2] ), cis-
diaminocyclohexanedichloroplatinum(II) ([Pt (dach) Cl2] ) , and
diammine (1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin) (Figure
1). It is noteworthy that these drugs, like cis-DDP, have ligands bound
in a cis geometry. At least one of these compounds, [Pt(en)C12], forms
an adduct spectrum that is very similar to that of cis-DDP (Eastman,
1983; Eastman, 1986). Due to the apparent requirement of
bifunctionality and a cis geometry for clinical activity, and the fact
that for stereochemical reasons trans-DDP can form neither the G*G* nor
A*G* adducts in which adjacent bases in the same strand are crosslinked
(Table 1), it is believed that the 1,2-crosslinks are responsible for
the unique biological activities of cis-DDP and the other clinically
active drugs (Pinto & Lippard, 1985a). The therapeutic ineffectiveness
of trans-DDP has been used to justify the contention that 1,3 intra- and
interstrand crosslinks are not important in the cytotoxicity mediated by
cis-DDP. Recent results, however, indicate that 1,3 intra- and
interstrand crosslinks formed by cis-DDP have significantly different
structural characteristics than those formed by trans-DDP.t The
possibility remains, therefore, that the cis-DDP 1,3 intra- or
interstrand crosslinks may be therapeutically relevant lesions.
1Both the cis- and trans-DDP interstrand crosslinks predominately
form at d(GpC)/d(GpC) sites. The cis-DDP adduct forms between the
guanines offset by 1 base on the adjacent strands whereas the
interstrand crosslink formed by trans-DDP is between a guanine residue
and the cytosine directly opposite (Brabec & Leng, 1993; Decoville et
al., 1993). Considering the 1,3 intrastrand crosslinks, the trans-DDP
G*NG* 1,3 adduct unwinds the DNA duplex by 9-10 ° and imposes a flexible
hinge joint bending on the helix whereas the comparable cis-DDP lesion
unwinds the DNA by 230 and produces a directed bend (toward the major
groove) in the DNA helix (Bellon et al., 1991; Keck & Lippard, 1992; Zou
et al., 1993). These structural differences allow differential
processing of 1,3 cis- and trans-DDP DNA lesions by various polymerases
(Corda et al., 1993). In conclusion, care should be exercised in
concluding that cis-DDP 1,3 intra- and interstrand crosslinks are
therapeutically unimportant based on analogy with the trans-DDP results.
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As mentioned above, cis-DDP binds to DNA at the N7 position of the
purine bases. In general, other N7 purine adducts (as formed by
aflatoxin B or by alkylating agents) destablize the glycosidic bond,
resulting in the release of the adducted base. Apurinic (AP) sites are
generated in DNA by this process. AP sites are SOS dependent
premutagenic lesions, and it has been postulated that they serve as a
common intermediate in the pathway leading to mutagenesis by many
chemical and physical agents (Schaaper & Loeb, 1981). The facile
generation of an AP site, leading to a mutation, is unlikely to be the
cause of cis-DDP induced mutations. cis-DDP DNA adducts actually
stabilize the glycosidic bond and are very resistant to treatments that
induce depurination (Royer-Pokora et al., 1981; Forsti et al., 1986).
They can, however, be removed from DNA in vitro by cyanide or thiourea
treatment, which reverses most adducts by breaking the coordinate bonds
between the platinum atom and the bases (Bauer et al., 1978; Lippard &
Hoeschele, 1979; Filipski et al., 1979). One cannot rule out the
possibility that some powerful intracellular nucleophile might act
similarly in vivo, although there is no evidence for such a "repair"
mechanism at present.
Mapping experiments utilizing exonuclease III digestion of (Tullius
& Lippard, 1981; Royer-Pokora et al., 1981) and replication blockage by
(Pinto & Lippard, 1985b; Hemminiki & Thilly, 1988; Villani et al., 1988;
Bubley et al., 1991; Murray et al., 1992) platinum modified DNA
demonstrate that for cis-DDP, enzyme blockage occurs at guanine bases
and at oligo (dG) sequences. trans-DDP treated DNA also poses a block
to replication and exonuclease III digestion, but exhibits less of a
sequence specificity with some indication of blockage at d(GpNpG)
sequences. The ability of these adducts to interfere with normal
enzymatic activity suggests that there is some aspect of the structure
of these adducts that may account for their biological activity.
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3. Structural Effects of Platinum-DNA Adducts
a. Macroscopic effects on the structure of platinum modified DNA
Many studies have focused on defining the detailed structural and
physical properties of platinum DNA adducts. The binding of both cis-
and trans-DDP to DNA in vitro shortens and unwinds the helix (Cohen et
al., 1979). In addition, spectroscopic studies have shown that the
binding of platinum compounds to DNA disrupts normal base stacking, and
results in a decreased melting temperature of the DNA (reviewed by
Sherman & Lippard, 1987). Studies with enzymatic probes sensitive to
the structure of DNA have also indicated that platinated DNA has an
abnormal structure. Single-strand specific nucleases can digest duplex
DNA platinated with either cis-DDP or trans-DDP (Mong et al., 1981;
Scovell & Capponi, 1982; Scovell & Capponi, 1984). Restriction
endonuclease digestion experiments with globally platinated DNA suggest
that the presence of a cis-DDP adduct within three base-pairs of a
recognition sequence can inhibit recognition and digestion by the enzyme
(Cohen et al., 1980; Ushay et al., 1981).
Antibodies that recognize each of the four DNA nucleosides have
been used as probes to define the extent of cis-DDP perturbation of DNA
structure (Sundquist et al., 1986). The antibodies recognize denatured
DNA, but do not bind to native duplex DNA. DNA treated with increasing
amounts of cis-DDP bind increasingly more antibodies to dC, and to a
lesser extent dA, and dT, but not those elicited against dG. DNA
treated with very low levels of the trans compound was able to bind all
four antibodies, whereas [Pt(dien)Cl]+ treated DNA was not recognized by
the antibodies. These results suggest that there is disruption of base
pairing upon binding of bifunctional platinum drugs, and that this
disruption is greater for trans-DDP than cis-DDP.
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An altered and destabilized DNA structure that may still
accommodate some form of hydrogen bonding between modified nucleotides
and their complements is consistent with the physical and biochemical
data presented above. It has been suggested that the high levels of
platination (1 platinum adduct in 5-10 nucleotides) required for single
strand nuclease digestion may lead to cooperative destabilization of the
helix, resulting in single stranded regions that would not ordinarily be
present in platinated DNA (Scovell & Capponi, 1982; den Hartog et al.,
1985a). This cooperativity could also explain the nonlinear increase in
anti nucleoside-antibody binding to DNA treated with increasing amounts
of cis-DDP (Sundquist et al., 1986); alternatively, while the antibodies
cannot bind to native duplex DNA, they may be able to bind to a
distorted duplex DNA, and thus binding may be an indication either of
distorted or single stranded regions of DNA.
As mentioned, many of the early biochemical and physical
characterization studies of cis-DDP modified DNA were performed at
levels of drug of up to 1 platinum adduct per 5-10 nucleotides.
Evidence is accumulating that the chemotherapeutic response to cis-DDP
is elicited from much lower levels of drug bound to DNA. Reed et al.
(1993) report that patients successfully treated with cis-DDP typically
accrue 1 adduct per 10-20,000 nucleotides of their genome. This finding
suggests that single adducts, and not the cooperative effects of two or
more closely spaced lesions, are the biologically relevent species in
eliciting the cytotoxicity of cis-DDP. Accordingly, the structural
effects of single cis-DDP adducts is addressed below.
b. Structural effects of single platinum DNA adducts
X-ray diffraction studies of the single stranded dinucleotide
cis-[Pt(NH3)2{d(pGpG)}] show that platinum binding destacks the adjacent
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guanine bases, resulting in a dihedral angle between the ring planes of
76-87 ° (Sherman et al., 1985). In the crystal form, the 3' deoxyribose
is in the conformationally more flexible C(2')-endo configuration that
is typical of the B-DNA architecture; the deoxyribose of the 5'-linked
nucleotide, by contrast, is in the more rigid C(3')-endo geometry
characteristic of A-DNA (Sherman et al., 1985).
The crystal structure of a single stranded dinucleotide is not
necessarily reflective of the structure of such lesions in larger DNA
contexts. NMR analysis of the cis-DDP modified d(GpG) dinucleotide is
consistent with the crystal structure result depicting a severe kink
(den Hartog et al., 1982). The G*G* adduct in the d(CpGpG)
trinucleotide, however, appears to be less disruptive, with the bases
able to adopt a stacking conformation consistent with B-DNA despite the
distortions imposed by platinum binding (den Hartog et al., 1985b).
Indeed, the structural repercussions of the G*G* adduct become
ameliorated as the lesion is incorporated into oligodexoynucleotides of
increasing length. For example, small oligodeoxynucleotides up to six
bases in length containing a single G*G* crosslink will not form duplex
structures (Caradonna et al., 1982; Sherman & Lippard, 1987). Singly
modified decamer sequences containing the G*G* crosslink will form
duplexes, however, indicating that the structural distortion of a G*G*
crosslink is fairly well localized (den Hartog et al., 1984; van
Hemelryck et al., 1984; den Hartog et al., 1985b). NMR studies on these
decamer sequences do not conclusively demonstrate the presence of
hydrogen bonding occurring at the platinum modified guanines, however,
it cannot be ruled out at present. Each study suggests that the NMR
data is consistent with the presence of a kink or bend induced in the
oligodeoxynucleotide by the adduct.
c. Platinum induced perturbation of duplex DNA
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The structural perturbation of DNA upon cis-DDP binding has been
evaluated in the context of native duplex DNA. Gel electrophoretic
mobility assays have been used to determine cis-DDP induced bend angles
in DNA. By using duplex oligomers containing G*G*, A*G*, or G*NG*
adducts, it was shown that each adduct imparts a directed bend in the
double helix, with bend angles calculated to be 32-35° for all three
adducts (Bellon & Lippard, 1990). The direction of the bend of the G*G*
adduct is toward the major groove (Rice et al., 1988); it is expected
that the other adducts also have bends directed toward the major groove.
By contrast, 1,3 intrastrand crosslinks formed by trans-DDP consist of
flexible hinge joints that allow the DNA to bend alternately toward
either the major or minor grooves (Bellon et at., 1991). Unwinding of
the DNA helix also occurs upon cis-DDP binding. The cis-DDP G*G* and
A*G* adducts both unwind the helix by 130 while the G*NG* adduct unwinds
the helix by 230; trans-DDP unwinds the helix by 90 (Bellon et al., 1991;
Keck & Lippard, 1992). The unwinding of the DNA duplex appears to be
more important than drug-induced bending in determining the biological
responses to platinum-modified DNA (Bellon et al., 1991).
The chemical reactivity of DNA bases to compounds that are
sensitive to the structure of DNA has provided enhanced resolution to
the picture of the local distortion induced by single cis-DDP-DNA
adducts (Marrot & Leng, 1989; Schwartz et al., 1989; Anin & Leng, 1990).
These data suggest that the helix is distorted to a greater extent on
the 5' side of A*G* and G*G* adducts than on the 3' side, but that this
asymmetrical distortion does not result in local denaturation in the
area of the lesion. These distortions differ for the two adducts,
however, as demonstrated by their different patterns of chemical
reactivity, with the A*G* adduct showing evidence of more distortion
than the G*G* adduct.
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In contrast to the cis-DDP 1,2 intrastrand crosslinks, where,
despite some distortion, the modified nucleotides retain base stacking
(den Hartog et al., 1985b) and base pairing abilities (van Hemelryck et
al., 1984), 1,3 crosslinks are more severely distorted. The structure
of the cis-DDP G*CG* adduct has been studied by NMR (den Hartog et al.,
1983; Marcelis et al., 1983). This lesion does not exhibit
characteristics consistent with normal base stacking, instead the
intervening cytosine is destacked, in effect "bulged out" or "turned
away" from the chelated guanines. The 1,3 intrastrand crosslinks at
d(GpTpG) and d(GpApG) sequences' appear to adopt similar conformations.
The disruption of hydrogen bonding occurring upon the destacking of the
intervening nucleotide is reflected in the thermal stability of the DNA
duplex. The melting temperatures of ds decamers containing any of the
cis-DDP 1,3 adducts (G*AG*, G*CG*, or G*TG*) are decreased by 300C.
This result suggests that these adducts are structurally similar (Urata
et al., 1992). Interestingly, the presence of a T opposite the
destacked central nucleotide stabilized the duplex form of DNA
containing any of the 1,3 adducts (Urata et al., 1992).
Destacking of the central nucleotide, similar to that observed for
the cis-DDP G*CG* adduct, occurs for trans-DDP adducts. The structures
of the G*TG* (van der Veer et al., 1986a), G*CG* (Gibson & Lippard,
1986), and G*AG* (Lepre et al., 1990) adducts have all revealed
destacking. The similarities in destacking exhibited by cis- and trans-
DDP 1,3 intrastand crosslinks, however, is insufficient to explain the
biological effects of these adducts. To give two examples, trans-DDP
adducts are easily bypassed by DNA polymerases (Comess et al., 1992;
'The G*GG* adduct is not expected to form. The N7 of the central
guanine is the most nucleophilic site in the d(GpGpG) trinucleotide
sequence and reacts first with cis-DDP to form a monoadduct. The
monoadduct then closes to a 1,2 intrastrand crosslink, preferentially
binding, at least in the sequence context studied, to the 3' guanine
residue (Yohannes et al., 1993).
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Corda et al., 1993) while cis-DDP adducts are not (Comess et al., 1992).
Additionally, 1,3 adducts formed by cis acting platinum compounds are
good substrates for UvrABC excision repair (Page et al., 1990) while the
comparable trans lesions do not appear to be repaired by this enzyme
(Popoff et al., 1987). As mentioned, cis- and trans-DDP 1,3 intrastrand
crosslinks bend and unwind the DNA duplex differently, likely accounting
for their different biological activities.
In summary, the cis-DDP intrastrand crosslinks induce bends in
duplex DNA toward the major groove of approximately 32-35° . Unwinding
of the helix is more severe, at 230, for 1,3 cis-DDP intrastrand
crosslinks than for either the A*G* or G*G* adducts, both of which
unwind the DNA duplex by 130. Base-pairing probably remains intact for
the A*G* and G*G* adducts, albeit in a distorted manner, and this
distortion is greater on the 5' side of the adduct than on the 3' side.
1,3 Intrastrand crosslinks disrupt the DNA duplex more severely, with
the central base destacking from the helix.
In addition to the consequences of localized structural
perturbation of the DNA architecture that results from single platinum
adducts, cis-DDP's chemotherapeutic effectiveness also has been proposed
to result from a larger disruption of the DNA duplex. These models are
based on the targeted binding of cis-DDP at certain nucleotide sequences
(Hemminki & Thilly, 1988; Jones et al., 1991). Such binding might
result in multiple adducts being formed in close proximity to each
other, allowing the cooperative distortion of DNA by multiple adducts.
Regions thought to be affected in this manner are alternating d(GpT),
and d(GpC), stretches (Johnson et al., 1992). These sequences are
almost always located in the 5' promotor region of "house-keeping genes"
and often in tissue specific gene promoters. cis-DDP modification
converts and stabilizes these sequences into the Z-DNA conformation,
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putatively inhibiting transcription of these essential genes ultimately
leading to cell death (Johnson et al., 1992). Another model is based on
the demonstration that cis-DDP modification disrupts the ordered
structure of oriented DNA fibers in vitro. This result was interpreted
to imply that cis-DDP could disrupt the orderly packing of DNA in the
chromosome with dire ramifications for the survival of a cell subjected
to such an insult (Rampino & Johnson, 1991; Rampino, 1992). A final
model is based on the ability of the G*G* cis-DDP adduct to form and
stabilize cruciform and hairpin structures. These structures are
substrates for the aforementioned HMG-box proteins that bind
specifically to cis-DDP modified DNA and may play a role in the
chemotherapeutic response to this drug (Yohannes et al., 1993).
4. Replication Blockage Effects of Platinum DNA Adducts
The therapeutic effects of cis-DDP are attributed, at least in
part, to the ability of platinum DNA adducts to block DNA replication
and transcription. cis-DDP treated DNA substrates have been shown to
inhibit human DNA polymerases in vitro (Harder et al., 1976), and the
sites of termination of eukaryotic DNA polymerase a have been mapped to
oligo d(G), sequences in the cis-DDP treated template (Villani et al.,
1988). More recently, an in vitro translesion synthesis assay
demonstrated that cis-DDP adducts were effective blocks to DNA
replication. The G*G* adduct was the most inhibitory (with as little as
2% replication bypass) and the G*NG* adduct was the least inhibitory (as
much as 25% replication bypass) (Comess et al., 1992). Similarly,
transcription elongation of DNA containing either A*G* or G*G* cis-DDP
adducts was blocked at the site of the lesion (Corda et al., 1991).
The ability of cis-DDP DNA adducts to block polymerases is derived
from the structural distortion these lesions impose on the DNA
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architecture rather than from the presence of the platinum moiety
itself. Monofunctional platinum adducts do not bend or unwind the DNA
helix to the extent that bifunctional crosslinks do, neither do they
provide a block to polymerases. In contrast, the cis-DDP G*G* and A*G*
adducts inhibit a variety of polymerases, allowing translesion synthesis
at a frequency less than 10% (Comess et al., 1992). Interestingly, the
thymine-thymine cyclobutane dimer, a lesion with structural
characteristics similar to the cis-DDP G*G* and A*G* adducts, is also a
potent inhibitor of DNA replication (LeClerc et al., 1991). Facile
bypass of trans-DDP 1,3 intrastrand crosslinks (Comess et al., 1992;
Corda et al., 1992) is attributable to one of two factors. First,
trans-DDP 1,3 intrastrand crosslinks can interconvert with the 1,4 form
(Comess et al., 1990), presumably by means of a monofunctional
intermediate. A polymerase stalled at such a lesion could reinitiate
replication while the adduct is in the monofunctional form and not
effective at blocking DNA synthesis. Alternately, the flexible hinge
joint of a trans-DDP adduct could allow the lesion to adopt a bypassable
conformation allowing a stalled polymerase to resume DNA replication.
35
Table 1. Comparison of the adducts formed by platinum(II) compounds.
Adduct cis-DDP trans-DDP" [Pt (dien) C1] Cla
DNA monofunctional adducts
dG* 3b yes yes
DNA intrastrand crosslinks
d(G*pG*) 65 no no
d(A*pG*) 20-30% no no
d(G*pNpG*) < 10% yes yes
DNA interstrand crosslinks
d(G*pC)/(G*pC) < 5% ? no
d(G*pC)/(GpC*) ? 5-20% no
DNA protein crosslinks < 1% yes no
a. The majority of DNA adducts formed by trans-DDP and [Pt(dien)Cl]C1
has not been quantitated.
b. Numbers indicate the percentage of each adduct compared to the total
binding spectrum. In cases where accurate numbers are not available,
the ability to form adducts is indicated by "yes" or "no".
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Figure 2. cis-DDP G*G*, A*G*, and G*TG* adducts. Only the chemical
composition of the cis-DDP DNA adducts are depicted. Structural
conformations are discussed at length in the text and are diagrammed in
the literature referenced therein.
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B. Cellular Effects of Platinum Anticancer compounds
1. Genotoxicity of Platinum-DNA Adducts
The genotoxicity of platinum DNA adducts is well established in a
variety of biological systems and is expected based on the in vitro
experiments that demonstrated cis-DDP adducts to be potent blocks to DNA
polymerases. Early work by Rosenburg and colleagues identified
inhibition of DNA synthesis as the mechanism by which cis-DDP reduced
the growth of E. coli (Rosenberg et al., 1967; Harder & Rosenburg,
1970). DNA adducts formed by [Pt(dach)C12], a chemotherapeutically
active cis-DDP analogue, are genotoxic in a plasmid-based assay (Husain
et al., 1985). The level of genotoxicity of these adducts, 5.5 adducts
per lethal hit, is comparable to that of DNA lesions formed by
benzo(a)pyrene-7,8-dihydrodiol-9,10-oxide (BPDE) or uv photoproducts
(Mizusawa et al., 1981; Strike & Roberts, 1981). Different platinum DNA
adducts exhibit variable levels of genotoxicity. In an SV40-based in
vitro replication system utilizing HeLa cell extracts, bifunctional cis-
DDP adducts inhibited DNA replication 30 fold more effectively than the
monofunctional DNA adducts formed by the therapeutically ineffective
compound [Pt(dien)Cl]+ (Heiger-Bernays et al., 1990). A site-
specifically located G*G* cis-DDP adduct in M13mp18 DNA reduced DNA
replication by 78% in E. coli (Bradley et al., 1993). In addition to
inhibition of DNA synthesis, cis-DDP exhibits other genotoxic effects
including chromosomal abnormalities (Kliesch & Adler, 1987) and sister
chromatid exchanges (Vogel et al., 1991). 1
'It should be noted, however, that gross chromosomal abnormalities and
sister chromatid exchanges may be a result of the transformed phenotype of
carcinoma cells and not a direct consequence of cis-DDP treatment.
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2. Mutagenesis of cis-DDP in E. coli
a. Mutagenesis in E. coli.
cis-DDP induced mutagenesis was first demonstrated in E. coli by
Beck & Brubaker (1975). cis-DDP is a base-pair substitution mutagen by
virtue of its ability to revert 2-aminopurine and N-methyl-N'-nitro-N-
nitrosoguanidine induced mutations and, conversely, by the ability of
these mutagens to revert cis-DDP induced mutations. As expected, the
frameshift mutagen ICR-191 is unable to revert any cis-DDP mutants.
cis-DDP mutagenesis is also dependent upon LexA (Venturini &
Monti-Bragadin, 1978) and RecA activities (Konishi et al., 1981), in
particular the recombinational capabilities of RecA (Jarosik & Beck,
1984). Mutagenic dependence on LexA activity, and the ability of the
mutagenesis enhancing plasmid pKM101 to increase the level of cis-DDP
induced mutants in various cell types (Venturini & Monti-Bragadin, 1978;
Jarosik & Beck, 1984) indicates that SOS processing of cis-DDP lesions
is required for mutagenesis. Direct evidence for SOS involvement in
mutagenic processing has been provided by Fram et al. (1985), who
demonstrated that cis-DDP mutagenesis is abolished in a umuD,C
background.
b. Mutational specificity of cis-DDP in E. coli.
The exact nature of the mutations of cis-DDP in E. coli has been
studied in several forward mutational assays but with conflicting
results. By using the endogenous E. coli lacI gene as the genetic
target, Brouwer et al. (1981) found that the mutations arising from
cis-DDP treatment to cells were primarily at d(GpApG) and d(GpCpG)
sequences. No mutations were detected with the trans compound. In this
work, no specific treatment was used to induce SOS other than the drug
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treatment itself. By contrast, Burnouf et al. (1987) found that the
majority (>90%) of mutations occurred at d(ApG) and d(GpG) sequences in
the tetR gene of cis-DDP modified pBR322 that was replicated in SOS
induced E. coli cells. The differences between the results of these two
studies could be due to differences in the mode of DNA damage (in the
former study intact cells were treated, whereas in the latter DNA was
modified and then introduced into the host for mutation fixation), to
differences in the range of mutations detectable in the respective
genetic systems, or to the state of SOS induction of the cells in which
the mutations were fixed. More recently, the mutagenicity of cis-DDP
G*G* (Bradley et al., 1993) and A*G* (Burnouf et al., 1990) adducts has
been determined site specifically. The results of these studies are
analyzed in detail in comparison with the site specific analysis of the
cis-DDP G*G*, A*G*, and G*TG* adducts done in the present work (see
Discussion).
3. Mechanism of cis-DDP Mutagenesis in Prokaryotes
a. SOS dependence of mutagenesis
A wide range of DNA damaging agents can induce the SOS response in
E. coli, including uv radiation, methylmethanesulfonate,
4-nitroquinolone-l-oxide, and aflatoxin B. cis-DDP also induces the
SOS response, as evidenced by its ability to stimulate the filamentous
growth of bacteria (Rosenberg et al., 1967), to induce prophage from
lysogenic bacteria (Reslova, 1971), and to induce increased cellular
levels of RecA protein (Salles & Lesca, 1982). As with many of the
treatments mentioned, cis-DDP is also an SOS-dependent mutagen; this
property will be described in detail in the next section. Thus the
state of SOS induction is important to any mutagenesis studies of
cis-DDP in E. coli. The SOS response of E. coli, therefore, will be
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examined in detail below.
The SOS response to DNA damage is characterized by enhanced DNA
repair activities, enhanced mutagenesis, inhibition of cell division,
and prophage induction.' This diverse array of physiological responses
result from the expression of an inducible set of genes that are under
the control of the RecA and LexA proteins. Most of the literature on
the SOS response describes the UvrABC exinuclease complex, which
efficiently repairs a wide array of bulky lesions in DNA (Sancar & Rupp,
1983), including adducts formed by cis-DDP (Brouwer et al., 1988). This
pathway has been extensively reviewed (Witkin, 1976; Little & Mount,
1982; Walker, 1984; Battista et al., 1990; Echols & Goodman, 1990; Lin &
Sancar, 1992; Altshuler, 1993; Grossman & Thiagalingam, 1993; Sancar &
Tang, 1993). The work done for this dissertation does not directly
address the repair of platinum-DNA adducts.2 This discussion,
therefore, will emphasize those aspects of the SOS response that
engender the mutagenic processing of damaged DNA.
Under physiologically normal cellular conditions, a repressor
protein, LexA, is bound to the operator regions of the at least 17-20
genes thought to comprise the SOS regulon. The SOS network is activated
when a cell is exposed to a DNA damaging agent. The inducing signal is
'The SOS response has been most extensively studied in E. coli and,
unless otherwise stated, this discussion describes the SOS response in
E. coli. It should be noted that related gram-negative bacteria mount
very similar responses to DNA damage. In addition, gram-positive
bacteria, exemplified by Bacillus subtilis also exhibit SOS-like
responses when confronted with DNA damage (Cheo et al., 1993) and it is
postulated that eukaryotes also have similar responses to DNA damage (Ho
et al., 1993).
2The possible role of DNA repair by UvrABC in mediating the
observed SOS-dependent enhanced survival of platinum drug modified M13
bacteriophage genomes replicated in E. coli is briefly addressed in the
dissertation in the experiments comparing the survival of cis-DDP
modified DNA transfected into either E. coli DL7 (wt) or DL6 (uvrA)
cells (see Figure 11).
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generally believed to be single stranded regions of DNA exposed as a
result of replication arrest at sites of DNA damage. In response, the
normal form of RecA is converted to an activated form, RecA*, which then
associates with and promotes the autolytic cleavage of LexA (reviewed by
Little, 1993). The cleaved form of LexA can no longer function as a
repressor, enabling the expression of the genes of the network. The
genes involved bind LexA to different extents, allowing the differential
activation of specific genes as is warranted by the magnitude of the
threat to the host. Therefore, low levels of inducing signal will
result in only some genes being turned on, while higher levels are
required to induce the system fully. As the DNA is repaired, the
inducing signal decreases, RecA* levels drop, the pool of uncleaved LexA
increases, and the genes of the network are in turn repressed.
b. The role of UmuDC and RecA in SOS mutagenesis
The phenotypic responses of the SOS system are the result of the
expression of the genes of this regulon. Generally, the genes involved
in excision repair are most easily induced. As indicated previously,
excision repair is an error free process, and it seems reasonable that
these genes would be involved as an early response to damage. If damage
levels are high, however, and the inducing signal persists, then the
umuD,C genes are expressed. These genes appear to play a key role in
the error-prone bypass of replication blocking lesions.
Early studies of E. coli deficient in the induction of mutations
by ultraviolet light implicated mutations at three chromosomal loci that
encode the umuA, umuB, and umuC genes. The umuA and umuB gene products
were determined to be the LexA and RecA proteins, respectively (Kato &
Shinoura, 1977; Steinborn, 1978). The umuC locus was demonstrated to
encode two polypeptides, the UmuD and UmuC proteins, both of which are
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required for uv and chemical induced mutagenesis (Bagg et al., 1981;
Elledge & Walker, 1983). This operon is under the coordinated control
of the recA and lexA gene products (Kitagawa et al., 1985). Uninduced
levels of umuDC expression yield about 180 molecules of UmuD and
undetectable amounts of UmuC. After the LexA repressor protein is
inactivated by RecA* cleavage, levels of UmuD increase to 2500 and UmuC
to 200 molecules per cell (Woodgate & Ennis, 1991). The disparity in
UmuD and UmuC synthesis is likely to be a result of inefficient
translational coupling at a one-base overlap between the UmuD and UmuC
cistrons (Perry et al., 1985; Woodgate & Sedgwick, 1992).
There are some reports that a low level of chemical and uv induced
mutagenesis is possible without induction of the SOS response (Bridges &
Woodgate, 1984; 1985; Fix, 1993). In most cases, however, two features
of the SOS response are required for mutagenic processing of bulky
lesions in DNA. First, SOS induction is necessary to achieve an
adequate level of UmuC protein. UmuC is not present in non-SOS induced
E. coli because (i) UmuC synthesis is inefficient compared to UmuD and
(ii), because UmuC is very susceptible to proteolytic digestion, with a
half life of only 6 min unless it is part of a multiprotein complex
(Donnelly & Walker, 1989). The chaperone proteins encoded by the groEL
and groES loci extend the half life of UmuC to 17 min. UmuC is even
more refractory to proteolysis in the presence of high (i.e. SOS-
induced) levels of UmuD; UmuC in a UmuD2C complex' has a t 100 min
(Battista et al., 1990; Donnelly & Walker, 1992).
A second reason that SOS induction is required for chemical and uv
'The t 100 is in the presence of GroEL and GroES proteins;
without these chaperone proteins, a UmuD2C complex has a t = 50-60 min.
E. coli groE mutants have greatly suppressed umuDC-dependent mutability.
This decrease may simply be due to the shorter half life of UmuC in groE
mutants. Alternately, GroES and GroEL may play a more direct role in
UmuDC mediated mutagenesis (Donnelly & Walker, 1989; 1992).
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induced mutagenesis in E. coli is that the DNA damage-activated form of
the RecA protein is required for this process. Although RecA is present
in high levels in non-SOS induced cells (Sommer et al., 1993), the
proteolytically cleaved, activated form of this protein, RecA*, plays 3
essential roles in UmuDC mediated mutagenesis. Initially RecA* promotes
cleavage of the lexA protein, thereby derepressing the expression of the
umuDC operon (Bagg et al., 1981; Nohmi et al., 1988) and allowing the
production of large amounts of the UmuD and UmuC proteins (Woodgate &
Ennis, 1991). In the presence of excess UmuD, UmuD and UmuC associate
into a UmuD2C complex. This complex is inactive until UmuD is
posttranslationally modified by proteolytic cleavage between Cys-24 and
Gly-25 by RecA* (Burckhardt et al., 1988; Nohmi et al., 1988). UmuD is
cut in its monomeric form; its C-terminal fragment, designated as UmuD',
is able to displace UmuD in the UmuD2C complex in an equilibrium
reaction: UmuD2C UmuD'DC Umu D'2C. The UmuD'2C complex is the
active species in chemical and uv induced mutagenesis (Woodgate et al.,
1989; Bailone et al., 1991a; Donnelly & Walker, 1992). A third
essential role of RecA* in SOS induced mutagenesis involves direct
intervention in UmuD'2C mediated bypass of a bulky DNA lesion. The
exact nature of the direct intervention of RecA* in effecting mutagenic
translesion synthesis is undetermined. Possibilities include RecA*
binding to ss DNA near a polymerase blocked by a DNA lesion, thereby
stabilizing the replication fork until UmuD'2C can locate and rescue the
stalled polymerase. Alternately, RecA* may play an active role in
directing the UmuD'2C complex to the site of DNA lesion (Sweasy et al.,
1990; Rajagopalan et al., 1992; Frank et al., 1993).
The protein complex comprised of RecA*, UmuD'2C, and PolIII, which
is responsible for SOS induced mutagenesis in E. coli, has been termed a
"mutasome" (Rajagopalan et al., 1992). The exact mechanism of mutasome
mediated mutagenesis remains unclear. Several mechanisms, however, have
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been proposed to explain low-fidelity replication past bulky DNA
lesions, such as cis-DDP adducts. These include (1) inhibition of the
3'-5' proofreading function of DNA polymerase III, (2) stimulation of
lesion bypass once a nucleotide has been inserted opposite a site of
damage, and (3) facilitated reinitiation of the polymerase after it has
dissociated from the site of blockage.
c. The role of UvrA and UvrB
In most cases, induction of the umuDC operon is sufficient for uv
and chemical induced mutagenesis in E. coli (Sommer et al., 1993).
There is some evidence, however, that the uvrA and uvrB gene products
also play a role in cis-DDP mutagenesis. In general, chemical and
physical agents producing lesions that are substrates for excision
repair show high lethality in excision repair defective cells. The same
repair defective cells are almost invariably much more susceptible to
the mutagenic effects of the treatment, as with uv mutagenesis
(Glickman, 1983). cis-DDP appears to be an exception to this rule.
Several studies have shown that mutation induction by cis-DDP in cells
carrying a mutant uvrA allele is greatly decreased (Konishi et al.,1981;
Brouwer et al., 1988), even in the presence of the plasmid pKM101
(Venturini & Monti-Bragadin, 1978); it is noteworthy, however, that
there has been one report to the contrary (Cunningham et al., 1981).
Cells deleted for uvrB are immutable by cis-DDP in an assay using the E.
coli lacI gene as the target (Brouwer et al., 1981). The same
experiment done in the presence of pKM101 gives the same result (Brouwer
et al., 1983). There exists a uvrB5 mutant of E. coli that is defective
for excision repair and is sensitive to the killing effects of cis-DDP.
Unlike the uvr mutants described above, this mutant can support cis-DDP
induced mutagenesis (Brouwer et al., 1988). It possesses a -1
frameshift within the uvrB5 gene and produces a truncated protein
46
consisting of the 113 N-terminal amino acids of the wild type UvrB
protein and a 43 amino acid tail encoded downstream from the -1
frameshift. Deletion studies of a plasmid carrying the uvrB5 gene
demonstrate that mutation induction mediated by UvrB5 is due to the 113
amino acids present in the wild type gene. Deletion of the uvrC gene
does not compromise the mutagenicity of cis-DDP (Brouwer et al., 1988).
These results suggest that the uvrA and uvrB gene products are
performing an active role in cis-DDP induced mutagenesis. This role
differs from that of UmuDC, since UmuDC activity is also required for
mutagenesis.
It is not unprecedented that uvrABC gene products are required for
mutation induction. Interstrand crosslinking reagents such as mitomycin
C and psoralen are not mutagenic in uvr backgrounds. In these cases it
is the normal excision repair activity that is apparently responsible
for converting the lethal crosslinks formed by these agents to mutagenic
monoadducts (Murray, 1979). A similar mechanism, however, is unlikely
to apply to cis-DDP because the frequency of cis-DDP interstrand
crosslinks is very low' (Pinto & Lippard, 1985a), and the mutability of
uvrC strains indicates that excision repair itself is not involved.
A possibly related phenomenon occurs with arylamine compounds.
AAF-DNA adducts can block DNA synthesis, induce SOS functions, and are
lethal in uvrA, uvrB, and uvrC strains. Aminofluorene (AF) DNA adducts,
by contrast, are not blocks to replication, do not induce SOS, and only
uvrC strains are sensitive to the killing effects of the compound. It
1Early reports indicated that interstrand crosslinks comprise 1%
of all cis-DDP DNA adducts. More recent results suggest that a much
higher proportion of all adducts, up to 5-10%, are interstrand
crosslinks (Brabec & Leng, 1993; Decoville et al., 1993). These
adducts, nevertheless, can be considered infrequent compared to the G*G*
(-65%) and A*G* (-25%) intrastrand crosslinks, both of which have been
demonstrated to be mutagenic.
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has been postulated that in the absence of UvrC, UvrA and UvrB can bind
to AF-DNA adducts producing a non-bypassable lethal complex (van Houten,
1990). It is possible that the binding of UvrA and UvrB to sites of
adduction by cis-DDP plays a role in platinum induced mutagenesis.
van Houten (1990) has compiled genetic evidence suggesting that
UvrA, UvrB, and UvrD perform some function that is essential for
viability in the absence of DNA polymerase I. Double mutants of polA,
which encodes DNA polymerase I, and any of these genes are lethal, but a
polA uvrC double mutant is not, indicating that this putative role is
different from excision repair activity.
In summary, cis-DDP is clearly an SOS dependent base-pair
substitution mutagen in E. coli. As will be shown in this dissertation,
sites of cis-DDP-induced mutations can be correlated with sites of
platinum modification, although not all sites of preferred chemical
reaction are those at which mutations arise most frequently.
4. umuDC-like Mutagenesis in Other Species
Mutagenic responses involving umu-like genes and proteins have
been detected in many other bacterial species, making it clear that umu-
like genes are widely distributed (Woodgate & Sedgewick, 1992; Ho et
al., 1993). An SOS-regulated umuDC operon has been characterized in
Salmonella typhimurium;1 the proteins encoded by this operon (umuDC,)
are highly homologous, both structurally and functionally, to their
'S. typhimurium commonly also have an additional umuDC-like operon,
samAB, encoded on the 60-MDa cryptic plasmid, pSLT. Interestingly,
despite the homology of SamA and SamB to UmuD and UmuC the former
proteins are not able to restore mutability to umuDC cells (Nohmi et
al., 1992).
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counterparts in E. coli' (Smith et al., 1990; Thomas et al., 1990).
UmuDC homologues are also encoded by a number of plasmids. The most
well known example is pKM101 (Monti-Bragadin et al., 1975; Beck and
Fisch, 1980). This plasmid encodes the MucAB proteins, which are
naturally occurring plasmid counterparts of the UmuDC proteins of E.
coli which play essential roles in SOS mutagenesis. The MucAB proteins,
when expressed in S. typhimurium, form the basis of the reversion assays
developed by Ames and coworkers (Ames et al., 1973; McCann et al., 1975)
and have been used to assess the mutagenicity of a wide range of
suspected environmental mutagens and other compounds, such as cis-DDP
and other platinum drugs (Beck & Fisch, 1980; Leopold et al., 1981).
The MucAB proteins are more efficient at inducing mutagenesis than
the UmuDC proteins. UV and chemical mutagenesis is increased in both E.
coli and S. typhimurium upon expression of the mucAB genes (Blanco et
al., 1986). Additional plasmids have been identified that carry umuDC-
like genes that are capable of restoring induced mutability in E. coli
umuDC mutants. The plasmid TP110, to give one example, encodes a 16 kD
protein with significant homology to UmuD and MucA as well as a 46 kD
protein homologous to UmuC and MucB (Lodwick et al., 1990). umuDC-like
genes are not limited to prokaryotes. Proteins necessary for the
mutagenic processing of DNA lesions induced by uv light and chemicals
1The umuDCs gene products, for example, have 71% amino acid
homology to the E. coli UmuD and UmuC proteins. The primary function of
UmuDC-like proteins has been proposed to be the mediated bypass of
replication blocking lesions in DNA and associated mutagenicity is a
non-essential secondary effect. Different homologues have greatly
varying abilities to impart induced mutabilities to their cellular
hosts. For example, the umuDCs gene products are weakly mutable, and
the samAB gene products are immutable compared to their umuDC and mucAB
counterparts (Koch et al., 1992; Nohmi et al., 1992). It remains
unclear why some of these proteins should impart mutability to their
host cells. Inducible mutagenesis has been described as a form of
inducible evolution for cells in stressful environments. The benefits
of such a system, however, are minimal and therefore are present (umuDC
and mucAB), weakly present (umuDC) or not present (samAB) as a
secondary effect of a system designed to provide the primary benefit of
bypass of replication blocking DNA lesions (Woodgate & Sedgwick, 1992).
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are being identified in eukaryotes. For example, the REVI mutant of
Saccharomyces cerevisiae is non-mutable when exposed to DNA-damaging
agents that are known SOS-dependent mutagens in E. coli and are also
mutagenic in wild-type S. cerevisiae (Larimer et al., 1989). It is
anticipated that any species which is mutated by agents such as uv light
will have a cellular response to DNA damage that involves proteins that
have umuDC-like functions (Woodgate & Sedgewick, 1992). Evidence for
such proteins is beginning to emerge for the mutagenic processing of uv
irradiated DNA in humans (Thomas & Kunkel, 1993).
5. Mutagenicity and Genotoxity of cis-DDP in Eukaryotic Cells
cis-DDP is mutagenic in mammalian cells (Wiencke et al., 1979;
Johnson, N. P. et al., 1980), and its mutation spectrum has been studied
in at least three eukaryotic systems. One analysis was carried out on
the SUP4-o gene of Saccharomyces cerevisiae (Mis & Kunz, 1990). Single
base-pair substitutions predominate (72% of the total mutations), and
86% of those occur at GC base pairs. Dipurine sequences are also
involved in 86% of the induced base pair substitutions, with the
majority of the substitutions occurring at d(GpG) and d(GpA) sequences.
Comparable results were obtained for cis-DDP induced mutations in exon 3
of the human hypoxanthine guanine phosphoribosyltransferase gene in B-
lymphoblasts. The majority of mutations was attributable to G T and
A - T transversions at the 5' base of d(GpG) and d(ApG) sequences,
respectively (Cariello et al., 1992). Finally, cis-DDP and carboplatin
induced mutations in the adeninephosphoribosyltransferase (aprt) gene of
CHO cells have also been investigated (de Boer & Glickman, 1989; 1992).
The mutations induced are very similar for both drugs. Substitutions at
G-C base pairs also predominate, with the majority occurring at d(ApGpG)
and d(GpApG) sequences. The role of A*G* adducts in mutagenesis in these
studies is ambiguous partly because in the former study there are
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relatively few d(ApG) sequences in which a mutation is detectable and,
in the latter study, mutations at d(ApGpG) sequences cannot be ascribed
with certainty to the presence of either an A*G* or G*G* adduct.
Taken together, the results of studies in mammalian cells and in
human cancer patients thus far indicate that both cis- and trans-DDP DNA
adducts are substrates for repair, and that the trans isomer may be
repaired to a greater extent than the cis compound. Excision repair is
involved in cis-DDP adduct removal and may be the activity responsible
for the initial rapid phase of adduct removal following treatment.
There are also indications that a second avenue of repair may exist. In
all cases, the G*G* adduct is the most abundantly formed, and its
prevalence is maintained during and after repair. Results suggest that
in both mammalian and bacterial cells, the G*G* and A*G* adducts of
cis-DDP play important roles in the genotoxic and mutagenic activity of
this anticancer drug.
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C. Platinum (IV) Anticancer Drugs
1. The Need for New Platinum Drugs
cis-DDP is a potent genotoxin and a highly effective anticancer
drug. It is a key component of drug therapies for the treatment of
testicular, ovarian, bladder, head and neck, and lung cancers.
Cisplatin based regimens also show limited activity against malignant
lymphomas and esophageal and stomach cancers (Greene, 1992). Although
one of the most successful cancer chemotherapeutic agents yet developed,
cis-DDP has several significant liabilities the foremost of which is
acute toxicity to the host at clinically used doses of drug. The short
term effects include nausea and vomiting (Krakoff, 1979; von Hoff et
al., 1979), whereas longer term cumulative exposure can cause severe
nephrotoxicity and neuropathy. Many patients also experience
gastrointestinal toxicity, ototoxicity, hypomagnesemia, cardiotoxicity,
myelosuppression, anaphylactic reactions, cerebral herniation, or
vascular toxicity (von Hoff et al., 1979; Walker et al., 1988; Hamers et
al., 1991; Icli et al., 1993). The clinical efficacy of cis-DDP is
further diminished by both intrinsic and acquired resistance in tumor
cells. An additional drawback is that cis-DDP requires intravenous
administration, necessitating costly and time consuming hospital or
clinical visits.
There has been considerable success in reducing the most severe
toxicities associated with cis-DDP chemotherapy. Nephrotoxicity can be
suppressed by administration of nucleophilic sulfur compounds (Basinger
et al., 1992). Neuropathy and other toxicities have been reduced by the
development of cis-diammine-l,1-cyclobutanedicarboxylate (carboplatin,
Figure 1), a less toxic second generation platinum drug. Unfortunately
carboplatin, also a platinum(II) compound, is not effective against cis-
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DDP resistant tumors and also requires intravenous administration.
These disadvantages, inherent with current platinum chemotherapy, have
led to an intense search for third generation platinum drugs.
The appearance of second malignancies in patients treated with
cis-DDP is another important concern associated with all platinum based
therapeutic regimens. cis-DDP is a mutagen in mammalian cells (Wienke
et al., 1979; Johnson et al., 1980) and, upon SOS-induction, also in
bacteria (Beck & Brubaker, 1975; Benedict et al., 1977). The strong
mechanistic link between mutagenesis and carcinogenesis implies that
cis-DDP is a carcinogen in humans as it is in rodents (Leopold et al.,
1981). This relationship, however, has not been established
conclusively for cis-DDP because the drug is typically administered in
conjunction with a battery of other anticancer drugs, some of which are
suspected human carcinogens (Greene, 1992). Although unproven, the
strong possibility that cis-DDP is carcinogenic suggests the
desirability for evaluating the mutagenicity, and implied
carcinogenicity, of all new platinum drugs. One of the major aspects of
this thesis, therefore, was a comparison of the mutagenicity and
mutational spectra of ACDP and cis-DDP by using the lacZ' -
galactosidase a-complementation forward mutational assay in E. coli.
2. Platinum(IV) Ammine/amine Dicarboxylates
A class of platinum(IV) complexes, ammine/amine platinum(IV)
dicarboxylates, has recently been introduced in an attempt to overcome
some of the drawbacks of cis-DDP and other related platinum(II)
analogues (Figure 1) (Kelland et al., 1992b). Because platinum(IV)
compounds are orally absorbed, they may afford an equally effective
treatment regimen with fewer toxic side effects (McKeage et al., 1993)
and greater ease of administration. Moreover, these compounds have been
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found to be active against cis-DDP resistant cell lines. To give two
examples, platinum(IV) dicarboxylates exhibit 25 fold enhanced
cytotoxicity against resistant human cervical squamous cell carcinoma
cell lines (Mellish et al., 1993) and up to 2 orders of magnitude of
enhanced cytotoxicity against cis-DDP resistant human ovarian carcinoma
cell lines (Kelland et al., 1992b). The latter finding alone could have
profound clinical implications for the 18,000 patients diagnosed with
ovarian cancer each year in the United States, two thirds of whom are
projected to ultimately die of their disease (Silverburg & Lubera,
1989). Of even broader scope, platinum(IV) drugs also are effective
against lung cancer cell lines possessing acquired resistance to
chemotherapeutic agents including cis-DDP (Twentyman et al., 1992). One
ammine/amine platinum(IV) dicarboxylate, cis, trans, cis-ammine(cyclo-
hexylamine)dibutyratodichloroplatinum(IV) (ACDDP, Figure 1) has recently
been introduced in clinical trials. A similar orally active
platinum(IV) compound, cis, trans, cis-ammine(cyclohexylamine)diacetato-
dichloroplatinum(IV), also shows activity against resistant tumor cell
lines in vitro and resistant tumors in mice and is poised to enter
clinical trials (Kelland et al., 1993). Considering that a major
driving force leading to the development of platinum(IV) drugs was
overcoming cellular resistance, it behooves us to take a detailed look
at the mechanisms responsible for resistance to platinum (II) drugs.
3. cis-DDP Resistance in Tumor Cells
Resistance to platinum(II) compounds is multifactoral, involving
one or more of an array of possible mechanisms including intracellular
detoxification by glutathione (Godwin et al., 1992) or metallothionein
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(Pattanaik et al., 1992), expression of oncogenes 1 (Isonishi et al.,
1991), or increased repair of DNA platinum adducts (Eastman & Schulte,
1988; Kelland et al., 1992a; Zhen et al., 1992). The enhanced efficacy
of ACDDP, the parent compound of ACDP, could be derived from its ability
to circumvent one or more of these modes of resistance. For example,
the effectiveness of ACDDP could arise from the ability of some its DNA-
reactive platinum(II) metabolites, other than ACDP, to form novel DNA
adducts not possible with cis-DDP or ACDP. These lesions, unlike cis-
DDP or ACDP adducts, could be refractory to repair, persist in the
cell's genomic DNA, and thereby mediate ACDDP's enhanced cytotoxicity.
This method of overcoming resistance probably does not apply to ACDDP,
however, as a human carcinoma cell line, CHlcisR, has been described
that retains resistance even to platinum(IV) ammine/amine
dicarboxylates, apparently as a consequence of facile DNA repair
(Kelland et al., 1992a).
Response to cis-DDP treatment in cancer patients as well as
sensitivity of tumor cells grown in culture to platinum compounds are
both correlated to high levels of platinum adducts on the genomic DNA of
the host (Reed et al., 1990; 1993; Gorodetsky et al., 1993). In
contrast, DNAs from patients ineffectively treated by platinum therapy
and from resistant cell lines both have low levels of platinum adducts.
The diminished levels platinum DNA adducts could be a consequence of (i)
cytoplasmic sequestering of platinum compounds preventing them from
interacting with the chromosome or (ii) facile or enhanced repair of
platinum DNA adducts.
'The expression of many oncogenes, however, does not confer cis-DDP
resistance (Perez et al., 1993). Nevertheless the link between cellular
growth-regulating protein and cis-DDP sensitivity remains intriguing
considering that testis cancer (against which cis-DDP is > 95%
effective) is one of the few types of cancer that is not characterized
by occurrence of mutations in the p53 protein (Peng et al., 1993).
55
a. Intracellular sequestration and conjugation of cis-DDP
A number of mechanisms has been proposed for the reaction of
intracellular components with cis-DDP that render the drug inactive to
DNA binding. For example, ribonucleotide triphosphates, particularly
ATP and GTP, can form complexes with cis-DDP and shield the drug,
preventing it from binding to cellular constituents, including its
therapeutic target, DNA. It is suggested that differences in
ribonucleotide levels from cell to cell (e.g. rapidly dividing tumor
cell have high levels) may partially explain cis-DDP resistance (Seki et
al., 1993). Considerably more evidence, however, implicates
overexpression of metallothionein and glutathione as causitive factors
in cis-DDP resistance as discussed below.
Metallothionein (MT) is a low molecular weight (6-7 kDa),
cysteine-rich protein that shows a high affinity for metals including
zinc, copper, cadmium, mercury, and platinum. cis-DDP binds to MT with
loss of its ammine ligands, suggesting that it is bound
tetracoordinately. Each MT protein binds -10 platinum molecules;
overall, a significant fraction of intracellular platinum can be bound
to MT (Pattanaik et al., 1992). Overexpression of MT in previously
sensitive Chinese hamster ovary cells renders them resistant to cis-DDP
(Koropatnik & Pearson, 1993). Furthermore, bladder tumor cells have
been described that derive cis-DDP resistance from increased synthesis
of MT (Satoh et al., 1993). An increase in MT synthesis in tumor cells
may be linked to oncogene expression. To give an example, the increased
expression of MT in mouse NIH 3T3 cells is correlated with the
expression of the c-Ha-ras oncogene (Isohishi et al., 1991).
Glutathione is a tripeptide containing a nucleophilic sulfur
derived from a cysteine residue. Glutathione plays a significant role
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in resistance to a variety of drugs and in the detoxification of
electrophilic compounds, therefore it is not surprising that it also has
been implicated in cis-DDP resistance. The cytotoxicity of cis-DDP is
enhanced in glutathione deficient cells (Ishikawa & Ali-Osman, 1993) and
decreased in cells that overexpress glutathione. Human ovarian
carcinoma cell lines that overexpress glutathione by 13-50 fold are 30-
1000 fold more resistant to killing by cis-DDP (Godwin et al., 1992).
Up to 60% of the total intracellular platinum in cis-DDP treated
resistant L1210 murine leukemia cells has been shown to be bound to
glutathione in a 2:1 glutathione:drug stoichiometric ratio. The
glutathione-cis-DDP conjugate can be effluxed from a cell in ATP-
dependent transport across the plasma membrane (Ishikawa & Ali-Osman,
1993). The resulting reduction in the intracellular accumulation of
drug is one mechanism that cells employ to effect cis-DDP resistance
(Timmer-Bosscha et al., 1992).
b. cis-DDP Resistance mediated by enhanced DNA repair
Sequestering of cis-DDP by metallothionein or its conjugation with
glutathione and subsequent efflux from the cell are hypothesized to form
a "front line" defense to prevent DNA damage. Enhanced DNA repair may
be a compensatory mechanism for cells that cannot utilize these
mechanisms to avoid formation of cis-DDP lesions in their genomes
(Dabholkar et al., 1992). Indeed, many cis-DDP resistant cells,
including L1210 murine leukemia cells1 (Eastman & Shulte, 1988), human
ovarian carcinoma cells (Parker et al., 1991), human cervical carcinoma
cells (Nishikawa et al., 1992) and Xeroderma pigmentosum and Fanconi's
1Eastman and Shulte (1988) recognized that resistance in L1210
murine leukemia cells was at least bifunctional as not all of the
observed resistance could be explained by increased DNA repair. These
cells were later found to also have enhanced levels of glutathione that
provided an additional level of drug resistance (Ishikawa & Ali-Osman,
1993), as mentioned above.
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amenia cells (Zhen et al., 1993) have significantly greater rates of
cis-DDP DNA adduct repair than their drug sensitive counterparts.
Repair of cis-DDP DNA adducts has not yet been well characterized
in eukaryotic cells. Early indications, however, are that this repair
is inducible. Burkle et al. (1993) report that cis-DDP induces
poly(ADP-ribosyl)ation and subsequent activation of nuclear proteins
implicated in DNA repair. Furthermore, repair of cis-DDP lesions is
gene and strand specific (Jones et al., 1991; Zhen et al., 1992;
Stevnsner et al., 1993).
4. Circumvention of cis-DDP Resistance by Platinum(IV) Drugs
The mechanism by which platinum(IV) drugs are able to circumvent
cis-DDP resistance does not appear to involve alteration of glutathione
or metallothionein synthesis or decreased DNA repair (Kelland et al.,
1992a; Mistry et al., 1992; Twentyman et al., 1992). Instead,
platinum(IV) drugs overcome cellular resistance to platinum(II)
compounds by a mechanism that is just now becoming apparent as the mode
of cis-DDP transport into cells is elucidated. Generally it has been
supposed that cis-DDP enters cells by passive diffusion and initially
achieves similar levels in all cells. Differences in drug sensitivity
of various cells were attributed to the aforementioned cytoplasmic
sequestration of cis-DDP or facile repair of DNA lesions. The low
levels of drug observed in some resistant cell lines was regarded as a
consequence of increased efflux of the drug.' Evidence for the model in
which cis-DDP enters cells by passive diffusion, which would allow
similar levels of drug initially to accumulate in both cis-DDP resistant
'Clearance of cis-DDP from some resistant cells can be mediated by
efflux of cis-DDP-glutathione conjugate across the plasma membrane by
active transport, as previously discussed.
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and sensitive cells, was compelling. This evidence included the
observations that accumulation is not saturable, is proportional to
extracellular drug concentration, and is not inhibited by structural
analogues of cis-DDP (reviewed by Gately & Howell, 1993).
In conflict with the passive diffusion model, however, was the
observation that cis-DDP, a relatively hydrophilic compound, is
effectively blocked by lipid membranes (Melvik et al., 1986), suggesting
that carrier mediated or active transport must play a role in the
cellular uptake of platinum(II) drugs (Andrews & Howell, 1990).
Recently, considerable evidence has been amassed to support protein-
mediated trans-membrane transport of cis-DDP (Gately & Howell, 1993;
Morikage et al., 1993). The exact nature of the cis-DDP transporter has
not yet been described but it appears to involve membrane-associated
tubulin (Christen et al., 1993). The fact that cis-DDP transport is
protein mediated implies that cells may effect resistance by down-
regulating the uptake of drug.1
Platinum(IV) compounds such as ACDDP are at least 5 orders of
magnitude more lipophilic than cis-DDP (Kelland et al., 1992b), a
characteristic that allows their passive diffusion through lipid plasma
membranes thereby facilitating entry into cells that fail to accumulate
cis-DDP. To give an example, when 41McisR human ovarian carcinoma cells
are treated with platinum(IV) compounds, the intracellular concentration
'A speculative mechanism has been proposed to explain how the
uptake of cis-DDP may be down regulated. Briefly, cis-DDP, being an
eukaryotic mutagen, could mutate the carrier protein to an inactive form
thereby abolishing transport of the drug into the cell (Gately & Howell,
1993). Evidence consistent with this model is the observation that a
gated channel protein is overexpressed on the membrane of cis-DDP
resistant murine lymphoma cell lines. This overexpression is postulated
to be an attempt to compensate for the functional loss of the channel
(if it had indeed been mutationally inactivated) which, in addition to
cis-DDP transport also plays other cellular roles (Kawai et al., 1990;
Gately & Howell, 1993).
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of drug reaches 100 fold higher levels than when the cells are dosed
with either cis-DDP or ACDP (Kelland et al., 1992a). As a consequence
of the higher intracellular drug concentration resulting from ACDDP
treatment, more DNA adducts form than when the cells are treated with
either platinum(II) compound. Assuming that the similarities between
cis-DDP and ACDP observed in the bacterial systems employed in this
thesis are predictive of their genetic effects in an eukaryotic system,
the platinum(II) metabolic derivatives of ACDDP, including ACDP, form
DNA adducts in tumor cells that have the same biological consequences as
cis-DDP DNA adducts. Therefore, it is plausible that the increased
number of DNA adducts that forms when cells are treated with the
platinum(IV) dicarboxylates (Kelland et al., 1992a), and not the
chemical properties of these lesions, that is responsible for the
greater sensitivity of tumor cells to ACDDP.
5. ACDP, a Cellular Metabolite of ACDDP, Forms DNA Adducts
a. DNA binding properties of platinum(IV) drugs
Once inside a cell, platinum(II) compounds such as cis-DDP lose
their chloride ions through hydrolysis covalently bind to DNA (Lippard,
1978) forming a variety of stable adducts (Eastman, 1983;
Fichtinger-Schepman et al., 1985). cis-DDP adducts inhibit DNA
replication in vitro (Pinto & Lippard, 1985b; Comess et al., 1992), and
in vivo both in bacterial (Alazard et al., 1982) and mammalian
(Ciccarelli et al., 1985; Heiger-Bernays et al., 1990) cells. This
inhibition of DNA replication results in cytotoxicity that is generally
accepted to contribute to the antitumor effects of cis-DDP.
Platinum(IV) compounds, on the other hand, are much more inert to ligand
substitution reactions (Hartley, 1973) and are expected to form DNA
adducts slowly, if at all (Kelland et al., 1992b). Platinum(IV)
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dicarboxylates, such as ACDDP, therefore, most likely function as
prodrugs that are reduced intracellularly, possibly by cellular
components such as protein sulfhydryls, glutathione or ascorbic acid
(Eastman, 1987; Gibbons et al., 1989), to form reactive platinum(II)
species (Blatter et al., 1984; van der Veer et al., 1986b). At least
six platinum(II) metabolites of ACDDP are produced in this manner
(Kelland et al., 1992b). The major metabolite in humans is cis-
ammine(cyclo-hexylamine)dichloroplatinum(II) (ACDP) .
ACDP binds to DNA in vitro to form a spectrum of adducts similar
to those formed by cis-DDP but with the notable exception that three
fold fewer adducts form at d(ApG) sites and about double the number at
d(GpNpG) sites (Hartwig & Lippard, 1992). Because these adducts block
DNA replication in vitro (Hartwig & Lippard, 1992), it seems likely that
ACDDP ultimately manifests its cytotoxic (and potentially
chemotherapeutic) effects by the same mechanisms employed by cis-DDP.
The toxicities of the drugs are examined in this thesis in vivo by
assessing the genotoxic effects of both cis-DDP and ACDP DNA adducts in
bacteriophage M13mp18 RF genomes in E. coli.
The genetic effects of DNA adducts formed by cis-DDP and ACDP are
influenced by two factors. First, the molecular processing of DNA
modified by both compounds is probably determined by structural
distortions of the duplex upon binding a square planar platinum(II)
compound (Bellon et al., 1991). Such compounds usually bind DNA at
similar nucleotide sequences, forming mainly 1,2-intrastrand crosslinks,
which lead to similar bending and unwinding of the duplex helix (Lippard
et al., 1983; Page et al., 1990; Hartwig & Lippard, 1992). Therefore,
1ACDP also is likely to be the major intracellular metabolite of
cis, trans, cis-ammine(cyclohexylamine)diacetatodichloro-platinum(IV),
another platinum(IV) compound with clinical aspirations (Kelland et al.,
1993).
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structural deformation of the DNA duplex is a major factor contributing
to the genotoxicity and mutagenicity of platinum DNA adducts, the
genetic effects of cis-DDP and ACDP would be expected to be very
similar. A second factor that could influence the biological effects of
platinum(II) compounds is the nature of the ligands attached to
platinum. In particular, the cyclohexyl ring of ACDP, a moiety absent
in cis-DDP, was predicted to have a significant impact on the molecular
and biological effects of this compound, as discussed below.
b. Mutagenic implications of the orientational isomerization exhibited
by ACDP DNA adducts
Unlike cis-DDP which is symmetrical, ACDP is asymmetrical owing to
its cyclohexyl ring. The asymmetry of the ACDP complex gives rise to an
interesting orientational isomerism when the complex forms 1,2-
intrastrand crosslinks with DNA (Hartwig & Lippard, 1992). As
illustrated in Figure 3 (a), with d(GpG) adducts the cyclohexylamine
ligand can point either toward the 5' or the 3' guanosine residue; both
orientational isomers form upon binding of the complex to DNA. It is
noteworthy that one of the isomers (II) potentially forms a favorable
hydrogen bond between the cyclohexylamine moiety of the drug and the 06
of guanine. With the d(ApG) adduct, by contrast, the analogous isomer
(IV, Figure 3 (b)) probably does not form, apparently because the
cyclohexylamine moiety sterically clashes with the exocyclic amino group
of the 5' adenine (Hartwig & Lippard, 1992). Thus the ACDP drug forms
fewer adducts at d(ApG) sites than cis-DDP. While cis-DDP forms an
adduct spectrum comprised of 65% G*G*, 25% A*G*, and 10% G*NG* adducts
the ACDP spectrum has approximately 58% G*G*, 8% A*G*, and 18% G*NG*
adducts, respectively. Because the ACDP spectrum has threefold fewer
highly mutagenic A*G* platinum adducts (this work, Burnouf et al., 1990;
Bradley et al., 1993), it is predicted that the overall mutagenicity of
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this compound would be lower than that of cis-DDP.
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Figure 3. Orientational isomerism of DNA adducts formed by ACDP at (a)
d(GpG) and (b) d(ApG) sequences. ACDP can bind to d(GpG) sequences with
the cyclohexylamine moiety oriented in either the 3' (I) or 5' (II)
direction. In contrast, the 3' orientational isomer (III)
preferentially forms at d(ApG) sequences as the 5' isomer (IV) forms an
unfavorable steric interaction between the cyclohexylamine moiety af
ACDP and the exocyclic amino group of the 5' adenine residue (adapted
from Hartwig & Lippard, 1992).
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D. Background of Experimental Systems Used in this Work
1. Site Specifically Situated versus Randomly Distributed DNA Adducts
Experiments with randomly modified DNA can provide insights into
the nature of the lesions most likely to play important roles in
genotoxicity and mutagenicity. In vivo survival assays with randomly
modified vectors allow one to determine the total number of adducts
required for a lethal event, and in vitro polymerase blockage
experiments can correlate sites of termination with putative sites of
modification. Therefore studies with randomly modified DNA, such as
those performed for cis-DDP and ACDP in this thesis, can implicate
lesions likely to be involved in mutagenesis. Such assays,
nevertheless, cannot definitively ascribe a specific genetic event to a
specific DNA adduct. Chemical synthetic and molecular biologic
techniques have made it possible to construct biologically active singly
modified genomes (Fowler et al., 1982; Green et al., 1984; Loechler et
al., 1984; reviewed in Basu & Essigmann, 1988). These tools can be used
to address the questions of what effect a specific adduct has on DNA
replication and mutagenesis, and what role DNA repair plays in
modulating those effects.
As mentioned, the multiplicity of DNA adducts formed upon treatment
of cells with DNA damaging agents complicates the identification of
lesions responsible for the genotoxic and mutagenic effects of the drug.
For cis-DDP, ACDP, or other drugs that form multiple lesions when
binding to DNA, it is highly desirable to assess the contribution of
each DNA adduct to overall biological activity. As mentioned
previously, if the genotoxic and mutagenic activity can be defined for
each adduct, it may be possible to use the information to guide the
development of safer and more effective drugs. A major focus of this
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ythesis was to perform a site specific comparison of the mutagenicity
and genotoxicity of the three major DNA adducts formed by cis-DDP.
a. Site specific modification of oligonucleotides
There are several methods for producing a site specifically
modified genome, and each requires the synthesis of an
oligodeoxynucleotide which contains a chemically modified nucleotide.
The three most common oligodeoxynucleotide synthetic strategies are:
(1) total synthesis, which involves the production of a modified
protected monomer that is used in the solution or solid phase synthesis
of the oligodeoxynucleotide, (2) chemical or physical modification of a
preformed oligodeoxynucleotide, and (3) enzymatic synthesis, in which
DNA or RNA polymerases are used to incorporate modified nucleotides into
the oligodeoxynucleotide. The total synthetic approach is often
preferred because it enables both the facile production of sufficient
amounts of material for full structural characterization, and it allows
for the placement of the adduct in any desired sequence context. The
choice of a method, however, depends on the chemical nature and
stability of the adduct or lesion to be studied. For example, some
adducts are unstable under the conditions required for total synthesis,
making this approach unfeasible with current technology. Similarly, the
treatment of a preformed unmodified oligodeoxynucleotide with a DNA
damaging agent may yield products too numerous to allow this approach to
be used effectively.
The modified oligodeoxynucleotided used for the work presented in
this dissertation were prepared by the second method described above,
i.e., by allowing an unmodified oligodeoxynucleotide to react with
cis-DDP. The sequences chosen, and the rationale for their selection,
will be presented in the next (Materials and Methods) section. The
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oligodeoxynucleotides were situated in a viral genome context by using
the methodology mentioned below and described in detail in the Materials
and Methods section.
b. Methods for constructing singly modified genomes
Modified oligodeoxynucleotides can be incorporated into the genomes
of viruses or plasmids in several ways. In one common method (Figure 4
(a)), the oligodeoxynucleotide is annealed to the single stranded genome
of a viral vector. The 3' terminus of the oligodeoxynucleotide then
acts as a primer for complementary strand synthesis by a DNA polymerase.
DNA ligase is used to seal the nick resulting from complete
complementary strand synthesis. This method has been used to construct
genomes containing site specifically situated thymine dimers (Huang et
al., 1992), psoralen DNA adducts (Kodadek & Gamper, 1988), and the cis-
DDP G*G* adduct (Szymkowski et al., 1992). A factor that limited the
usefulness of this approach in the present work is the secondary
structure present in M13 genomic DNA. M13 DNA assumes secondary
structure of sufficient stability to prevent efficient replication of
the M13 genome (Reckmann et al., 1985). The holoenzyme form of the T4
polymerase can be used to overcome secondary structure problems
associated with M13 replication (Kodadek & Gamper, 1988; Szymkowski et
al., 1992). Unfortunately the proteins comprising the T4 DNA polymerase
holoenzyme are not easily available in their native forms, further
limiting the usefulness of this method. An additional drawback of
contructing singly modified genomes by using this approach is the ds
nature of the construct produced. As discussed below, M13 ds genomes
are susceptible to strand replication bias effects that prevent a single
replication blocking adduct from being replicated during DNA synthesis.
Ideally, M13-derived ss genomes are preferred substrates for site
specific studies of replication blocking lesions.
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In a second method used to construct singly modified genomes
(Figure 4 (b)), a duplex genome is constructed in which one strand
contains a gap opposite a sequence that is complementary to that of the
modified oligodexoynucleotide to be used. The modified
oligodeoxynucleotide is annealed to the gapped duplex genome, and the
nicks on either side of the oligodeoxynucleotide are covalently joined
by DNA ligase. This method can be adapted to produce ss genomes by
engineering a non-ligatable nick in the strand not containing the
adduct. This strand can then be removed by heat denaturation. To give
two examples, this technique has been used to study arylamine adducts
(Reid et al., 1990) and 8-hydroxyguanine residues (Wood et al., 1990).
In some cases, yet another method is preferred for the construction of a
ss singly modified genome. This third technique, used in the present
work, involves the digestion and removal of the hairpin region of the
M13mp7L2 ss genome with EcoR I, followed by annealing and ligation of
the modified oligodeoxynucleotide into a gap formed with the aid of a
scaffold oligodeoxynucleotide, as outlined in Figure 4 (c).
2. M13 Bacteriophage
The vector used to study the mutagenesis induced by specific
cis-DDP adducts is the M13 system developed by Messing (1983) and
adapted for use in site specific genome construction by C. Lawrence and
coworkers (Banerjee et al., 1988; LeClerc et al., 1991). In addition to
the site specific genetic analysis of the cis-DDP G*G*, A*G*, and G*TG*
adducts, the same M13 bacteriophage system, with minor variations, was
used for a comparative assessment of the DNA binding spectra,
genotoxicities, and mutagenicities of cis-DDP and ACDP. The following
is a short description of the biology of the bacteriophage M13, and of
the relevant modifications made in the phage genome to facilitate its
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use as a cloning vector (Meyer & Geider, 1982; Messing, 1983; Zinder &
Horiuchi, 1985) and vehicle for the lacZ' mutational assay.
a. Life cycle and replication of M13
M13 is a ss F-specific filamentous bacteriophage that infects E.
coli harboring an F factor plasmid. During infection, the rod shaped
phage adsorbs to the F pilus of the host and the coat proteins are
removed as the circular (+) strand of DNA enters the cell. The phage
DNA is the template for synthesis of the complementary DNA (-) strand by
the host cell replication apparatus, producing a double stranded
replicative form (RF) molecule. The M13 RF serves as a template for
replication, by a rolling circle mechanism (Figure 5), and for
transcription of mRNA species encoding viral proteins.
The protein product of the M13 gene II is required for rolling
circle replication. It cleaves the (+) strand at a specific site, and
the 3' terminus thereby produced then acts as the primer for replication
by the host cell machinery. The 5'end of the (+) strand is displaced as
the apparatus moves around the (-) strand template. Once the
replication apparatus has returned to the origin, termination occurs
when the displaced (+) strand is cleaved and its 5' and 3' ends
subsequently are ligated to form a genome-length ss circle. The double
stranded RF is sealed and supercoiled, and can again serve as a
substrate for gene II and the replication apparatus. Early in
infection, the (+) strands formed are replicated to produce RF
molecules. Later in the infection process (after approximately 15-20
min), the cellular levels of the product of viral gene V, a single
stranded DNA binding protein, are high enough that all of the newly
displaced (+) strands are sequestered by the protein, and are thus
unable to enter the replication cycle. In this way a steady state level
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of 100-200 molecules of RF are maintained in the cell. The gene V
protein-coated (+) strands are translocated to the cell membrane where
the viral coat proteins are imbedded, and the DNA is packaged and
finally extruded from the cell. M13 does not lyse its host; the
"plaques" seen when the phage are plated are actually areas of slowly
growing infected cells.
Because the M13 bacteriophage is not packaged into preformed
capsids, but rather is encapsidated as it emerges from the cell, DNA of
almost any length can be packaged. The M13 genome also contains a small
intergenic "polylinker cloning" region into which DNA can be inserted
without adverse effects to phage viability. Messing (1983) took
advantage of both of these features for the development of a series of
M13 molecular cloning vectors.
b. Strand bias effects
The viability of bacteriophage M13 genomes in either the ds or ss
forms leads to an interesting, but noisome, phenomenon known as strand
bias. Strand bias effects arise from the ability of either strand of
M13 to give rise to progeny independent of the other strand. A
consequence of this mode of replication, is that a replication blocking
lesion in either strand can render that strand inactive, and direct the
formation of all progeny from the other, undamaged strand. A
replication blocking lesion in a ds M13 genome, therefore, would not be
replicatively bypassed and its genetic effects would not be exhibited.
This liability can be avoided by constructing a ss genome containing the
DNA lesion; with no undamaged strand present to serve as a template for
replication, the adduct must be replicated for the M13 genome to be
viable.
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3. The M13 lacZ' Forward Mutational Assay
a. Forward mutational assays
Forward mutational assays in non-essential genes have the ability
to detect a wide range of single-base substitutions, as well as other
classes of mutagenic events such as insertions and deletions at a large
number of sites. The high degree of sensitivity afforded by a forward
mutational assay was essential in order to detect subtle differences
that might exist in the mutational spectra of the two very similar
compounds, cis-DDP and ACDP, studied in this work. The lacZ' forward
mutational assay utilized in this study has been employed by others to
examine the mutagenicity of a variety of DNA damaging agents including
UV irradiation (LeClerc & Istock, 1982; LeClerc et al., 1984), singlet
oxygen (Decuyper-Debergh et al., 1987), oxygen radicals (Reid & Loeb,
1992), aflatoxin (Sahasrabudhe et al., 1989), N-acetoxy-N-acetyl-2-
aminofluorene (Gupta et al., 1991), ionizing radiation (Ayaki et al.,
1986; Hoebee et al., 1989), 4-aminobiphenyl (Lasko et al., 1988), and
apurinic/apyrimidinic (AP) sites (Kunkel, 1984). A survey of these
studies revealed that the lacZ' forward mutational assay is a sensitive
and broad target for the detection of mutations, with 141 single-base
substitutions detected at 98 different sites along with additional
additions and deletions.
b. Molecular basis of lacZ' mutational assay
The lacZ' forward mutational assay is based on a series of
proteins that have -galactosidase activity. Mutations that disrupt the
-galactosidase activity of these proteins are phenotypically identified
colorimetrically in the M13 plaque forming assay. Wild-type 3-
galactosidase encoded by the lacZ gene of the E. coli lac operon is a
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116,353 dalton, 1023 amino acid residue protein (Kalnins et al., 1983).
-galactosidase is enzymatically active as a tetramer. Certain strains
of E. coli are chromosomally deleted of the lac operon but carry the F'
lacIZ M15 episome that codes for production of the M15 protein. M15 is
a naturally occurring mutant of -galactosidase lacking amino acid
residues 11-41. The M15 protein exists as dimers in solution but are
unable to form tetramers, and despite have a strong substrate binding
site, lacks enzymatic activity (Langely et al., 1975).
The M15 protein attains -galatosidase activity in a process known
as a-complementation. Complementation, by definition, is the
restoration of biological activity by the non-covalent interaction of
two (or more) different proteins. In this case, a-complementation
involves two polypeptides, an a-acceptor and an a-donor as shown in
Figure 6. When the M15 protein functions as the a-acceptor, the a-donor
can be any of several peptide fragments containing the amino acids 11-41
that are deleted from M15; for example peptide fragments 3-92 or 3-41 of
wild-type -galactosidase (Welpy et al., 1981b). The -donor utilized
in the M13 lacZ' mutational assay is supplied by the lacZ' polypeptide
encoded by the modified M13 bacteriophage genome created by Messing et
al. (1983). The lac regulatory region and the first 146 amino acid
residues of the lacZ gene, produced by Hind II restriction of the E.
coli lac operon DNA, was inserted into the major intergenic region of
the M13 genome. The peptide coding region has been further elongated by
the addition of a polylinker cloning region in the "mp" series of M13.
For example, M13mp18, the construct used in the comparison of the
genetic effects of cis-DDP and ACDP DNA adducts in this dissertation,
contains an additional 18 amino acid residues so that the entire lacZ'
peptide fragment is 164 residues in length.
The M13 lacZ' polypeptide fragment, comprised of 164 amino acid
73
residues, is considerably longer than required for the a-complementation
process. As shown in Figure 7, the lacZ' polypeptide can be divided
into three regions, the N-terminal overlap, the M15 host deletion, and
the C-terminal overlap. It is well established that the overlapping
regions are not essential for a-complementation because the polypeptide
encoded by these DNA sequences is duplicated in the M15 a-acceptor
protein. The polypeptide chain required to attain -galactosidase
activity, therefore, can be supplied by either the M15 a-acceptor
protein or the M13 lacZ' a-donor polypeptide (Zabin, 1982; Welpy et al,
1981). The significance of these regions of the M13 lacZ' DNA sequence
to the mutational assay is that the N- and C-terminal overlapping
regions (Figure 7) are not expected to be as sensitive to the detection
of mutations as the lacZ' DNA sequence coding for the amino acids
deleted from the M15 a-acceptor protein. In addition, the lacZ'
regulatory region is also expected to give rise to detectable mutations.
Mutations in the ribosome binding site, for example, influence the
production of mRNA, resulting in expression of activity ranging from 1
to 130% of wild-type, depending on the mutation (Guillerez, et al,
1991).
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Figure 4. General methods used to construct site specifically modified
M13 based bacteriophage genomes. (a) A modified oligodeoxynucleotide
is annealed to a circular ss DNA template and acts as a primer for
synthesis of a complementary strand by T4 DNA polymerase. T4 DNA ligase
covalently seals the newly synthesized strand, resulting in a singly
modified, covalently closed circular (Form I) ds genome. (b) A
modified oligodeoxynucleotide is annealed into a "gapped heteroduplex"
genomic construct and its ends are covalently linked to the shorter of
the two genomic strands by using T4 DNA ligase. (c) In a variation of
the method outlined in (b), a modified oligodeoxynucleotide is annealed
into a "gap" created by the annealing of a "scaffold"
oligodeoxynucleotide into an EcoR I linearized M13mp7L2 ss genome. Once
again, the modified oligodeoxynucleotide is covalently joined to the
genomic DNA by using T4 DNA ligase. Details of all three methods are
described in the references given in the text, in addition, the last
method (c) was used to construct the singly modified cis-DDP G*G*, A*G*,
and G*TG* containing genomes used in this dissertation and is described
in detail in the Materials and Methods section.
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Figure 5. Outline of the life cycle of the M13 bacteriophage (from
Bradley, 1991). The natural infection of an E. coli cell by the ss
viral form of the M13 bacteriophage genome is shown. It should be noted
that, upon introduction into a cell by artificial methods (such as CaCl2
transformation or electroporation), both the viral (ss) and replicative
(ds) forms of the M13 genome are viable. Both forms of DNA were used in
this work; ss for the site specific analysis of the cis-DDP G*G*, A*G*,
and G*TG* DNA adducts and ds for the comparison of the genetic effects
of DNA adducts formed by cis-DDP and ACDP.
77
phag phage
.1 DNA
Packaging
(+)
host cell
replication
apparatus
gene V
late
host cell
replication
apparatus
<
early
gyrase
host cell
replication
apparatus
)
I.\ '
k+) V 
(+)
gene 11
rolling circle
78
1
(+)
, gyrase
gene 11
W
phage phage
(+)
Figure 6. Molecular basis of the lacZ' mutational assay. The lacZ' a-
complementation process restores -galatosidase activity to the M15
protein. When complemented with the wild type lacZ' polypeptide, the
M15 protein tetramerizes and attains -galactosidase activity that is
observed phenotypically by the cleavage of the X-gal prochromophore
resulting in the formation of blue plaques when plated with E. coli
GW5100 cells in the plaque forming assay. If the DNA sequence has been
mutated, the lacZ' polypeptide might not be synthesized (due to a
nonsense mutation in the coding region or by disruption of the
regulatory region upstream of the coding sequence) resulting in
colorless plaques. Alternately, the lacZ' polypeptide might be
synthesized, but be functionally compromised, resulting, once again, in
no -galactosidase activity (colorless plaques) or, in some cases,
diminished activity (light blue plaques). The lacZ' region of the
M13mp18 genome is depicted in greater detail in Figure 7.
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Figure 7. Functional regions of the lacZ' DNA sequence of the M13mp18
genome. Mutations can be detected in a 370 bp region of the lacZ'
sequence of the M13mp18 genome. This DNA sequence can be divided into
two regions: The regulatory region, containing the CAP binding site, -
35 promoter, operator, -10 promoter, and ribosome binding site, and the
lacZ' polypeptide coding sequence (See Figure 18 for more detail on the
exact DNA sequences involved). The lacZ' coding sequence can be divided
into 3 subregions: The N-terminal overlapping region, the M15 deletion
region, and the C-terminal overlapping region. Only the portion of the
lacZ' polypeptide (shown as the gray pie wedge) corresponding to the
amino aicds deleted from the M15 a-acceptor protein is required to
effect a-complementation. The N- and C-terminal overlapping regions of
the lacZ' polypeptide are duplicated in the M15 protein and are not
necessary for -galactosidase activity. As will be described (see
Discussion and Figure 20) the overlapping regions may in fact provide
steric constraints that prevent optimal complementation and result in
diminished enzymatic activity.
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III. MATERIALS AND METHODS
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A. Materials
Restriction endonucleases (except for Stu I and Sca I, from
Boehringer-Mannhein), T4 polynucleotide kinase and T4 DNA ligase were
purchased from New England Biolabs. Phosphatases and DNAses were from
Sigma. The E. coli cell lines used were: DL7 (AB1157; lacaU169, uvr+),
DL6 (DL7; uvrA) (Lasko et al., 1988) and GW5100 (JM103, P-, from G.
Walker, MIT). Bacterial culture media was from Difco Laboratory.
M13mp7L2 bacteriophage genomes were a gift of C. W. Lawrence (U. of
Rochester). Sequencing reagents were obtained from United States
Biochemical Corporation (Sequenase) or New England Biolabs
(CircumVentRT M). The oligodeoxynucleotides used as sequencing primers
were purchased from New England Biolabs or synthesized by the
Biopolymers Lab, MIT and purified by denaturing polyacrylamide gel
electrophoresis (PAGE).
Laboratory chemicals and reagents were purchased from
Mallinckrodt, with the following exceptions. [a-3 S]dATP (600 Ci/mmol)
was purchased from Amersham, [y-32P]ATP (6,000 Ci/mmol) was purchased
from New England Nuclear (DuPont). Acrylamide:bis-acrylamide (19:1),
TEMED, and ultrapureT phenol was purchased from BioRad. TRIS was from
Boehringer-Mannhein. IPTG and X-gal were purchased from Gold
Biotechnology (St. Louis, MO) or Biosynth International (Skokie, IL).
cis-DDP was purchased from Sigma and purified as described (Raudaschl et
al., 1983) and ACDP was synthesized as described (Hartwig & Lippard,
1992). DNA purification systems were from the QIAGEN or Promega
corporations. Oligodeoxynucleotides used in the construction of the
singly cis-DDP modified genomes were synthesized by using Applied
Biosystems reagents and a Model 381 DNA synthesizer.
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B. SOS-Induction of E. coli DL6 and DL7 Cells
The mutability of many bulky DNA adducts is an SOS dependent
phenomenon in E. coli. Since this work involved the study of such
lesions, it was essential to determine the conditions required to induce
the SOS response in the E. coli DL6 (uvrA) or DL7 (wt) cells that served
as hosts for the replication of platinum drug modified genomes. SOS
induction was achieved by irradiating the E. coli cells with uv light to
damage their chromosomal DNA. A recovery period allowed for the
expression of SOS proteins in response to this DNA damage. Platinum
modified M13mp18 genomes were transfected into the uv irradiated E. coli
cells. The occurrence of platinum induced mutations indicated that the
SOS response had been induced; this section describes the optimization
of conditions required for the induction of the SOS response in E. coli
DL6 and DL7 cells.
1. cis-DDP Modification of M13mp18 Bacteriophage Genomes
Purified cis-DDP was dissolved in TE by incubating at 37°C for 1
hour with frequent mixing. The purity and concentration of the drug
solution was determined by the uv-vis spectrum from 220-570 nm. Purity
was assessed by comparing the observed A301/A246 and A301/A348 ratios to the
expected values of 4.9 and 5.3, respectively. The molar concentration
of the cis-DDP solution was determined by the OD value at 301 nm with E
= 131 (Raudaschl et al., 1983). Modification of M13mp18 RF DNA was
achieved by incubating 5.2 pmole of DNA with 0, 5, 10, 15, 20, 50, and
100 fold molar excesses of cis-DDP in a 500 l solution of 3 mM NaCl,
0.5 mM Na2HPO4 and 0.5 mM NaH2 PO4 (pH 7.2) for 18 hours at 370C.
Platination reactions were terminated by the addition of NaCl to a final
concentration of 0.5 M. Unbound cis-DDP was removed by ethanol
precipitation of the DNA followed by two 80% ethanol washes. The amount
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of DNA recovered after precipitation and resuspension in TE buffer was
quantitated by An2 OD readings and the levels of cis-DDP bound to DNA (rb
values) were determined by flameless atomic absorption spectroscopy on a
Varian AA1475 instrument equipped with a GTA95 graphite furnace.
2. Transformation of E. coli with cis-DDP Modified M13mp18 Genomes
E. coli DL6 and DL7 cells were grown in 100 ml batches in Luria-
Bertani broth (Maniatis et al., 1989) to a cell density of approximately
108 cells/ml. Bacterial cells from each 100 ml culture were harvested
by centrifugation at 4000 g for 5 min at 40C, resuspended in 100 ml of
chilled water, and recentrifuged at 8000 g for 10 min. The cells were
then resuspended in 40 ml of water and a final centrifugation was done
at 13000 g for 10 min. The cells were resuspended in water to give a
final volume of 1.0 ml and kept on ice until needed. Unmodified genomes
as well as the M13mpl8 RF DNA modified with various levels (5.9, 11, 14,
20, 32, and 72 adducts per genome) of cis-DDP were used to transform the
prepared E. coli cultures by the process of electroporation. The cell
suspension (120 Al, about 109 viable cells) was mixed with 10 1 (10 ng)
of DNA and transferred to a prechilled electroporation cuvette. Cells
were electroporated in a BTX Electro Cell Manipulator 600 at 50 F, 129
Q, and 11.5 kV/cm. One ml of SOC media (Hanahan, 1985) was mixed with
the cell suspension following electroporation. A portion of the
transformed bacteria was plated immediately in the presence of E. coli
GW5100 cells, isopropylthio-3-D-galactoside (IPTG), and 5-bromo-4-
chloro-3-indoyl-p-D-galactoside (X-gal) (Messing, 1983) to obtain
independent infective center plaques that were counted to obtain
survival data. The remainder of the transformed bacteria was incubated
for 2 hours at 370C to allow for phage replication followed by
centrifugation at 17000 g for 10 min to pellet the cells. The phage-
containing supernatant was stored at 40C and later plated with E. coli
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GW5100 cells, IPTG and X-gal to obtain mutational frequency data.
3. UV Irradiation of E. coli DL7 Cells
E. coli DL7 cells' were grown in 100 ml batches in LB media to a
cell density of approximately 108 cells/mi. Cells from each 100 ml
culture were harvested by centrifugation at 4000 g for 5 min and
resuspended in 50 ml of 40C 10 mM MgSO4 and maintained on ice. The cell
suspension (25 ml) was pipetted into 150 mm diameter petri dishes. The
cells were exposed to uv irradiation at 1.1 - 1.2 J/m2 with gentle
shaking over a range of fluences from 5 to 80 J/m2. Further handling of
the uv irradiated cells was done under yellow lights to avoid reversal
of the uv-induced damage in their chromosomal DNA by photoreactivation.
An equal volume of 2x LB media, prewarmed to 37°C, was added to the
cells immediately after uv irradiation. The cells were incubated for 40
min at 370C to allow for expression of SOS proteins. Aliquots of cells
were plated on LB plates before and after irradiation to determine the
rate of mortality caused by the uv treatment. Subsequent preparation
for electroporation was done as described above for the non-uv
irradiated cells. M13mp18 RF DNA modified with 32.1 cis-DDP adducts per
genome, a level of modification determined to both allow the detection
of mutations and provide an adequate level of survival, as described
above, was electroporated into the E. coli DL7 cells (at 11.0 kV/cm)
that had been uv irradiated at fluences between 5 and 80 J/m2.
'These experiments were originally intended to be done in both E.
coli DL6 (uvrA) and DL7 (wt) cell lines. However, due to technical
limitations (to be discussed in the Results section), only the wild-type
DL7 cells were used in subsequent experiments.
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C. Site Specific Comparison of cis-DDP DNA Adducts
1. Preparation of cis-DDP Modified Oligodeoxynucleotides
a. Design of oligodeoxynucleotide sequence
The sequences of the oligodeoxynucleotides used in the site
specific comparison of the cis-DDP G*G*, A*G*, and G*TG* adducts were
chosen based on the following criteria:
i. The platinum binding site was chosen to be located in the
recognition site for a restriction endonuclease. The structural
distortion imposed on duplex DNA prevents restriction endonucleases from
digesting platinum-modified recognition sites. This feature is of aid
in the characterization of genetically engineered bacteriophage genomes
constructed with these oligodeoxynucleotides since platinum modified
genomes are refractory to digestion while their unmodified counterparts
remain susceptible to digestion.
ii. The restriction sites must be chosen to contain either the d(GpG),
d(ApG), or d(GpNpG) nucleotide sequence to allow formation of the G*G*,
A*G*, and G*NG* adducts, respectively.
iii. Drug induced mutations that occur within a restriction site render
the site refractory to digestion, a feature that is essential for the
selection of mutants. Restriction sites added by genetic engineering,
however, must not occur elsewhere in the M13mp18 genome so that the
selected sequences will form unique restriction sites, and allow
selection for mutants, as will be discussed further below. The
restriction sites selected were Stu I, d(AGGCCT), Sca I, d(AGTACT), and
ApaL I, d(GTGCAC) for formation of the G*G*, A*G*, and G*NG* adducts,
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respectively. One necessary drawback of this approach is its failure to
detect nontargeted mutations that fall outside the restriction site.
iv. A step in the construction of singly modified genomes involves
annealing the cis-DDP modified oligodeoxynucleotides to complementary
DNA templates. The significant structural distortion caused by platinum
binding to DNA requires that flanking regions be added to each side of
the drug-targeted restriction site to facilitate the annealing process.
The flanking regions must avoid nucleotide sequences (i.e. purines) that
compete for platinum binding; therefore, d(TCT) repeats were chosen.
Considering the above criteria, the following oligodeoxynucleotide
sequences were selected (containing the indicated restriction sites):
d(TCT TCT TCT AGG CCT TCT TCT TCT) - Stu I
d(TCT TCT TCT CTA GTA CTC TCT TCT) - Sca I
d(TCT TCT TCT GTG CAC TCT TCT TCT) - ApaL I
where the restriction sites are shown in bold and the potential sites
for platinum binding are underlined. The nomenclature used to describe
these oligodeoxynucleotides is Stu 24, Sca 24, and ApaL 24 for the
unmodified samples and Stu Pt, Sca Pt, and ApaL Pt for their platinated
counterparts.
b. Synthesis of Platinated Oligodeoxynucleotides
i. Synthesis of unmodified oligodeoxynucleotides
Oligodeoxynucleotides were synthesized on an Applied Biosystems
Model 381 DNA synthesis machine on a 10 mole scale by using -
cyanoethyl phosphoramidite chemistry (reagents from Applied Biological
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Sciences). After synthesis, oligodeoxynucleotides were deprotected by
incubating for 16 hr at 550C in concentrated ammonium hydroxide followed
by vacuum drying in a Savant speed-vac system. Oligodeoxynucleotides
were purified by polyacrylamide gel electrophoresis (PAGE).
Approximately 3.6 mg of crude material was resuspended in 0.5 ml 50%
formamide, heated for 2 min at 900C and run on a denaturing 35 x 43 x
0.15 cm 20% polyacrylamide gel. The gel was run at 1200 V for 9-12 hr
until the bromphenol blue dye migrated to the bottom of the gel. Full
length material, approximately comigrating with xylene cylanol dye, was
identified by uv shadowing on a fluorescent TLC plate and excised from
the gel. DNA was removed from the gel slices by the process of
electroelution by using AMICON's Centrieluter apparatus with Centricon-3
concentration devices. Following electroelution, TBE buffer and traces
of urea were removed from the samples by performing five washes with TE
(by performing repeated 2.0 ml to 100 l concentration centrifugations
in Centricon-3s at 5000g). Purified oligodeoxynucleotides were
quantitated by taking OD readings at 260 nm and the DNA concentrations
were determined from the extinction values of E = 211,600 for Stu 24, E
= 215,300 for Sca 24, and E = 211,600 for ApaL 24. The yield after
purification was typically 30-35%. Purified material was aliquoted and
stored at -800C until needed.
ii. Platination of oligodeoxynucleotides
cis-DDP was dissolved in TE to a concentration of about 2 mM. A
1.5 fold molar excess of cis-DDP was incubated with 50 M Stu 24, Sca 24
or ApaL 24 in TE at pH 7.4. Nitric acid was added to the Stu 24 sample
to reduce the pH to 5.2 in order to protonate the N7 position of the
adenine residue in the d(AGGCCT) Stu I recognition site. Such a
protonation directs selective modification of the d(GpG) site.
Reactions were allowed to proceed for 16-20 hr at 370C. Typically 50-
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70% of oligodeoxynucleotide was platinated. Reaction products were PAGE
purified as described in the previous section.
The purity of the 24-mers was monitored by 5' phosphorylation of
the oligodeoxynucleotides in conjunction with analytical PAGE.
Phosphorylation was done in a 30 Al reaction by using 20 units of T4
polynucleotide kinase with 0.05 g DNA and 25 Ci y-32P ATP and the
reaction buffer supplied with the enzyme. The reaction mixture was
incubated at 37C for 45 min followed by heat inactivation of the enzyme
at 68C for 15 min. Two Al of the phosphorylation reaction (with 2 Al
of formamide dye) was run on a denaturing 35 x 43 x 0.04 cm 20%
polyacrylamide gel at 1500 V until the xylene cyanole dye migrated to
within 5 cm of the bottom. The purity of the oligodeoxynucleotides was
determined by PhosphorImager analysis.
iii. Characterization of platinated oligodeoxynucleotides
Putatively cis-DDP modified oligodeoxynucleotides migrate slower
during PAGE than do their unmodified counterparts. Platinated
oligodeoxynucleotides can be treated with cyanide ions to remove the
cis-DDP DNA adducts as Pt(CN)4. Subsequent to cyanide treatment, the
deplatinated oligodeoxynucleotide should comigrate with unmodified
material, thereby confirming that the retarded migration was indeed due
to the presence of a platinum-DNA adduct. Cyanide treatment of Stu Pt,
Sca Pt, and ApaL Pt was done by incubating 0.02 g of 5' y-32P labeled
oligodeoxynucleotide in 0.3 M NaCN (pH=9.0) solution for 36 hours at
370C (Schwartz et al., 1990).
The cyanide treated oligodeoxynucleotides were run on denaturing
20% polyacrylamide gels with unmodified controls to confirm the removal
(and therefore the prior existence) of the cis-DDP adduct. Once the
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presence of a cis-DDP adduct was confirmed, further characterization was
done by enzymatically digesting the oligodeoxynucleotides to their
constituent deoxynucleosides. Digestion was done by combining 1.0 OD
unit of DNA in 50 mM NaOAc (pH=5.5), 20 mM MgC12 with 4,000 units of
DNAse I (Sigma) and 10 units P nuclease in 125 Al and incubating for 16
hours at 370C. Then, to dephosphorylate the monomeric deoxynucleotides,
25 Al 1.0 M TRIS (pH=9.0), 10 1 alkaline phosphatase (-10 units, Sigma)
and 1.0 Al calf intestinal phosphatase (-24 units, Boehringer Mannheim)
were added and incubation was continued for 4 hours. Deoxynucleosides
were resolved by reverse phase HPLC by using an Ultramex 5 micron 4 mm x
25 cm analytical column. Under these HPLC conditions, the nucleoside
standard dC eluted at 11.3 min, dG at 16.6 min, dT at 17.8 min and dA at
21.9 min on a 0-20% acetonitrile gradient over 40 min in 0.1 M ammonium
acetate buffer at a flow rate of 1 ml/min. A Pt(dG)2(NH3)2 standard
(from S. Bellon, MIT) eluted at 19.0 min. The identity of the
deoxynucleosides obtained from the digestion of the 24-mers was
determined by comparison of their elution time with that of
deoxynucleoside standards. The identity of the peaks was confirmed
further by spectral analysis by using a Hewlett-Packard 1040A (diode
array) Detection System. The relative abundance of each deoxynucleoside
was determined from the integration of peak areas, normalized by the
relative extinction coefficients of 15,400, 7,300, 11,700, and 8,800 for
dA, dC, dG, and dT, respectively.
2. Preparation of cis-DDP Modified Genomes
Bacteriophage M13-derived ss genomes containing the cis-DDP G*G*,
A*G*, and G*TG* adducts were constructed based on methodology described
by Banerjee et al. (1988) and outlined in Figure 8. Briefly, M13mp7L2
SS DNA was digested with the restriction endonuclease EcoR I to remove a
42 nucleotide hairpin structure, thereby creating a linearized ss
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genome. Scaffold oligodeoxynucleotides, 64 bases in length, were
annealed to the linearized genomes resulting in a 24 nucleotide "gap"
complementary to the platinated or unmodified 24-mers. 5'-
Phosphorylated 24-mers were annealed to their complementary sequence in
this gap and T4 DNA ligase was utilized to covalently incorporate the
platinated, or unmodified, oligodeoxynucleotide 24-mers into the M13 ss
genomes.
a. Scaffold oligodeoxynucleotides
Scaffold oligodeoxynucleotides were synthesized by the MIT
Biopolymers Laboratory and gel purified as previously described with the
exception that a 15%, instead of 20%, gel was used. The sequences of
the scaffold 64-mers are (underlined regions are complementary to the
indicated 24-mers, the flanking 20 nucleotides are complementary to
either end of the linearized M13mp7L2 ss genomes):
Stu 64 (complementary to the Stu 24 and Stu Pt oligodeoxynucleotides):
5'- AAA ACG ACG GCC AGT GAA TTA GAA GAA GAA GGC CTA GAA GAA GAC ACT GAA
TCA TGG TCA TAG C -3'
Sca 64 (complementary to the Sca 24 and Sca Pt oligodeoxynucleotides):
5'- AAA ACG ACG GCC AGT GAA TTA GAA GAG AGT ACT AGA GAA GAA GAC ACT GAA
TCA TGG TCA TAG C -3'
ApaL 64 (complementary to the ApaL 24 and ApaL Pt
oligodeoxynucleotides):
5'- AAA ACG ACG GCC AGT GAA TTA GAA GAA GAG TGC ACA GAA GAA GAC ACT GAA
TCA TGG TCA TAG C -3'
b. Preparation of linearized M13mp7L2 ss genomes
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M13mp7L2 phage were propagated in E. coli GW5100 cells grown in 2x
YT media and isolated by PEG/NaCl precipitation as described by Yamamoto
& Alberts (1970). Single stranded DNA was obtained from the phage by
multiple phenol:chloroform extractions followed by a chloroform
extraction. The M13mp7L2 DNA was purified further by elution through a
hydroxylapatite (Biorad DNA grade, batch 35354) column in buffer that
was 76 mM in Na2HPO4 and 76 mM in NaH2PO4 followed by dialysis into TE
with 4 buffer changes. One hundred and thirty pmole (312 mole)
M13mp7L2 ss DNA was digested by incubating with 4000 units of EcoR I for
2 hours at 230C in 50 mM NaCl, 100 mM TRIS (7.5), 5 mM MgC1 2 and 100
Ag/ml BSA. The extent of digestion was determined by running 0.5 g of
SS DNA on an agarose gel capable of resolving the circular and linear
forms of M13 viral genomes (Gel conditions: 1.0% agarose, run in TBE
buffer at 3 V/cm for 4-5 hours and then stained in 1.0 g/ml ethidium
bromide solution for 0.5 hour).
c. Phosphorylation of oligodeoxynucleotide 24-mers
The Stu 24, Stu Pt, Sca 24, Sca Pt, ApaL 24, and ApaL Pt
oligodeoxynucleotides were 5' phosphorylated by using T4 polynucleotide
kinase. Phosphorylation conditions were 280 pmole oligodeoxynucleotide,
1.0 mM ATP, x kinase buffer supplied with the enzyme and 30 units of
enzyme in 50 l incubated for 45 min at 370C followed by heat
inactivation of the enzyme at 680C for 15 min. The extent of
phosphorylation was not determined for these particular reactions
because the reaction conditions used previously had been demonstrated to
result in complete phosphorylation.
d. Annealing and ligation reactions
Scaffold oligodeoxynucleotides were annealed to the EcoR I
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restricted linear M13mp7L2 ss genomes by combining 5.6 pmole of the
bacteriophage genome with 560 pmole (a 100 fold excess) of either Stu
64, Sca 64, or ApaL 64 in a volume of 75 1. Annealing was effected by
heating at 800C for 15 min, incubating at 650C for 30 min followed by
cooling to 160C over 5 hours. The extent of annealing was analyzed by
running 1 g aliquots on an agarose gel as described above. Seven
replicas of each of the Stu 64, Sca 64, and ApaL 64 scaffold
oligodeoxynucleotide-genome mixtures were processed. One replica of
each set of seven served as a no oligodeoxynucleotide control, 0.56
nmoles (a 100 fold excess) of the appropriate unmodified 24-mers were
added to 3 replicas, and 0.56 nmoles of the respective platinated 24-
mers were added to the remaining 3 replicas. The phosphorylated 24-mers
were covalently ligated into the ss genomes by incubating with 1000
units of T4 DNA ligase (New England Biolabs) per sample in the buffer
supplied with the enzyme for 16 hours at 160C.
An alternate approach to genome construction was to add 11.2 pmole
(a 2 fold excess) of the appropriate 24-mer to the scaffold
oligodeoxynucleotide-genome mixtures before the annealing process. The
advantages of this methodology was that a much smaller excess of 24-mer
(2 fold vs. 100 fold) oligodeoxynucleotide could be used1 and the entire
annealing process was completed in a one step reaction. Accordingly,
'The advantages of using a greatly reduced amount of
oligodeoxynucleotide are twofold. First, from a practical perspective,
it is considerably easier to construct and characterize modified
oligodeoxynucleotide to be used in a 2 fold excess compared to the
amount required for a 100 fold excess. More importantly, purer genomes
can be constructed. To explain, if the oligodeoxynucleotide contained a
1% impurity, there would be sufficient amount of this contaminant to
ligate into all of the genomes if this material was used in a 100 fold
excess and it ligated into the genome much more efficiently than the
modified oligodeoxynucleotide. By contrast, if a 2 fold excess was used
with a 1% impurity, the maximum amount of impurity incorporated into the
genome would be 2%. My suspicions with regard to this latter point, the
purity of the resultant site specifically modified genome, have been
confirmed by another laboratory colleague, Elisabeth Bailey, who is
working with oligodeoxynucleotides containing aflatoxin adducts (E.
Bailey, personal communication).
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Stu 24, Stu Pt, Sca 24, Sca Pt, ApaL 24, or ApaL Pt
oligodeoxynucleotides were added in a volume of 20 1 and annealing was
performed as before.
e. Characterization of genetically engineered genomes
The genetically engineered, singly cis-DDP modified M13mp7L2 ss
genomes were characterized by heat denaturation to remove the scaffold
oligodeoxynucleotide. Heating at 900C for 2 min to remove the scaffold
resulted in a linear ss genome if either a 24-mer oligodeoxynucleotide
had not been ligated into its complementary "gap" or if it had only been
covalently attached at either its 5' or 3' end. Such linear M13 ss
genomes are biologically inactive. Conversely, if the 24-mer had been
ligated at both its 5' and 3' termini, a completely covalently closed
circular genome is formed that should remain circular after heat
treatment. These circular genomes were distinguished from the
incompletely ligated, linear genomes by agarose gel electrophoresis (as
described above) to provide an estimate of the ligation efficiency.
3. Genotoxicities of cis-DDP Modified Genomes
The genotoxicities of the cis-DDP G*G*, A*G*, and G*TG* adducts
were determined by transfecting the Stu Pt, Sca Pt, and ApaL Pt
M13mp7L2-derived genomes into bacterial cells in parallel with the
unmodified Stu 24, Sca 24, and ApaL 24 control genomes. Survival was
determined by counting the relative number of infective centers formed
by cis-DDP modified, compared to unmodified, genomes, in the M13 plaque
forming assay.
Transfection of the site-specifically cis-DDP modified genomes
into E. coli DL7 cells was done as previously described with minor
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differences. Immediately before electroporation 40 ng of each genome'
was diluted to 100 1 in water and heated at 900C for 2 min to remove
the scaffold and maintained on ice to prevent its reassociation. One
hundred 1 of cells was added to the heat treated DNA and the resulting
mixture was electroporated. Infective centers were plated to obtain
survival values that represented the genotoxicity of each adduct.
Survival was determined for genomes that underwent replication in both
SOS induced and non-SOS induced E. coli DL7 cells. Progeny phage were
grown and processed, as described below, to determine the mutagenicity
of each adduct.
4. Mutagenicity of Site-Specifically Modified Genomes
The mutagenicities of the cis-DDP G*G*, A*G*, and G*TG* adducts
were determined by analysis of progeny phage obtained from the
transfections, as described in the previous section, of the cis-DDP site
specifically modified genomes into E. coli DL7 cells (see Figure 9).
Progeny phage from multiple transfection samples were pooled and used to
produce RF DNA. The RF DNA was digested with the appropriate
restriction enzyme to enrich for genomes that had putatively platinum
induced mutations within the Stu I, Sca I, or ApaL I restriction sites
resulting from the cis-DDP G*G*, A*G*, or G*TG* adducts, respectively.
The digested DNA was transfected into E. coli DL7 cells in parallel with
uncut buffer control DNA (steps 3A and 3B, respectively, of Figure 9).
Putative mutation frequencies were obtained by counting infective center
plaques. Only mutant DNAs in the digested samples should remain uncut
'The relative amounts of cis-DDP modified and unmodified genomes
were determined by uv flourescence of the DNA electrophoresed in an
agarose gel in the presence of ethidium bromide as described by Bradley
et al. (1993). This method of quantitation had previously been
estimated to be accurate within 5%, which implies that between 38 and 42
ng of DNA would have been used in each replicate, a range of variability
that is negligible in view of the actual survival differences observed
between unmodified and platinum modified genomes (see Results section).
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and produce infective center plaques. By contrast, the DNA in the
buffer control samples should be 100% viable. The relative number of
plaques from the digested samples compared to the buffer control samples
represent putative mutation frequencies. The actual mutation
frequencies were obtained by sequence analysis of putative mutants. The
details of this process, used to determine the fraction of progeny that
is mutant, is described in greater detail below.
a. RF DNA preparations from progeny phage
Progeny phage from the transfection of cis-DDP G*G*, A*G*, and
G*TG* modified genomes as well as their unmodified counterparts into E.
coli DL7 cells were used to infect GW5100 cells to produce RF M13
genomic DNA. A single GW5100 colony was grown to saturation (about 14
hours) in 2x YT media. One ml of the cell culture was added to 100 ml
of 2x YT media followed by a 0.5 hour incubation at 370C. Approximately
106 phage representing each of 30-32 independent transfections were
combined for each of the Stu 24, Stu Pt, Sca 24, Sca Pt, ApaL 24 and
ApaL Pt M13 ss genomes that had been replicated in SOS-induced E. coli
DL7 cells. Similarly, phage were combined from 18-20 replicates for
each of the genetically engineered M13 ss genomes that had been
replicated in non-SOS induced cells. The pooled phage from each of
these samples was added to the pregrown 100 ml GW5100 culture and
incubated for 2.5 hours. An additional 100 ml of 2x YT media was added
and incubation was continued for another 2.5 hours. RF DNA was isolated
from the cells by using the QIAGEN 'midi' plasmid purification system.
Approximately 100 g of DNA was obtained from each preparation.
Typically the RF DNA was contaminated with fragmented chromosomal E.
coli DNA, ss M13 DNA and a -800 bp deletion mutant that necessitated
further purification.
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RF DNA was purified by agarose gel electrophoresis. One half of
each preparation (-50 g DNA in 0.5 ml TE, 0.1 ml 40% sucrose loading
dye) was run on a 200 ml (prepared in a 12.6 x 20.0 cm gel support) 0.8%
agarose gel with 0.5 g/ml ethidium bromide in TAE buffer at 3 V/cm for
4 hour. Covalently closed circular RF DNA migrated as supercoiled
material and was excised from the gel upon visualization with uv light.
The DNA was electroeluted from the gel into Centricon-100 devices and
desalted by performing five washes with TE (by repeated 2.0 ml to 100 1 l
centrifugation concentrations at 1000g in Centricon-100s). The DNA was
quantitated by taking A2, OD readings, typically a yield of 10 g was
obtained from each agarose gel.
b. Restriction digestion of M13 bacteriophage RF DNA
Gel purified RF DNA was digested with either Stu I (G*G* and GG
genomes), Sca I (A*G* and AG genomes), or ApaL I (G*TG* or GTG genomes).
Digestion conditions were 1.0 g RF DNA, 10 units enzyme, and 5.0 il of
the 10x buffer supplied with the enzyme in a total volume of 50 Al.
Digestion was done by incubating for 2 hours at 370C. In parallel,
buffer control samples, identical in composition but lacking enzyme,
were incubated. Digests were performed in quadruplicate on RF DNA
originating from each type of the site-specifically constructed genomes
that had been replicated in either SOS induced or non-SOS induced cells.
The extent of digestion was estimated by using agarose gel
electrophoresis.
c. Determination of mutation frequency
Putative mutation frequencies engendered by the cis-DDP G*G*,
A*G*, and G*TG* adducts were determined by parallel transfection of
digested and buffer control RF DNA into E. coli DL7 cells. Typically
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five ng of DNA per sample was transfected by the electroporation
methodology previously described. Infective center plaques were counted
to determine the relative survival of the digested and uncut DNA
samples. In the restriction digested samples, only DNA with a mutation
in the restriction site should remain uncut and be capable of producing
infective center plaques. To ensure that these plaques did indeed
represent mutants, plaques were picked and used to produce ss DNA
samples that were sequenced by using the dideoxy chain termination
method described by Sanger et al. (1977) with either primer P6285 or
P6331 shown in Table 2.
d. Determination of mutational specificity
The putative mutation frequencies determined by the relative
survival of digested and uncut DNA samples included any mutations that
occurred in the 6 bp restriction sites recognized by the Stu I, Sca I,
or ApaL I restriction endonucleases. To ascribe mutations to the cis-
DDP G*G*, A*G*, or G*TG* adducts specifically, it was necessary to
compile comprehensive mutational spectra for each of the restriction
sites from both platinated and unmodified genomes replicated in both SOS
induced and non-SOS induced E. coli DL7 cells. Preliminary DNA
sequencing analysis revealed the presence of wild type and parental
M13mp7L2 genomes. Further enrichment for mutants, therefore, was
desirable and entailed a second round of RF DNA preparations and
restriction endonuclease digestions. Progeny phage from the initial
transfection of digested DNA samples into E. coli DL7 cells was used to
obtain RF DNA by using the QIAGEN plasmid purification system as before.
The second round of restriction digests was done with a greater
enzyme:DNA ratio than initially used in order to eliminate any residual
wild-type genomes. EcoR I was included in the reaction to digest the
contaminating parental M13mp7L2 genomes. Reaction conditions were: 250
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ng RF DNA, 25-30 units of Stu I, Sca I, or ApaL I as appropriate, and
5.0 1 of 10x buffer supplied with the enzyme in a volume of 50 Al.
Incubation at 370C was done for 1 hour, and then 5 M NaCl was added to a
concentration of 125 mM along with 20 units of EcoR I. Incubation was
continued for another hour. The extent of digestion was estimated by
agarose gel electrophoresis. Transformation of digested DNA and buffer
controls into E. coli DL7 cells was done by electroporation as before.
Single stranded DNA grown from infective center plaques was sequenced to
determine mutations.
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Table 2. Primers used for sequencing of mutant DNAs and adduct mapping
of platinated genomes.
Primera Sequence
M6027 CCC GCG CGT TGG CCG ATT C
M6086 GCG GGC AGT GAG CGC AAC GC
M6209 AAC AGC TAT GAC CAT G
M6306 CAA CGT CGT GAC TGG G
P6285 GTA AAA CGA CGG CCA GT
P6331 AAG TTG GGT AAC GCC
P6507 CAG TAT CGG CCT CAG G
P6527 GTT TGA GGG GAC GAC
P6704 CCA ATA GGA AAC GCC ATC
a. M designates primers complementary to the (-) strand, P for those
complementary to the (+) strand; the number designates the 5' nucleotide
position that the primer anneals to in the M13mp18 RF genome.
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Figure 8. Method used to construct singly cis-DDP modified M13 ss
genomes based on methodology developed by C. Lawrence (Banerjee et al.,
1988; LeClerc et al., 1991). The cis-DDP G*G*, A*G*, and G*TG* adducts
(collectively represented as "Pt" in the diagram), along with unmodified
controls, were introduced into M13 ss genomes by using this method, as
described in greater detail in the text. The figure shows the alternate
approaches used in genome construction: A two step process (bottom)
involving preannealing the scaffold 64-mer followed by annealing and
ligation of the 24-mer or a one step (top) annealing reaction of both
the 64-mer and 24-mer followed by a ligation reaction.
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Figure 9. Method of mutational analysis. Singly cis-DDP modified M13
ss genomes were replicated in E. coli cells, progeny phage were isolated
and used to produce RF DNA. In the diagram, 1/4 (25%) of the RF DNA
molecules contain a mutation in the restriction site (bold) used for
mutational analysis. The putative mutation frequency, in this example,
after restriction digest, transfection into E. coli, and enumeration of
infective center plaques would be determined to be 25%. Sequence
analysis of the undigested RF molecules, in this example, revealed that
1/5 (20%) of the putative mutants is a genuine cis-DDP induced event.
The overall mutation frequency in this example is 5% (i.e. 25% x 20%).
*Wild type progeny are assumed to arise because of enzymatic
inefficiency at step 3A.
**Other non-specific mutant progeny are assumed to be either induced
spontaneously or by the genetic engineering manipulations used. These
mutations generally are present at frequencies < 0.1%.
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D. Comparison of the Mutagenicities, Genotoxicities, and
Adduct Distributions of cis-DDP and ACDP DNA Adducts
1. Random Platination of Bacteriophage M13mp18 RF Genomes
Platination of M13mp18 RF DNA was achieved by incubating 25 g of
DNA in 500 l solutions of 3 mM NaCl, 0.5 mM Na 2HPO4, and 0.5 mM NaH2PO4
(pH 7.2) with either cis-DDP or ACDP for 16 hours at 370C. In addition,
M13mp18 RF DNA was incubated under these conditions, but with neither
drug present, to serve as an unmodified control. The platination
reactions were terminated by the addition of NaCl to a final
concentration of 0.5 M. Unbound platinum was removed by ethanol
precipitating the DNA and washing twice with 80% ethanol. Levels of
platinum bound to DNA were determined by flameless atomic absorption
spectroscopy.
2. Transfection of Platinated M13mp18 RF Genomes
The cis-DDP and ACDP modified M13mp18 genomes were transfected
into E. coli DL7 cells by the electoporation methodology previously
described. Typically, 10 ng of platinated or unmodified RF DNA was
transfected into SOS induced or non-SOS induced cells. A portion of the
transformed bacteria was plated immediately in the presence of E. coli
GW5100 cells, IPTG, and X-gal to obtain infective center plaques that
were counted to determine survival or were isolated and used to produce
ss DNA that was subjected to sequencing analysis. The remainder of the
bacteria was incubated for 2 hours at 370C to allow for phage
replication. The resultant progeny phage were stored at 40C and later
plated to obtain mutation frequency data.
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3. Assay of -Galactosidase Activity
Ten ml cultures of E. coli GW5100 (2 X 109 cells) were infected
with 10l° wild-type or mutant M13mp18 phage and incubated for 0.5 hour at
370C. IPTG was added to a final concentration of 2 mM and incubation
continued for 60 min. Cell extracts were prepared by the method of
Wickner et al. (1972). -Galactosidase activity was measured by using
the ONPG (o-nitrophenol--D-galactopyranoside) assay described in
Maniatis et al. (1989) or in an assay employing CPRG (chlorophenol red
$-D-galactopyranoside) as the chromophore (Eustice et al., 1992).
4. Identification and Sequencing of Mutants
Mutations that led to the disruption of the a-complementation
process in the lacZ' mutational assay gave rise to phenotypically
distinct plaques in the M13 plaque forming assay. Mutant plaques were
distinguished from wild-type plaques by the intensity of the blue
chromophore produced by -galactosidase cleavage of X-gal. Putative
mutants were replated to verify phenotypic purity by a published method
(Kunkel, 1984). Single-stranded DNA derived from mutant plaques was
isolated and sequenced according to the method of Sanger et al. (1977)
by using primers P6331 and P6507 (Table 2). Mutations that occurred
more than once in an individual electroporation sample were not scored
to ensure that each mutant represented an independent event.
5. Replication Mapping of cis-DDP and ACDP DNA Adducts
Replication mapping of DNA adduct experiments were done by using
VentRTM(exo) DNA polymerase (New England Biolabs) with five M13mp18 RF
DNA samples (unmodified, cis-DDP at 12 and 35 adducts per genome, and
ACDP at 6.6 and 45 adducts per genome) and the primers shown in Table 2.
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Typical reaction conditions were 0.10 pmole RF template DNA, 3.0 pmole
primer, 20 iCi [(-35 S]dATP, 10 mM KC1, 10 mM (NH4)2SO4, 20 mM TrisHC1 (pH
8.8), 5 mM MgSO4, 0.1% Triton X, 60 M dATP, 300 M dCTP, dGTP, and
dTTP, with 5 units of VentRTM(exo') DNA polymerase. Reactions were
carried out in a Coy TempCycler II thermalcycler with a 2 min 95
0C
denaturation step, a 1 min 550C annealing step, a 1 min 72
0C primer
extension followed by a final denaturation step at 950C. In parallel,
unmodified M13mp18 RF DNA was sequenced by using the CircumVentTM (New
England Biolabs) thermal cycle dideoxy DNA sequencing methodology. The
DNA fragments generated in these reactions were separated by using
denaturing PAGE and quantitatively analyzed with a Molecular Dynamics
PhosphorImager. The values for the stop sites were normalized by the
method described in Figure 10 to take into account the additional [a-
35S]dATP molecules incorporated into longer fragments.
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Figure 10. Method for quantitation of stop sites used in the
replication mapping of cis-DDP and ACDP DNA adducts. (a) M13mp18 RF
genomes were digested with the restriction enzymes shown to generate a
set of linearized DNA fragments. A mixture, containing equimolar ratios
of each digestion product, was prepared and subjected to primer
extension reactions with each of the primers shown (and listed in Table
2) to generate several sets of primer extended fragments of defined
length (based on the distance from the primer to restriction site). The
fragments generated by each primer were separated by denaturing PAGE and
quantitated by use of a Molecular Dynamics PhosphorImager. (b) The
intensity of stop sites increased as a function of distance from the
primer due to additional incorporation of [a-35S]dATP. Although this
increase in intensity is a function of the thymidine content of the DNA
strand undergoing replication (the radiolabeled dATP is incorporated
opposite T's), a linear curve (y = -0.118 + 5.50*10 3x, R = 0.886) by
Cricket Graph (Cricket Software) fit the data well and was used to
normalize the intensity of the restriction mapping stop sites as a
function of their distance from primer.
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IV. RESULTS
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A. SOS Induction of E. coli DL7 cells
1. Transformation of E. coli with cis-DDP modified M13mpl8 RF Genomes
M13mp18 RF genomes that were incubated with cis-DDP were analyzed
by atomic absorption spectroscopy to determine the level of drug that
bound to the DNA. Platinum levels of 0, 5.9, 11, 14, 20, 32, and 72
adducts per genome were determined for RF DNA that had been incubated
with 0, 5, 10, 15, 20, 50, and 100 fold molar excesses of cis-DDP,
respectively. The plaque-forming ability of these genomes, when
replicated in either E. coli DL6 or DL7 cells, decreased in a dose
dependent manner as the level of cis-DDP adducts increased Figure 11).
In the repair proficient E. coli DL7 cells, a modification level of 32
adducts per genome reduced survival to about 0.1% compared to unmodified
genomes. This level of survival corresponded to approximately 100,000
independent infective centers per 10 ng of cis-DDP modified RF DNA. A
sample of this size was adequate to obtain statistically significant
mutation data; therefore, these genomes were used in the determination
of the uv dose necessary to induce the SOS response in E. coli DL7
cells. Not surprisingly, the genotoxicity of cis-DDP modified genomes
was much greater in the excision repair deficient E. coli DL6 (uvrA)
cells, as evidenced by the data shown in Figure 11.
2. UV Irradiation of . coli DL7 Cells
UV irradiation of E. coli DL7 cells' resulted in a dose-dependent
'Initially, these experiments were planned to be done with both E.
coli DL7 and DL6 cells. A number of technical factors made it difficult
to continue experimentation with the repair deficient E. coli DL6 cells.
First, cis-DDP modified genomes were so lethal in these cells that it
was unlikely that at levels of modification allowing for survival >1%
that there would be any lesions in the 370 bp lacZ' region of M13mp18
where mutations are detected. The chance of detecting mutations was
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decrease in survival. Only -5% of the cells were viable after uv
irradiation with a fluence of 80 J/m2 when treated by using the
experimental conditions described (Lasko et al., 1988; Bradley, 1991).
Survival increased significantly (Figure 12) when the cells were kept
chilled on ice until immediately before uv irradiation and prewarmed
(370C) 2x LB was added promptly after irradiation. M13mp18 RF DNA
modified with 32 cis-DDP adducts per genome was transfected into E. coli
DL7 cells that had been uv irradiated at various fluences up to 80 J/m2
and subsequently allowed to recover for 40 min to express SOS proteins.
Progeny phage were plated and mutants were phenotypically identified (by
using the lacZ' mutational assay that is described in detail elsewhere
in this dissertation). The mutation frequency as a function of uv dose
to the host E. coli DL7 cells is given in Figure 13. The mutation
frequency increased in an exponential-like manner up to -30 J/m2 and
remained relatively constrant to -60 J/m2. Due to the variability of
the data it was unclear if the apparent increase in the mutation
frequency between 60 and 80 J/m2 were a real result; regardless, the low
cell survival at 80 J/m2 (see Figure 12) precluded the use of cells
experiencing such high levels of irradiation. Practically, a fluence of
> 30 J/m2 was sufficient to achieve an adequate level of mutagenesis
while a fluence of < 40 J/m2 maintained high cell survival (Figure 12).
Accordingly, subsequent experiments utilized fluences of between 35 and
40 J/m2 to SOS induce E. coli DL7 cells.
further diminished by reports that UvrA, which is defective in E. coli
DL6 cells, is required for the mutability of cis-DDP DNA adducts.
Furthermore, induction of the SOS response required uv doses to the host
cell of <5 J/m2, fluences too low accurately reproduce (the apparatus
used for uv irradiating the cells was accurate within 2 J/m2, which is a
significant error range compared to 5 J/m2, but is manageable compared
to the higher doses of >30 J/2 used with the wild-type cells). These
factors made it improbable that a mutagenic evaluation of cis-DDP
adducts could be done successfully in the E. coli DL6 cells.
Nevertheless, the comparison of survival of cis-DDP modified genomes in
these two cell lines (Figure 11) offers insights into the molecular
processing of these adducts, as addressed in the Discussion section.
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Figure 11. Genotoxicity of cis-DDP modified DNA replicated in host E.
coli with various levels of repair proficiency. Survival of M13mp18 RF
genomes, modified with increasing levels of cis-DDP, was determined in
the M13 plaque forming assay. E. coli DL6 (uvrA) cells showed a
genotoxicity of 1.2 adducts/lethal hit, the comparable value for repair
proficient E. coli DL7 cells was 4.6 adducts/lethal hit. Upon induction
of the SOS response in the wild type cells (DL7), survival increased,
requiring 10 adducts/lethal hit.
116
100
10
1
0.1
0.01
0.001
0.0001
0 20 40 60 80
Platinum adducts per M13mpl8 RF genome
117
Figure 12. Survival of E. coli DL7 cells after uv irradiation.
Survival decreased in a dose-dependent, linear manner for cells that
were uv irradiated by using previously described methodology (Lasko et
a;!., 1988; Bradley, 1991). Optimization of the uv irradiation process
(as described in the text) resulted in enhanced survival at low levels
of uv irradiation (up to -40 J/m2). Above 40 J/m2 cell survival
decreased more rapidly (the curve approximating this response on the
diagram is a computer generated 3rd order polynomial having no physical
significance).
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Figure 13. Mutation frequency as a function of uv dose given to host E.
coli DL7 cells. M13mpl8 RF genomes modified with an average of 32 cis-
DDP DNA adducts were transfected into bacterial cells uv irradiated at
the indicated fluences up to 80 J/m2. The data were approximated by a
3rd order polynomial determined by Cricket Graph (Cricket Software; y =
0.000x3 - 0.052x2 + 2.511x + 0.597). The mutation frequency increased in
an exponential-like manner up to -30 J/m2 and remained constrant to -60
J/m2. Due to the variability of the data it was unclear if the apparent
increase in the mutation frequency between 60 and 80 J/m2 were a real
result; regardless, the low cell survival at 80 J/m2 (see Figure 12)
precluded the use of cells experiencing such high levels of uv
irradiation. Practically, a fluence of >30 J/m2 was sufficient to
achieve an adequate level of mutagenesis while a fluence of <40 J/m2
maintained high cell survival (Figure 12). Accordingly, subsequent uv
irradiation was done at fluences of 35-40 J/m2.
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B. Comparison of the Genotoxicities and Mutagenicities of
the cis-DDP G*G*, A*G*, and G*TG* DNA Adducts
1. Preparation of cis-DDP Modified Oligodeoxynucleotides
The Stu 24, Sca 24, ApaL 24 unmodified and the Stu Pt, Sca Pt, and
ApaL Pt cis-DDP modified oligodeoxynucleotides were characterized after
synthesis and gel purification. Greater than 99.7% of 5' y_32p labeled
Stu 24, Sca 24, and ApaL 24 unmodified oligodeoxynucleotides ran as a
single band on a denaturing 20% polyacrylamide gel (determined by
PhosphorImager analysis) indicating that these samples were of high
purity. The migration of the cis-DDP modified oligodeoxynucleotides was
retarded by about 6% on a 20% denaturing polyacrylamide gel, resulting
in a separation of 2 cm between platinum modified and unmodified samples
run on a 35 x 43 cm gel. This degree of separation allowed for
efficient gel purification of the modified oligodeoxynucleotides. Stu
Pt was >99.7% pure, Sca Pt about 99.4% homogenous, while ApaL Pt was
purified to approximately 98% homogeneity. None of the platinated 24-
mers were contaminated by a detectable amount (i.e. <0.05% by
PhosphorImage quantitation) of unmodified material. The -2%
contamination in the ApaL Pt sample migrated within 2 mm of the
putatively G*TG* modified oligodeoxynucleotide during denaturing PAGE
indicating that this material probably was cis-DDP modified at sites
other than G*TG*. This contaminant also coeluted under a variety of
HPLC conditions making it practically impossible to purify ApaL Pt to
greater than 98% homogeneity. It is interesting to note that these
impurities disappeared upon cyanide treatment of ApaL Pt, confirming
that they were a consequence of cis-DDP modification, possibly as
monoadducts and 1,2- or 1,4-intrastrand crosslinks. The identity of
this contaminant is explored further below.
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The purified oligodeoxynucleotides were characterized further by
HPLC analysis of their constituent monodeoxynucleosides. The base
composition analysis revealed that all of the 24-mers were of the
expected composition. A detailed description of the base analysis will
be included in this report only for the ApaL 24 and ApaL Pt
oligodeoxynucleotides, although all oligodeoxynucleotide 24-mers were
similarly analyzed.
Unmodified ApaL 24 oligodeoxynucleotide was digested in triplicate
and analyzed by using reverse-phase HPLC. Peaks were identified by
spectral analysis and comparison to monodeoxynucleoside standards. The
area of the peaks corresponding to each deoxynucleoside was integrated
and normalized based on its extinction coefficient, and then further
normalized based on the most abundant base, dT. The following data are
from the 3 ApaL 24 digests:
Base Expected ApaL 24 Data
dC 8 7.75 ± 0.13
dG 2 1.65 ± 0.10
dT 13 13
dA 1 1.15 0.10
The ApaL 24 oligodeoxynucleotide is of the expected composition when
values are rounded to the nearest integer. ApaL Pt should be identical
to ApaL 24 after treatment with cyanide to remove the cis-DDP G*TG*
adduct. This premise is supported by the observations that cyanide
treated ApaL Pt coelutes with ApaL 24 on reverse phase HPLC and
comigrates under denaturing polyacrylamide gel electrophoresis. Further
evidence that the two species are identical is derived from the
digestion and HPLC analysis of cyanide treated ApaL Pt (designated ApaL
Pt (C):
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Base Expected ApaL Pt (CN) APaL 24
dC 8 7.72 7.75 ± 0.13
dG 2 1.56 1.65 ± 0.10
dT 13 13 13
dA 1 1.08 1.15 0.096
The base composition values for the cyanide treated sample, ApaL
Pt(CN), are within the values previously established for the unmodified
ApaL 24 sample (previous page and right column above). These data
support the finding that the retarded mobility of cis-DDP treated ApaL
24 during gel electrophoresis is due to the presence of a platinum
adduct that was removed during the cyanide treatment. The identity of
this putative G*TG* adduct was confirmed by HPLC analysis of the
digestion products of ApaL Pt:
Base Expected ApaL Pt AnaL 24
dC 8 7.59 7.75 ± 0.13
dG 0 0.061 1.65 ± 0.10
dT 13 13 13
dA 2 1.03 1.15 ± 0.10
The disappearance of dG corresponded to the appearance of a new peak
that coeluted with a Pt(dG)2(NH3)2 standard (from S. Bellon, MIT),
indicating that most of the ApaL Pt oligodeoxynucleotide contained the
desired G*TG* cis-DDP adduct. The presence of a small dG peak, however,
reinforced the PAGE observation that this oligodeoxynucleotide contained
- 2% impurity (i.e. not all of the dG was cis-DDP modified, allowing
some monomeric dG to form. No monomeric dG, and therefore no dG peak,
would be expected from a sample containing 100% G*TG*). The observation
that there was slightly less than expected dC and dA (0.04 for dC and
0.02 for dA based on the ApaL Pt data compared to the ApaL 24 data)
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suggested the nature of the impurity in the ApaL Pt
oligodeoxynucleotide. The "missing" dC and dA could be due to the
presence of cis-DDP 1,2 G*C*, 1,4 G*TGC*, and 1,3 G*CA* intrastrand
crosslinks.
The composition of the 2% impurity contaminating the ApaL Pt
oligonucleotide was explored by polyacrylamide gel purification of
material running close (within 5 mm) to the band containing the desired
G*TG* adduct. This material (denoted as ApaL Pt'), after 5' y-32p
labeling, ran as a smear on an analytical gel, suggesting that it is a
mixture of several cis-DDP intrastrand crosslinks. Digestion and HPLC
analysis showed significant, but less than expected, modification at dG
positions:
Base Expected AnaL Pt' ADaL 24
dC 8 6.94 7.75 i 0.13
dG 0 0.39 1.65 ± 0.10
dT 13 13 13
dA 1 0.78 1.15 ± 0.10
In parallel with the appearance of unmodified dG (0.39), 0.81 fewer dC's
and 0.38 fewer dA's were observed than expected based on the previous
analysis of ApaL 24. This analysis is consistent with the previous
hypothesis that the observed impurities are 1,2 G*C*, 1,4 G*TGC*, and
1,3 G*CA* cis-DDP adducts.
The Stu 24, Stu Pt, Sca 24, and Sca Pt oligodeoxynucleotides were
subjected to similar (but less extensive due to the absence of
detectable levels of impurities) analysis and determined to be of the
desired base and adduct composition. Even further confirmation that
these samples were of the intended composition was obtained, somewhat
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indirectly, after the oligodeoxynucleotides were incorporated into M13-
derived SS genomes. Replication of these genomes in E. coli resulted in
progeny that were subjected to DNA sequencing. In all cases the progeny
contained sequences corresponding to the putative oligodeoxynucleotide
sequences, once again confirming the composition of the cis-DDP modified
and unmodified oligodeoxynucleotide 24-mers.
2. Preparation of Singly cis-DDP Modified M13 SS Genomes
Bacteriophage M13-derived ss genomes containing the cis-DDP G*G*,
A*G*, and G*TG* adducts were constructed based on the methodology
outlined in Figure 8. Scaffold oligodeoxynucleotides were purified to
>95% homogeneity, with only a small amount of contaminating 63-mer and a
trace of 62-mer present. Based on previous work (Banerjee et al., 1988)
this level of purity was within acceptable limits to allow the scaffold
oligodeoxynucleotides to be utilized for genome construction.
EcoR I digestion of M13mp7L2 ss genomes resulted in complete
conversion of circular DNA to the linear form as determined by agarose
gel electrophoresis. Annealing of the Stu 64, Sca 64 or ApaL 64
scaffold oligodeoxynucleotides to the linearized ss genomes restored
about 50% of the material to the circular form. This circular material
apparently had both ends of the scaffold annealed to the respective ends
of the linear genomes with a 24 nucleotide gap complementary to the 24-
mers in between. 5'-Phosphorylated Stu 24, Stu Pt, Sca 24, Sca Pt, ApaL
24 and ApaL Pt were ligated into genomes containing their respective
complementary sequences. The ligation reactions were determined to be
highly efficient, with essentially all of the 50% of the material that
was in the circular form after the scaffold/genome annealing process
remaining circular even after the scaffold oligodeoxynucleotides had
been removed by heat denaturation. These genomic constructs could only
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remain in the circular form if the 24-mers had been covalently
incorporated into the linear genomes at both their 5' and 3' termini.
In contrast, all of the originally circular material was converted back
to linear form after heat denaturation of the scaffold in samples that
were subjected to ligation conditions, but without 24-mer present. This
control ensured that ligation across the 24 nucleotide gap did not occur
under the conditions used, ensuring that the 5' and 3' ends of the
linearized M13mp7L2 genomes did not religate.
A test transformation was performed to demonstrate that linear M13
ss genomes were biologically inactive and therefore incapable of
producing progeny in E. coli DL7 cells. Portions of the ligation
reactions done without 24-mer present were linearized by heat
denaturation and transfected into E. coli DL7 cells in parallel with
control samples comprised of DNA from samples where the ligation was
done with unmodified 24-mer present. Infective center plaques were
counted to ascertain the relative biological activity of the linear and
circular genomes. The linear genomes formed only 0.05-0.2% as many
plaques as the unmodified circular genomes. DNA sequence analysis
showed that the plaques from this putatively linear DNA arose from a low
level of contaminating parental M13mp7L2 genomes that remained uncut
during and EcoR I digest and undetected during the agarose gel
electrophoresis that had been used to assess the extent of the EcoR I
digestion. No progeny were found that were derived from the EcoR I
linearized form of M13mp7L2 DNA. From the number of plaques sequenced,
combined with the survival of the linearized DNA, it was estimated that
the linear ss genomes had a plaque forming ability at least 105 fold
lower than the circular form of the genome. These results demonstrated
that the genetically engineered genomes could be used without further
purification, since only the desired product, a circular genome with a
24-mer covalently ligated at both ends, was biologically viable.
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3. Genotoxicities of Singly cis-DDP Modified M13 SS Genomes
The genotoxicities of the cis-DDP G*G*, A*G*, and G*TG* adducts
were determined by transfecting the Stu Pt, Sca Pt, and ApaL Pt M13
derived ss genomes' into E. coli DL7 cells in parallel with equal
amounts of the unmodified Stu 24, Sca 24, and ApaL 24 genomes.
Initially, survival values were determined separately for genomes made
with either a 2-fold or 100-fold excess of the 24-mer
oligodeoxynucleotides (See Figure 8). Results from these experiments,
done in non SOS induced E. coli DL7 cells reveal no differences between
genomes constructed by either methodology (Figure 14).2 Therefore, no
further distinction was made between results obtained by using genomes
constructed by either method. Survival was also determined for the cis-
DDP modified and control genomes replicated in SOS induced cells.
Results for toxicities under SOS conditions, compared with the data from
the non SOS induced samples, are given in Figure 15. Without SOS
induction, the G*G* adduct was the most genotoxic lesion with a survival
of only 5.16 + 1.15% compared to unmodified genomes. Genomes containing
the G*TG* adduct had a 2.5 fold higher survival at 13.5 + 2.5% while
survival for A*G* containing genomes was even higher at 21.6 + 2.6%.
Upon SOS induction, survival for genomes with G*G* and A*G* cis-DDP
adducts increased to about the same absolute level, 30.8 + 5.4% and 32.4
'The nomenclature of the site-specifically cis-DDP modified genomes
and their unplatinated counterparts is as defined in the list of
abbreviations.
2As previously mentioned, if the platinated 24-mer
oligodeoxynucleotides were contaminated with unmodified 24-mers, the
unmodified material might be incorporated in the M13 genomes more
efficiently than the platinated 24-mers. To give an example, if an 100-
fold excess of 24-mer was used, a 1% unmodified contaminant
theoretically could be incorporated into 100% of the genomes, but only
into 2% if the genomes if a 2-fold excess of 24-mer was used. Since no
differences were observed between genomes made by either method,
however, it is reasonable to assume that the cis-DDP modified genomes
were not contaminated with unplatinated material. This conclusion is
consistent with the analysis that showed that the platinated 24-mers
contained <0.03% of unmodified material.
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± 4.9%, respectively. The relative increase in survival, however, was
much higher for the G*G* adduct (-6 fold) than for the A*G* adduct (0.5
fold). Interestingly, survival was not enhanced upon SOS induction for
the G*TG* adduct, remaining at 14.4 + 3.7%, a value not significantly
above the 13.5 + 2.5% survival seen for replication in non-SOS induced
cells.
4. Mutagenicities of Singly cis-DDP Modified M13 SS Genomes
The mutation frequencies of the cis-DDP G*G*, A*G*, or G*TG*
adducts situated in genomes replicated in either SOS induced or non-SOS
induced E. coli DL7 cells were determined in parallel with unmodified
control genomes. Putative mutation frequencies, determined after the
restriction digest mutation selection scheme (Figure 9), are listed in
Table 3. As anticipated from the results of previous studies, the
highest mutation frequencies were obtained from cis-DDP modified genomes
replicated in SOS induced cells. The putative mutation frequencies for
cis-DDP modified genomes were much lower when replicated in non-SOS
induced cells, as was the situation for unmodified genomes replicated in
either SOS induced or non-SOS induced cells.
Only samples that contained a single (or in some cases tandem)
base changes in the six nucleotide restriction sites were scored as
putative mutants. Samples not scored as putative cis-DDP induced
mutants fit into one of five categories:
a. M13mp'7L2 contaminating parental genomes from incomplete EcoR I
digestion
b. "Wild type" genomes corresponding to the sequence of the
genetically engineered constructs
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c. Large (-800 bp) deletions of a specific composition
d. Variable, mid size (-30-80 bp) deletions, generally lacking
the entire sequence corresponding to the 24-mer and varying
lengths of the adjacent DNA sequence
e. A specific 15 bp deletion consisting of the restriction site
and one of the flanking d(TCT TCT TCT) sequences
The parental M13mp7L2 and "wild type" genomes were present at
frequencies up to 1%, the various deletions were less abundant,
occurring at frequencies less than 0.1%.
The identification of a large number of mutants, from both cis-DDP
modified and unmodified samples, was required to determine which
mutations were platinum induced as compared to those arising
spontaneously. To facilitate the identification of mutants, a second
round of selection was done to enrich for the desired base pair
mutations occurring within one of the Stu I, Sca I, or ApaL I
restriction sites. The RF DNA preparations, restriction digestions,
transfections and sequencing of infective center plaques was done as in
the initial selection process with a modification of the restriction
digest step. EcoR I was added to the digestion reactions to remove
contaminating M13mp7L2 genomes. A larger excess of the selection enzyme
(Stu I, Sca I, or ApaL I) was used to ensure complete elimination of any
residual wild type genomes. Sequencing after this second round of
selection yielded from 90% to over 99%, depending on the sample, of the
desired restriction site mutants. The remainder of the samples was the
large (c, above) or 15 bp (e, above) deletion mutants. These genomes
lacked the requisite restriction sites and were refractory to cutting
and, therefore, could not be selected against during the digestion
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reactions. By contrast, the mid-sized (d, above) deletion mutants
retained at least one EcoR I site1 and were eliminated along with the
residual wild type and parental M13mp7L2 genomes.
The relative abundance of the various mutations seen in the Stu I,
Sca I, or ApaL I restriction sites are given in Table 4 a, b, and c,
respectively. Genomes containing either cis-DDP G*G* or A*G* adducts
that were replicated in SOS induced cells experienced significantly
enhanced frequencies of specific mutations that occurred at the site of
cis-DDP modification. For example, 75% of the 81 mutants identified in
the G*G* spectrum (Table 4 (a)) were G T transversions at the 5' dG of
the d(AGGCCT) sequence suggesting that these mutations were a
consequence of cis-DDP modification. Additionally, tandem mutation of
the d(ApG) nucleotides of the Stu I recognition sequence to d(TpT) and
d(CpT) was adduct specific, albeit at a much lower frequency. The
combined cis-DDP induced mutations occurred at a frequency of 1.39%
(Table 5). Similarly, mutations occurring in A*G* genomes replicated in
SOS induced cells were highly targeted, with 65% of the 100 mutants
identified consisting of A - T transversions at the 5' base of the A*G*
adduct (Table 4 (b)). Also similar to G*G*, a tandem d(TpA) d(CpT)
double mutation was adduct specific; it only appeared in cis-DDP
modified genomes replicated in SOS induced cells. Less definitive is
the A G transition that is 2.7 fold more prevalent in the modified
samples (at 16%) than in the unmodified samples (at 5.9%). Considering
the A G transition to be platinum specific,2 the A*G* adduct produced
1The presence of the EcoR I site indicated that these deletion
mutants were progeny of undigested M13mp7L2 parental genomes (a, above).
2An A G transition arising at the 5' nucleotide of the cis-DDP
A*G* was also observed at approximately the same relative abundance in
another site specific study (Burnouf et al., 1990 - see Discussion for
detail). It should be noted that if the 5' nucleotide of a cis-DDP 1,2
intrastrand crosslink does have a propensity to induce N G mutations,
these mutations would not be observed for the G*G* adduct (i.e. G - G is
not a mutation) and would only show up in the mutational spectra of
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a 5.98% mutation frequency. The data summarizing cis-DDP induced
mutations are given in Table 5.
By contrast to the mutational spectra induced by the cis-DDP A*G*
and G*G* containing genomes, the mutational spectrum arising genomes
containing the cis-DDP G*TG* adduct that had been replicated in SOS
induced E. coli DL7 cells showed no targeted mutations. As can be seen
from Table 4 (c), the most abundant mutation, 23% of the total 143
samples analyzed, was a C T transition at the 5' dC of the d(GTGCAC)
sequence. This mutation was even more prevalent (at 29%) in the
unmodified spectrum, suggesting that it was not cis-DDP induced.
Additionally, no mutations occurred at the cis-DDP modified dGs at a
rate significantly higher than in the control mutational spectra. It is
clear that the cis-DDP G*TG* adduct is not mutagenic under cellular
conditions that induce high mutation frequencies for the cis-DDP G*G*
and A*G* adducts.
Control experiments were done in which platinated genomes were
replicated in non-SOS induced E. coli DL7 cells. In addition,
unmodified genomes were replicated in both SOS induced or non-SOS
induced cells. The results of these experiments (Table 4 a, b, and c,
bottom three panels) revealed mutations that were broadly distributed
with no apparent pattern that would indicate that the observed mutations
were induced by the cis-DDP DNA adducts. The platinated samples did not
experience a significantly greater occurrence of mutations at the bases
modified with cis-DDP than at any other base within the restriction
sites. In fact, the platinated and unmodified genomes produced similar
mutational patterns, suggesting that these background mutations
(occurring at the frequencies indicated in Table 5) were likely a
A*G*. Considering these two factors, this A G transversion was
deduced to be a legitimate platinum induced mutation.
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consequence of the genetic engineering processes used to construct the
singly modified genomes. These control experiments also confirmed that
cis-DDP mutagenesis is an SOS dependent process in E. coli.
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Table 3. Putative mutation frequencies induced
or G*TG* adducts
by cis-DDP G*G*, A*G*,
Restriction cis-DDP SOS MFb after Mutants/ Adjusted
Sitea modified induced digestion Totalc MFd
AGGCCT + + 5.1 % 11/32 1.7 %
- + 1.4 % 8/32 0.35%
Stu I + - 0.75% 19/56 0.25%
- - 0.12% 15/38 0.05%
AGTACT + + 9.1 % 24/32 6.8 %
- + 1.3 % 2/32 0.08%
Sca I + 1.3 % 5/32 0.20%
- - 1.2 % 0/30 < 0.04%
GTGCAC + + 4.1 % 41/128 1.3 %
- + 2.9 % 4/32 0.36%
Apal I + - 0.89% 25/32 0.70%
- - 0.88% 26/32 0.72%
a. The restriction recognition sites containing the three cis-DDP DNA
adducts (underlined) are shown.
b. After digestion with the appropriate restriction enzyme only mutated
sequences should be viable and give rise to progeny, the proportion of
these species are given in relation to undigested controls. In theory,
these values would be the platinum induced mutation frequencies (MF),
but, in practice they may include nonspecific mutations or wild type
sequences that escaped selection (for a more detailed discussion, see
text and Figure 9).
c. Putative mutants from (b) were sequenced. The numbers given are the
number of mutants per total number of independent replicas analyzed by
sequencing.
d. The adjusted MF is equal to the putative mutation frequency from (b)
multiplied by the fraction of mutants detected in (c). It should be
noted that the adjusted MF includes all single (and double) base pair
changes detected in the restriction sites. Mutation analysis was
performed as described in Table 4 and Table 5 to determine cis-DDP
induced mutations.
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Table 4 (a). Relative abundance of mutations induced by the cis-DDP
G*G* adduct.a T A G G C C T
SOS(+) A 4 .9 1.2 1.2
Pt'd C 1.2 2.5 2.5 
G __
(n=81) T 3.7 75 25
A 1.2
otherb T(C) -T 2 5 CCT 1.2
SOS(+) A 6.4 3.2 4.8 4.8
Unmod. C 4.8 9.5 1.6 3.2 4.8
G 1.6 4.8 4.8
(n=63) T 4.8 4.8 7.9 4.8 4.8
A 3.2 9.5 9.5 1.6
other =_
SOS(-) A _____ 16 5.3 
Pt'd C 32 21 
G 5.3 
(n=19) _T .5.. 11 :
A 5.3
other
Unmod. C 17 5.2 6.9 II"~ . 1.7
G 1.7 7 1.7
(n=58) T 6.9 52 35 86 
A 5.2 8.6 12
other | +C 1.7
........ ,, I 'I I;L' '"'. ,. . .......
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Table 4 (b). Relative abundance of mutations induced by the cis-DDP
A*G* adduct.
T A G T A C T
SOS(+) A 1 0 ____ _____Ez. 1.0
Pt'd C 4.0 _____1~~~ .0
G 16 ll
(n=100) T _________ 65 ___________ _ _ 4.0 i
A = === 1.0
other C-T 7.0
SOS(+) A | 14 3.9 2.0 5.9
Unmod. C 5.9 _ 18 5.9 3.9
G 5.9 _____ 3.9 2.0
(n=51) T 14 = _ 2.0
A 5.9 2.0
insertion 2.0 2.0
SOS(-) A lms 7 9 79 __I___ 
Pt'd C 5.3 7.9 11
(n=38) T m:.:::: 5.3 9 7. m
A 11 2.6 7.9 5.3 18
other
SOS(-) A |____ 29 ____
Unmod. C _ ~14 29 9 _______
(n=) T 
~1A 2 29
other
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Table 4 (c). Relative abundance of mutations induced by the cis-DDP
G*TG* adduct. T G T G C A C
underlined bases, is given in large type across the top of the table.
Mutations observed in this DNA sequence after replication in SOS induced
or non induced cells are indicated in the boxes below th sequence. The
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numbers given are the relative proportion of each mutation observed,
given as a percentage of "n" (where n = the total of all mutations
determined for each panel).
b. Both the d(GpC) and d(CpA) sequences were mutated to d(TpT) at the
indicated frequencies.
c. Both the d(GpC) and d(CpA) sequences were mutated to d(TpT) at the
indicated frequencies.
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Mutations induced by the cis-DDP G*G*, A*G*, and G*TG*
A G* G* C C T
T 1.31 %
0.044 %
0.044 %
Background Mutation Frequencies
SOS(+) Platinated: 0.35%
Unmodified: 0.35%
SOS(-) Platinated:
Unmodified:
0.25%
0.05%
1.39 %
T A*G*T A C Background Mutation Frequencies
SOS(+) Platinated: 0.82%
T 4.42 %
G 1.09 %
Unmodified:
SOS(-) Platinated:
0.48 % Unmodified:
5.98 %
G* T G*C A C
No cis-DDP induced
mutants observed
SOS(+) Platinated:
Unmodified:
SOS(-) Platinated:
Unmodified: 0.72%
a. Mutations were determined to be cis-DDP induced by analysis of the
mutational spectra presented in Table 4. Mutations that occurred at a
significantly higher frequency at or near the site of platinum
modification in the SOS(+) cis-DDP modified samples compared to the
unmodified and SOS(-) samples were deemed to be drug induced. The
remainder of the mutations were nonspecific events comprised the data
indicated under "Background Mutation Frequencies.".
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Table 5.
adductsa
T--T
C--T
Total:
C--T
Total:
0.08%
0.20%
< 0.04%
Background Mutation Frequencies
1.31%
0.36%
0.70%
Figure 14. Survival of singly cis-DDP modified M13 ss genomes in non-
SOS induced E. coli DL7 cells. The survival of genomes constructed with
either a 100-fold or 2-fold excess of 24-mer oligodeoxynucleotide was
determined by using the M13 plaque forming assay. The values given,
relative to unmodified control genomes and including 11-12 replicas per
data point, indicate that no differences exist between genomes made by
either method. In subsequent experiments no distinction is made between
either type of genome.
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Figure 15. Survival of singly cis-DDP modified M13 ss genomes in SOS
induced, or non induced, E. coli DL7 cells. Survival values were
determined in the plaque forming assay and are relative to unmodified
control genomes. The data for the non SOS induced cells are pooled
values of the results shown in Figure 14 with 23-24 replicas per sample.
The data from the SOS induced samples is the average of 40-42 replicas.
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C. Comparison of the Mutagenicities, Genotoxicities and
Adduct Distributions of cis-DDP and ACDP DNA Adducts
1. Survival of cis-DDP and ACDP Modified M13mpl8 RF Genomes
A key goal of this thesis work was to compare the genotoxicity of
cis-DDP and ACDP. Accordingly, M13mp18 RF DNA was modified with both
platinum compounds. Atomic absorption spectroscopy indicated that
almost all the drug present in solution bound to the M13mp18 RF DNA in
the 16 hour platinum reactions. Adduct levels of the cis-DDP and ACDP
treated M13mp18 RF genomes are given in Table 6. In a plaque forming
assay, transformation efficiencies of E. coli DL7 with unmodified
M13mp18 RF DNA were 1-4 x 109 transformants/ug DNA for non-SOS induced
samples and slightly lower (from 1-5 x 108 transformants/Ag DNA) for SOS
induced samples. Increasing numbers of DNA adducts reduced the number
of infective centers in a dose-dependent manner for genomes modified
with either platinum compound (Figure 16). cis-DDP appeared to be
slightly more genotoxic than ACDP, averaging 3.33 adducts per lethal
hit compared to 5.22 adducts per lethal hit for ACDP (Table 7). When
the host DL7 cells were pretreated with UV irradiation to induce the SOS
response, survival relative to unmodified genomes increased
approximately threefold for DNA treated with either drug.
2. Identification of Mutants
'In an earlier experiment, cis-DDP was slightly less toxic than in
the present experiment. The earlier value of 4.61 adducts/lethal hit
(see Figure DL7,/DL6) for cis-DDP modified genomes replicated in non SOS
induced cells was very close to the genotoxicity of ACDP reported here.
Interestingly, the earlier genotoxity of 10.1 adducts/lethal hit for
cis-DDP in SOS induced cells is essentially identical to the present
value of 10.3 adducts/lethal hit.
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The mutational assay used in this study is based on the ability of
the lacZ' peptide fragment encoded by the M13mp18 viral genome to serve
as an -donor to complement the host bacterial M15 protein, the -
acceptor, to produce -galactosidase activity in a process known as -
complementation (LeClerc et al., 1984). With X-gal used as the
prochromophore, -galactosidase activity arising from the lacZ' -
complementation process results in blue plaques when M13mp18
bacteriophage are plated with IPTG, X-gal and E. coli GW5100 cells.
Mutations in the M13mp18 lacZ' regulatory or peptide coding regions that
affect -complementation give rise to phenotypically distinct plaques.
The colors of mutant plaques observed in this study ranged along a
continuum from having no detectable -galactosidase activity (colorless
plaques) to slightly less than wild-type activity (light blue plaques)
as observed previously (LeClerc et al., 1984; Decuyper-Debergh et al.,
1987). Interestingly, a few mutants exhibited much greater than wild-
type -galactosidase activity and formed intensely dark blue plaques.
Quantitation of their -galactosidase activity revealed up to 60 fold
enhancement of enzyme activity over wild-type (Table 8).
3. Determination of Mutation Frequency
The mutation frequency was determined by dividing the sum of
colorless, light blue and dark blue mutant plaques by the total number
of plaques. The mutation frequencies for replicates showed high
standard error margins (±-35%) making it necessary to repeat the
mutation frequency experiments several times to enable statistically
valid comparisons between the two drugs (Table 9). Mutagenesis was SOS-
dependent for both platinum drugs. Under the appropriate SOS conditions
the mutation frequency increased in an adduct dependent manner for both
compounds, with cis-DDP being approximately twofold more mutagenic than
ACDP (Figure 171.
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4. LacZ' Mutational Spectra of cis-DDP and ACDP Modified DNA
Mutations in the lacZ' DNA sequence of M13mp18 which had been
identified by phenotypically distinct plaques were determined by DNA
sequencing. A total of 303 mutants was identified by sequencing, 142
from ACDP-modified DNA, 115 from cis-DDP-modified DNA, and 46 from
unmodified control genomes. Most of the mutations induced by either
drug were single base substitutions with a smaller number of single base
deletions or insertions, as shown in Figure 18. Spontaneous mutations
arising from unmodified DNA are shown in Figure 19. A few samples had
multiple substitutions or large deletions or both; these mutants are
described in Table 10. A summary of all mutations by type is given in
Table 11. The amino acid changes resulting from mutations in the DNA
sequence corresponding to the coding region for the lacZ' polypeptide
are listed in Table 12.
Mutational spectra for the platinum compounds were derived from
genomes with an average of 1.85 cis-DDP or 2.36 ACDP adducts in the 370
nucleotide segment of the lacZ' DNA sequence that was the target for
detectable mutations (Figure 18). At these adduct levels, the mutation
frequency was approximately eight and five fold higher than the
spontaneous mutation frequency for cis-DDP and ACDP modified genomes,
respectively (Figure 17). The induced spectra, therefore, would be
expected to be comprised of 10-20% spontaneous mutants. Nevertheless,
the spontaneous mutational spectrum was significantly different than
that induced by either platinum drug. Considering single base changes,
the induced spectra had twice as many transversions as transitions in
contrast to the spontaneous spectrum, which had almost a 3:1 ratio of
transitions to transversions. CG TA transitions comprised almost half
of the spontaneous mutations. In addition, the spontaneous spectrum had
relatively more deletions and multiple base changes than the induced
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spectra. Seven of the 46 spontaneous mutations were two specific large
deletions; from position 5970 to 6172 and from 6250 to 6396. The 6250-
6396 deletion comprises the same region that is absent from the M15 -
acceptor protein; similar mutations have been observed in other lacZ'
mutational assays and are attributable to recombination with the F'
episome of the host bacterium (LeClerc et al., 1984). The 5970-6172
deletion is also possibly due to a recombination event suggesting that
these large deletions, although observed in the drug induced spectra (at
much lower frequencies) are the result of spontaneous events and not a
consequence of the cis-DDP or ACDP DNA adducts.
5. Replication Mapping of DNA Adducts
The secondary structure of double-stranded M13mp18 RF genomes
required that adduct mapping experiments be performed by using one
thermal cycle with VentRTM (exo-) DNA polymerase (see Discussion). The
signal from single cycle reactions was considerably weaker than from the
multicycle reactions employed by others who have used this methodology
(Bubley et al., 1991; Murray et al., 1992). Fragments up to 150 bases
in length were difficult to visualize by autoradiography on x-ray film,
but could be seen after exposure to a phosphorimaging plate (Amemiya &
Miyahara, 1988) followed by analysis with a Molecular Dynamics
PhosphorImager. Fragments longer than 200 bases gave stronger signals,
but were difficult to align at base resolution on the concurrently run
sequencing ladder. These restrictions required that the lacZ' region be
mapped by using primers offset by 100 to 150 nucleotides, generating at
least two sets of fragments for every nucleotide position. Fragments
having fewer than 150 bases could be aligned precisely with the
sequencing ladder and were used to determine location of the termination
sites. Longer fragments corresponding to the same termination sites,
but generated by a more distant primer, were used to determine the
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intensity of the stop site by PhosphorImager quantitation. The pattern
of termination sites was very similar for DNA modified at either low
(11.6 adducts per genome for cis-DDP or 6.6 adducts per genome for ACDP)
or high (35.4 or 45.0 adducts per genome, respectively) levels. The
major difference was that the genomes containing fewer adducts gave rise
to a greater amount of high molecular weight material corresponding to
fragments of more than 500 nucleotides in length. Conversely, the
genomes platinated with the higher levels of drug produced almost no
fragments above 400 bases in length. Consequently shorter fragments
were more abundant and gave enhanced signal intensity; therefore, only
the highly modified samples were subjected to rigorous quantitation.
ThLe resulting adduct distributions are graphically displayed in Figure
18.
The adduct mapping experiments showed that DNA modification
predominantly occurred at d(GpG) sites, especially at runs of three or
more G's and, to a lesser extent, at d(ApGpG) sites, for both drugs.
Weaker termination sites were detected at d(ApG), d(GpNpG), and a
variety of other sites. PhosphorImager quantitation of strong
termination sites yielded accurate information on the relative abundance
of G*G* and, to a lesser extent, A*G* and G*NG*, adducts.
Unfortunately, two factors complicated the quantitative evaluation of
weak termination sites. First, the limitation of the single cycle
methodology used in the adduct mapping experiments resulted in the
weaker binding sites giving signals barely above background, making
quantitation of some of these sites difficult. The second, and more
intractable, obstacle was the observation that many potential adduct
formation sites overlap. The problem is exemplified by the (+) strand
sequence from 6.395 to 6398: 5'-d(GpApGpG)-3'. This sequence has the
potential to form an A*G*, G*NG*, or G*G* adduct. DNA polymerases can
halt when encountering the first (3') nucleotide of a platinum adduct,
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but do so more often at the second (5') nucleotide or even at the
nucleotide 5' to the adduct (Comess et al., 1992). Consequently, the
uncertainty of where the adduct would form in this sequence, coupled
with the variability of where the polymerase would stop when
encountering a given adduct, leads to the conclusion that a stop site
corresponding to the adenine at position 6396, for example, could be
attributed to any one of the three possible adducts.
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Table 6. Adduct levels of genomes modified with cis-DDP or ACDP
Pt adducts per Adducts per lacZ' Bound drug to
Drug M13mp18 RF genome mutational target nucleotide ratio
none
cis-DDP
ACDP
0 0
6.2
11.6
14.2
19.8
24.3
29.5
35.4
61.6
0
0.33
0.61
0.75
1.04
1.24
1.54
1.85
3.22
0.64
2.5
6.6
17.6
23.4
45.0
85.7
0.41
0.80
0.98
1.37
1.68
2.02
2.44
4.25
0.03
0.13
0.35
0.92
1.23
2.36
4.49
0.04
0.17
0.46
1.21
1.61
3.10
5.90
x 10 - 3
x 10-3
x 10-3
x 10 -3
x 10-3
x 10 -3
x 10 -3
x 10 -3
x 10-
X 10 - 3
X 10 - 3
X 10 - 3
X 10 - 3
x 10 -3
x 10 -3
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Table 7. Comparative survival for M13mp18 RF DNA modified with either
cis-DDP or ACDP.
Pt adducts per Survival(%)a Survival(%)
Drug M13mpl8 RF genome SOS(-) SOS(+)
100
23.1
14.6 + 9.9b
4.10 + 2.1
2.5 ± 1.6
4.4 + 2.6
0.7 + 0.33
1.1 + 0.51
0.02 + 0.01
100
52.8 + 19.8
7.6 + 1.4
19.7 + 13.3
17.0 + 9.8
5.0 + 4.8
5.5 + 2.7
0.3 + 0.2
Adducts per lethal hitc: 3.33 : 2.04 10.3 4.77
100
93.4
35.7 + 14.2
23.5 + 11.5
9.4 + 4.2
3.1 + 1.6
0.8 + 0.6
100
59.3 + 20.5
49.9 + 15.4
20.2 + 7.2
12.4 + 3.4
1.9 + 0.9
0.2
Adducts per lethal hit: 5.22 2.97 16.3 5.71
a. Survival values were determined relative to unmodified M13mp18 RF
genomes.
b. Error margins are given for the 95% confidence level (s.d. x 1.96).
c. Adducts per lethal hit calculated for 37% survival based on curve
fitting by Cricket Graph. Equations for curve fit lines are for cis-
DDP, SOS(-): y=0.58(105X), R=0.951; SOS(+): y=0.99(10' 2x), R2=0.899;
for ACDP, SOS(-): y=0.64(10'05 x), R2 =0.942; SOS(+): y=0.74(100 '(l),
R2=0. 986.
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cis-DDP 0
6.2
11.6
14.2
19.8
24.3
29.5
35.4
61.6
ACDP 0
0.64
2.5
6.6
17.6
23.4
45.0
85.7
Table 8. Location, mutation and
dark blue mutants.
enhanced -galactosidase activity of
Number Fold -gal Consequence for
Mutation Position observed enhancements peptide structure
GC - TAb 6219 1 n.d.c Met Ile
(1st coding residue)
CG deletion 6416-6418 1 n.d. frameshift - causing
stop codon @6434
CG e TA 6418 1 47.6 Gln e stop codon
2 44.4
3 50.5
CG - TA 6421 1 n.d. Gin e stop codon
GC - TA 5442 1 58.1 Glu - stop codon
2 55.2
GC e AT 6459 1 8.5 Trp e stop codon
GC e TA 6472 1 n.d. Glu e stop codon
a. Enhancement is expressed relative to the average activity determined
for 6 independent wild type samples.
b. The first nucleotide of each pair is derived from the viral (+)
strand, the second from the (-) strand of the M13mp18 RF genome.
c. Not determined.
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Table 9. Mutation frequency of cis-DDP and ACDP modified M13mp18 RF
genomes
Adducts pera Number of Mutants per Mutation
Drug lacZ' target experiments total plaques frequency(x104)
none 0 18 113/205,565 5.5 2.5b
cis-DDP 0.61 6 153/82,914 18.5 + 7.7
1.04 6 213/67,134 31.7 + 2.3
1.24 6 240/81,005 29.6 + 9.8
1.54 6 208/56,088 37.1 + 7.7
1.85 8 359/84,882 42.3 + 9.9
ACDP 0.13 13 172/165,827 10.4 + 2.2
0.35 13 206/176,929 11.8 + 3.7
0.95 15 180/108,357 16.6 + 6.3
1.23 17 198/97,990 20.2 + 4.6
2.36 16 446/180,544 24.7 + 8.6
a. The number given represents the average number of adducts located in
the 370 nucleotide DNA sequence
the target for the detection of
b. Error margins are given for
of the lacZ' region of M13mp18 that was
mutations.
the 95% confidence level (s.d. x 1.96)
153
Table 10. Miscellaneous spontaneous and induced lacZ' mutations
Identity Number Type of mutation
Spontaneous 7
4 Large deletion (5970-6172)
3 Large deletion (6250-6396)
cis-DDP 6
2 Large deletion (5970-6172)
2 Large deletion (6250-6396)
1 6248-6251: d(CpCpGpG) d(CpApG)a
(del C or G, with C or G - A)
1 6463-6467: d(CpCpGpG) d(CpApG)a
(del C or G, with C or G A)
ACDP 4
1 Large deletion (6250-6396)
1 6338-6340: Deletion of 2 (CG)'s
1 polylinker region deleted, replaced
with sections of the other strand
(totaling the same number of bases
that were deleted)
1 6463-6467: d(CpCpGpG) d(CpApG)a
(del C or G, with C or G - A)
a. Only the sequence for the viral (+) strand is shown although the
mutation could be derived from either strand
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Table 11. LacZ' mutational spectra of cis-DDP and ACDP modified and
unmodified M13mp18 RF DNA listed by types of mutations
Mutation cis-DDP ACDP Spontaneous
Transversions
GC - TAb
CG - AT
AT -e TA
TA - AT
GC - CG
CG -e GC
AT - CG
TA - GC
Transitions
CG - TA
GC AT
TA - CG
AT - GC
Other mutations
Single base insert.
Single base delet.
Miscellaneousc
61a 59
22
23
0.9
13
1.7
0.9
20
21 13
2.223
4.2
8.5
0.7 4.3
0.7
1.4
32 28
20
8.7
2.6
0.9
54
17
4.2
4.9
1.4
7
43
2.2
2.2
6.5
13
0.9
0.9
5.2
26
4.9
4.9
2.8
11
15
a. Numbers given are percentages of the total 115 cis-DDP, 142 ACDP and
46 spontaneous mutations identified.
b. The first nucleotide of each pair is derived from the viral (+)
strand, the second from the (-) strand of the M13mp18 RF genome. For
the induced mutations, the sequence context of the mutation, combined
with the adduct mapping data showing the location of the platinum DNA
adducts, allowed assignment of the mutation to one strand or the other
as shown in Figure 18.
c. Miscellaneous mutations are listed in Table 10.
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Table 12. Amino acid changes in the lacZ' peptide fragment that result from
transition or transversion mutations
Position Mutation a. a.a change Position Mutation a. a. change
N- terminal
6218 (2 )b
6219 (3)
6236 (2)
6237 (3)
6242 (2)
6245 (2)
6247/6249
6258 (3)
6261 (3)
6262 (1)
6266 (2)
6270 (3)
6293 (2)
31 a. a. ri
6305 (2)
6307 (1)
6310 (1)
6311 (2)
6313 (1)
6313 (1)
6314 (2)
6314 (2)
6316 (1)
6317 (2)
6317 (2)
6319 (1)
6319 (1)
6320 (2)
6320 (2)
6320 (2)
6321 (3)
6321 (3)
6322 (1)
6327 (3)
6340 (1)
6340 (1)
6344 (2)
6344 (2)
6347 (2)
6347 (2)
6349 (1)
6350 (2)
6350 (2)
6352 (1)
6353 (2)
6353 (2)
6356 (2)
6359 (2)
6360 (3)
6361 (1)
overlapping
TA - GCC
GC - TA
CG - AT
GC - TA
CG - AT
TA - AT
CG - ATe
TA - AT
AT - TA
GC - TA
GC - AT
CG - AT
TA - CG
esidue M15 di
TA - AT
CG - TA
CG - TA
GC - AT
CG - TA
CG - AT
GC - AT
GC - TA
GC - TA
AT - GC
AT - TA
TA - AT
TA - CG
GC - CG
GC - AT
GC - TA
GC - TA
GC - AT
GC - TA
CG - AT
CG - TA
CG - AT
TA - CG
TA - GC
AT - TA
AT - CG
CG - AT
GC - TA
GC - AT
CG - TA
TA - AT
TA - CG
CG - GC
CG - TA
AT - GC
CG - TA
region
Met - Arg
Met - Ile
Ser - stop
noned (Ser)
Ser - stop
Val Glu
Pro - Thr
noned (Pro)
noned (Leu)
Glu - stop
Ser - stop
noned (Thr)
Leu Pro
aletion
Leu - stop
Glu - stop
Arg - Cys
Arg - His
Arg - Cys
Arg - Ser
Arg - His
Arg - Leu
Asp - Tyr
Asp - Gly
Asp - Val
Trp - Arg
Trp - Arg
Trp - Ser
Trp - stop
Trp - Leu
Trp - Cys
Trp - stop
Glu - stop
Asn - Lys
Gln - stop
Gln - Lys
Leu - Pro
Leu - Arg
Asn - Ile
Asn - Thr
Arg - Ser
Arg - Leu
Leu - His
Leu - Phe
Leu - His
Leu - Pro
Ala - Gly
Ala - Val
noned (Ala)
His Tyr
31 a. a. residue M15 di
6365 (2) CG - TA
6365 (2) CG - AT
6367 (1) CG - AT
6368 (2) CG - TA
6371 (2) TA - CG
6372 (3) CG - AT
6376 (1) AT - TA
6377 (2) GC - TA
6377 (2) GC - AT
6378 (3) CG - AT
6379 (1) TA - AT
6380 (2) GC - AT
6380 (2) GC - TA
6381 (3) GC - CG
6382 (1) CG - TA
6382 (1) CG - AT
6383 (2) GC - TA
6383 (2) GC - AT
6391 (1) GC - TA
6394 (1) GC - TA
6395 (2) AT - TA
C-terminal overlapping
6397 (1) GC - TA
6398 (2) CG - TA
6400 (1) CG - AT
6400 (1) CG - TA
6401 (2) GC - AT
6413 (2) CG * AT
6416 (2) CG - TA
6416 (2) CG - AT
6418 (1) CG - TA
6421 (1) CG - TA
6427 (1) CG - TA
6434 (2) TA - AT
6436 (1) AT - TA
6438 (3) TA - AT
6439 (1) GC - TA
6440 (2) GC - TA
6442 (1) GC - TA
6447 (3) GC - TA
6451 (1) TA - CG
6459 (3) GC - AT
6464 (1) CG - TA
6464 (1) CG - AT
6469 (1) CG - TA
6469 (1) CG - AT
6470 (2) CG - AT
6472 (1) GC - TA
6482 (2) CG - TA
6482 (2) CG - AT
sletion (cont)
Pro - Leu
Pro - His
Pro - Thr
Pro - Leu
Phe - Ser
Phe - Leu
Ser - Cys
Ser - Ile
Ser - Asn
Ser - Arg
Trp - Arg
Trp - stop
Trp - Leu
Trp - Cys
Arg - Cys
Arg - Ser
Arg - Leu
Arg - His
Glu - stop
Glu - stop
Glu - Val
region
Ala - Ser
Ala - Val
Arg - Ser
Arg - Cys
Arg - His
Pro - His
Ser - Phe
Ser - Tyr
Gln - stop
Gln - stop
Arg - Cys
Leu - Gln
Asn - Tyr
Asn - Lys
Gly - Cys
Gly - Val
Glu - stop
Trp - Cys
Phe - Leu
Trp - stop
Pro - Leu
Pro - Gln
Pro - Ser
Pro - Thr
Pro - Gln
Gln stop
Pro - Leu
Pro - Gln
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Table 12. (cont)
a. a. a. designates amino acid.
b. Numbers in parentheses are codon positions.
c. The first nucleotide of each pair is derived from the (+) strand, the
second from the (-) strand of the M13mp18 RF genome.
d. Neutral mutations that do not lead to an amino acid change; each of these
samples, with the exception of the TA - AT transversion at position 6258, had
phenotypically detectable missense mutations elsewhere.
e. A double mutant with this base change at both the 1st and 3rd codon.
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Figure 16. Survival of cis-DDP and ACDP modified M13mp18 RF genomes in
E. coli DL7 cells. Survival was determined by using the M13 plaque
forming assay for cells either not treated (a) or treated (b) with uv
irradiation to induce the SOS response. Survival values were determined
relative to unmodified M13mp18 RF genomes; each data point represents
the average of 6-9 replicas. Error margins are given for the 95%
confidence level (s. d. x 1.96). Adduct/lethal hit (37% survival)
values were calculated from curve fit lines generated by Cricket Graph
(Cricket Software).
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Figure 17. Mutation frequency as a function of adduct level in the 370
nucleotide DNA sequence of M13mp18 RF genomes that forms the target for
detectable mutations in the lacZ' region of cis-DDP () or ACDP ()
modified M13mp18 RF genomes. The error bars represent 95% confidence
intervals (s.d. x 1.96).
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Figure 18. Mutation and DNA binding spectra for the lacZ' region of
M13mp18 RF DNA. The lacZ' DNA sequence is represented in four segments:
(a) upstream regulatory region; (b) 29 residue lacZ' peptide coding
sequence that forms the N-terminal overlap with the M15 a-acceptor
protein; (c) lacZ' peptide coding sequence corresponding to the 31
residue (93 bp) deletion in M15; and (d) 30 residues of the lacZ'
peptide coding sequence that forms part of the 54 residue C-terminal
overlap with M15. Bars indicate relative adduct levels, mutations are
designated by letters, arrows are intended to provide visual clarity in
defining the location of mutations occurring at sites without measurable
adducts. Mutations were assigned to the (+) or (-) strand based on
adduct position and known sites of platinum induced mutations.
Mutations potentially attributable to adducts in either strand, or not
clearly arising from either strand, are indicated in bold italic form.
Adducts and mutations representing the cis-DDP spectra are shown above
the strands, and the ACDP spectra are located below the strands.
Deletions are indicated by (A), insertions by (+); underlined sequences
represent any one of the possible bases that was deleted when a deletion
mutation occurred at runs of identical nucleotides. Adduct
distributions were not determined for positions >6450 in the (+) strand.
The T-T at positions 6247-6249 indicates a d(GpGpG) d(TpGpT) double
mutation.
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(a)
TI A(+) 5'- TAATGGAG TAGCCAC ACAC CCCAT ACACTTATG CTTCCGGCC GT GAATTGTG AGCGGATAAC
|sllI ' +1,I IIII 'IA
A
TI
T1
T
T
T
T
T
A
CAP binding site -35 promoter
6110 6120 6130 6140 6150
operator
6160 6170 6180
-10 promoter
6190 6200 6210
ribosome
binding site
A
A A
T A
II I 
(-) 3 - AATTACACTC AATCGAGTGA
T11111T A
T A
A
I A I T
.GTAATCCGTG GGGOCCGAAA TGTGAAATAC GAAGGCCGAG CATACAACAC
I ii I11 g . .
"I "1I I' A A 
r | A T
A
III II
ACCTTAACAC TCGCCTATTG TTAAAGTGTG TCCTTGTCGA
IIII I I
(b)
(+)5'- ATG ACC ATG ATT ACG AT
A
AT A
t I, t 1
TCG AGC TCG TA CCC GGG
AT I
T
I I II
GAT CCT CTA GAG TCG ACC
I III'
TGC AGG CAT GCA AGC
1 I11 '
I, II .TTG GCA CTG GCC GTC GTT
I1 I 
lacZ' coding sequence - (N-terminal overlap)
6220 6230 6240 6250 6260 6270 6280 6290 6300
polylinker cloning region
.. lI ,i 111 Eu II ,,ilI 1.1 . 11
(-) 3 - TAC TGG TAC TAA TGC TTA AGC TCG AT CAT G CCC CTA GGA GAT CTC AGC TGG ACG TCC GTA CGT TCG AAC CGT GAC CGG CAG CAA
Ij III 111 1 I' [[ [I I C| IT l | T A C
A T A
T-T
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(C) T
T
C T
C T
A T
A TA TA T
A A T
T lii+A TT ATT T T
It'1' I I IITTA CAA CGT W CCT GC; cT G-A CAT CCC CCT C GCC c
T AT
T A T T
T +A T
A +A
*G AA
AG
lacZ' coding sequence - (M15 93 bp deletion)
6310 6320 6330 6340 6350 6360 6370 6380 6390
G
G
T T
T T 
C T
CI I
-)3'-AAT GT GCA GCA CTG ACC
II 11I ''I1II
T A AT T +
T
T +T +G
T +T
.+ GG +T
AT
A
T
T
T T A
T G T
T
'
I II I
G TA I
GTA T
T
A
AG
T
A II
AG Coo TCG ACC GCA TA TCG CTT CTC
"IIII I ' '
A
(d)
T
CGC ACC GAT CGC CCT TCC CAA CAG TTG CGC
T
T
,, II , 1 I I
AGC CTG AAT GGC GAA T CGC T GCC TGG TTT CCG GCA CCA GAA GCG GTG CCG GAA
AT T
T T
T
lacZ' coding region - (C-terminal overlap)
6400 6410 6420 6430 6440 6450 6460 6470 6480
A
A A
A AG A
T T A
T A T T
ii L ll 1 s GT li
(-)3'- CG GCG TGG CTA GCG GA AGG TT GTC AAC GCG TCG GAC TTA CCG CTT ACC GCG AAA CGG ACC AAA IC CGT GGT CTT CGC
I I I 1 I Ii I I ' I I ' II 1 11 AA T TA A
A G A A
A A~~~~~~~~~~~~AA
A
,II,
CAC GGC CTT
T
A
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Figure 19. Spontaneous mutational spectra for single base changes.
Underlined sequences represent any one of the possible base pair deleted
when deletion occurred at runs of identical nucleotides. Deletions are
indicated by (A). Other spontaneous mutations are described in Table 11.
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(+) 5'-CACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACAC
(-) 3' -GTGAGTAATCCGTGGGGTCCGAAATGTGAAATACGAAGGCCGAGCATACAACACACCTTAACACTCGCCTATTGTTAAAGTGTG
TT T
A A A
6210 6220 6230 6240 6250 6260 6270 6280 6290
AGGAAACAGCTATGACCATGATTACGAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTGG
TCCTTTGTCGATACTGGTACTAATGCTTAAGCTCGAGCCATGGGCTAGGAGATCTCAGCTGGACGTCCGTACGTTCGAACCGTGACCII I ·
TA
AC
AG
C
AG
C
6300 6310 6320 6330 6340 6350 6360 6370 6380
CCGTCGTTTTACAACGTCGTTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTCGCCAGCTGGCGTA
GGCAGCAAAATGTTGCAGCACTGACCCTTTTGGGACCGCAATGGGTTGAATTAGCGGAACGTCGGCGGTCGCCGCT
4 44 4 s TGT AAGGGCACGA
T TT C AA
A AA G T
T T
A A
T
A
T
A
T
A
C TGT
G ACA
AC
G
AC
G
T
A
6390 6400 6410 6420 6430 6440 6450 6460 6470
ATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTTTCCGGCAC-3'(+)
TATCGCTTCTCCGGGCGTGGCTAGCGGGAAGGGTTGTCAACGCGTCGGACTTACCGCTTACCGCGAAACGGACcAAAGGCGTG-5' (-)
TT T T
AA A A
T T
A A
T
A
T
A
C
G
T
A
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V. DISCUSSION
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This dissertation describes the comparative genotoxicity and
mutagenicity of platinum-DNA adducts from two perspectives. First, cis-
DDP G*G*, A*G*, and G*TG* adducts site-specifically situated in M13-
derived ss viral genomes exhibited different relative genotoxicities and
mutagenicities when replicated in E. coli DL7 cells. The differential
mutagenicities of the various cis-DDP DNA adducts suggested strategies
for the design of novel platinum drugs that would be less mutagenic than
those currently in use. For example, the A*G* adduct, which is 4-5 fold
more mutagenic than the G*G* adduct, should be minimized in the DNA
binding spectra of future drugs. Accordingly, the second aspect of the
work described in this dissertation involved the evaluation of ACDP.
ACDP is a metabolite of ACCDP, a promising platinum(IV) drug, which has
DNA binding properties similar to cis-DDP with the notable exception
that it forms three-fold fewer adducts at d(ApG) sites. The less
frequent occurrence of the more highly mutagenic A*G* adduct suggested
that the overall mutagenicity of ACDP would be lower than that of cis-
DDP. This hypothesis was experimentally tested and confirmed.
A. Genotoxicities of the G*G*, A*G*, and G*TG* Adducts
1. Comparison to Previous Results
The genotoxicities of the cis-DDP A*G* and G*NG* adducts have not
been determined previously. The genotoxicity of the G*G* adduct,
however, has been studied in E. coli. Bradley et al. (1993) report a
survival level of 22% for this adduct located in M13mp18 genomes
replicated in non-SOS induced E. coli DL7 cells. This value was
considerably higher than the 5.2% survival observed under the same
biological conditions in the present work. The discrepancy in survival
can be attributed to differences in the genomes employed in each study.
The previous work utilized a G*G* adduct situated in the (-) strand of
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replicative form (RF) M13mp18 bacteriophage genomes. The complementary
(+) strand had been subjected to uv irradiation to damage the DNA. The
resulting thymine-thymine cyclobutane dimers served to inhibit DNA
replication. Since the damaged (+) strand could no longer serve as a
template for replication, DNA synthesis of the adduct containing (-)
strand was ensured, thereby circumventing the strand bias effects
inherent in M13 replication.l The presence of the (+) strand, however,
was detrimental inasfar as it provided a ds DNA template amenable to
repair by the UvrABC complex (UvrABC is the cellular system that is
primarly responsible for the repair of cis-DDP adducts in E. coli). It
was likely, therefore, that some of the G*G* adducts situated in the ds
genomes used by Bradley et al. (1993) were repaired. This hypothesis is
consistent with the location of the G*G* in the (-) strand. Before
M13mp18 RF DNA can be replicated in E. coli, a number of viral genes,
all encoded by the (-) strand, must be transcribed. Strand specific DNA
repair in E. coli is linked to transcription (Mellon & Hanawalt, 1989;
Selby & Sancar, 1991; Kinnala & Brash, 1992; Oller et al., 1992) and
shown to be applicable to cis-DDP DNA adducts in the M13 bacteriophage
system (K. Yarema, unpublished data) suggesting that the G*G* adduct in
the (-) strand of M13mp18 RF genomes would be susceptible to repair by
the UvrABC repair complex. Conversely, such repair is not possible in
the ss genomes used in this thesis work. Without UvrABC mediated
repair, it is reasonable that the survival of genomes containing the
G*G* was fourfold lower in the current system.
2. Comparative Genotoxities of cis-DDP adducts
'As a result of the modified rolling circle replication of M13
genomes (Figure M13), a replication blocking lesion in either strand of
a M13 RF genome can render that strand inactive by directing
preferential replication of the other, undamaged, strand. All progeny,
therefore, would be derived from the undamaged strand and the adduct
containing strand would remain unreplicated and the genetic effects of
the DNA lesion would not be observed.
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The viability of M13-derived ss genomes containing any of the cis-
DDP adducts was significantly reduced compared to unmodified genomes.
The cis-DDP A*G*, G*TG*, and G*G* adducts reduced the plaque-forming
ability of M13 ss genomes replicated in non-SOS induced E. coli DL7
cells by 79%, 87%, and 95% respectively (Figure 15). While each of
these adducts can be qualitatively considered to be an effective
deterent to replication, the quantitative differences in survival are
statistically significant and warrant further discussion. The factors
most likely to account for adduct to adduct variabilty are (i)
differential ability of the adducts to be repaired or (ii) differential
ability of the adducts to be bypassed by DNA polymerases.
a. Differential repair
cis-DDP DNA adducts are primarily repaired by the UvrABC repair
complex in E. coli (Husain et al., 1985). Although the UvrABC exicision
repair system is under regulatory control of the inducible SOS system,
significant levels of UvrA, UvrB, and UvrC proteins (20, 200, and 10 per
cell, respectively (van Houten, 1990)) are present in non-SOS induced
cells allowing for repair of infrequently occurring DNA lesions. The
cis-DDP lesions introduced into E. coli by transfection of singly-
modified M13-derived genomes fit into this category. The possibility
exists, therefore, that the cis-DDP G*G*, A*G*, and G*TG* adducts are
repaired at different rates by the UvrABC system, thereby accounting for
the observed differences in survival of the genomes containing these
lesions. Several lines of evidence, however, suggest that this
situation does not apply. First, UvrABC is not expected to be active on
ss DNA (van Houten, 1990) because a ds template is required for the
tracking mechanism employed by the UvrA2B proteins to locate DNA lesions
(Grossman & Thiagalingam, 1993). Furthermore, no structural basis
exists to account for differential recognition of these adducts by
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UvrABC that would explain the observed differences in survival (the
structural implication of UvrABC recognition of the G*G*, A*G*, and
G*TG* adducts are discussed in detail in the next section). The G*NG*
adduct imposes more local distortion of the DNA duplex than the A*G* or
G*G* adducts and might be expected, if anything, to be better recognized
by UvrABC (Sancar & Sancar, 1988). Indeed, the G*NG* adduct formed by
the cis-DDP analogue cis-diaminocyclohexanedichloroplatinum(II)
([Pt(dach)C12], Figure 1) is a much better substrate for UvrABC than
either the A*G* or G*G* adducts (Page et al., 1990). These results are
in clear conflict with the relative survival of the singly-modified
genomes observed in this thesis work, implying that UvrABC mediated
repair does not account for the survival differences experienced by the
cis-DDP G*G*, A*G*, and G*TG* adducts.
Repair of cis-DDP adducts that elude processing by UvrABC has been
reported (Germanier et al., 1984). Mismatch repair (Fram et al., 1985)
and recombinational repair (Husain et al., 1985) have been implicated as
secondary repair systems for cis-DDP modified DNA. Both of these modes
of repair operate post-replicatively and, unlike UvrABC, are therefore
expected to be able to operate on lesions in ss DNA, such as the cis-DDP
DNA adducts located in the genomes employed in this work. It is not
clear, however, from what is known about mismatch and recombinational
DNA repair how these mechanisms could account for the survival
differences observed between the cis-DDP A*G*, G*G*, and G*TG* adducts.
Recombinational repair occurs when a polymerase encounters certain
replication-blocking DNA lesions. The polymerase stops replication and
reinitates about 1000 bases beyond the adduct, thus generating a ss gap
containing the DNA lesion. This post-replication gap is filled in by
RecA protein, which transfers the complementary strand from a sister
171
duplex into the gap (Sancar & Sancar, 1988). Similarly, mismatch repair
involves post-replicative processing of DNA, requiring that the lesion
first must be successfully bypassed during DNA synthesis (reviewed by
Modrich, 1987). These mechanisms appear to balance each other and might
be expected to diminish differences between adducts. For example,
adducts that are easily bypassed might be better candidates for mismatch
repair whereas adducts more effective at blocking DNA replication would
be more likely to produce the -1000 nucleotide gaps processed by the
recombinational repair system. Few details, however, are known about
the processing of cis-DDP adducts by either of these systems and it is
unclear how either system could discriminate between cis-DDP G*G*, A*G*,
and G*TG* adducts to produce the differential plaque-forming abilities
of these adducts situated in M13-derived ss genomes.
b. Translesion synthesis
Although cis-DDP DNA adducts potently inhibit DNA synthesis, they
are not absolute blocks to DNA replication. E. coli polymerase I has
been shown to bypass cis-DDP in vitro, with G*G* adducts in M13 ss
genomes more inhibitory to replication the A*G* adducts (Hoffman et al.,
1989). This result was not quantitatively analyzed, but it is
qualitatively in agreement with the 4 fold higher survival of A*G*
containing genomes compared to G*G* containg genomes in E. coli DL7
cells utilized in the present experiment. Comess et al. (1992) utilized
site-specifically situated adducts in M13 genomes to investigate the
ability of cis-DDP G*G*, A*G*, and G*CG* to inhibit DNA replication in
vitro. Frequency of replication bypass of the cis-DDP G*G*, A*G*, and
G*CG* adducts by E. coli polymerase III was 6%, 9%, and 4%,
respectively. The value of 6% compared well with the 5% survival of the
G*G* containing genome replicated, presumably also by Pol III, in E.
coli DL7 cells. These results are consistent with the interpretation
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that the G*G* adduct was not repaired in vivo and survival was entirely
due to translesion synthesis. The in vivo survival of the A*G* and
G*TG* adducts, at 21% and 13%, respectively, were significantly higher
than the 9% and 4% observed in the in vitro assay.
The quantitative discrepancies between the in vivo and in vitro
results could be due to the A*G* and G*TG* adducts being repaired by
some poorly understood mechanism while the G*G* adduct remained
unrepaired. Alternately, repair may be completely inoperative and
translesion synthesis may have been the sole mechanism to account for
survival of the various cis-DDP modified genomes. In the latter case,
the in vitro replication conditions used by Comess et al. (1992) may
have been sufficiently different than the in vivo conditions employed in
the present work to account for differences in the in vitro and in vivo
results. For example, the frequency of translesion synthesis of cis-DDP
adducts is strongly dependent on salt and nucleotide concentrations (K.
Yarema, unpublished observations), which could be significantly
different inside a cell than in vitro. Furthermore, intracellular
translesional synthesis could be aided by accessory proteins absent from
the in vitro experiments. Notwithstanding these caveats, the relative
in vitro replication bypass results are quantitatively consistent with
the in vivo results obtained in E. coli DL7 cells, suggesting that
bypass of the cis-DDP G*G*, A*G*, and G*TG* adducts plays a major role
in determining their genotoxicities.
3. Mode of SOS-Dependent Survival Increase
Survival of M13-derived ss genomes containing either a G*G* or
A*G* cis-DDP adduct increased significantly when replicated in SOS
induced E. coli DL7 cells. The observed survival increase is
attributable to three possible causes: (1) repair of the adduct by the
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UvrABC excision complex, (2) repair by some other mechanism, or (3) to
enhanced bypass of the lesion. Enhanced bypass of the adducts is the
favored explanation as there is considerable evidence to suggest that
cis-DDP adducts would not be repaired in M13-derived ss genomes. These
possibilities will be discussed below, leading to the conclusion that
the SOS dependent increased survival is best explained by increased
translesion synthesis past cis-DDP adducts during DNA replication.
a. Enhanced survival is not due to repair by UvrABC
There is considerable evidence that the UvrABC excision repair
complex, the major system responsible for repair of cis-DDP adduct in E.
coli, is not responsible for the SOS-dependent increase in survival
experienced by genomes containing the G*G* and A*G* adducts. In
addition to the factors discussed above, the anticipated lack of repair
of these adducts is supported further by the experimental observation
that the G*TG* cis-DDP adduct does not experience an SOS-dependent
increase in survival similar to the G*G* and A*G* adducts. In the
unlikely event that UvrABC excision repair was responsible for the
observed SOS-dependent increase in survival', the G*TG* adduct should
also be affected as it is expected to be a substrate for these enzymes
based on two factors. First, DNA adducts formed by trans-DDP, most of
'The constitutive levels of the UvrABC proteins, 20, 200, and 10
per cell respectively, proficiently repair low levels of cis-DDP DNA
adducts. This conclusion is based on the data shown in Figure DL7/DL6.
Cells withou UvrABC repair (E. coli DL6) show a 3.7 fold greater
sensitivity to cis-DDP than repair proficient (E. coli DL7) cells (1.24
and 4.60 adducts/lethal hit, respectively). Upon SOS induction of the
wild-type cells, survival increased, but only 2.2 fold, to 10.1
adducts/lethal hit. The SOS dependent increase in repair is conceivably
a consequence of the increased level of the UvrA and UvrB proteins (to
200 and 1000 per cell, respectively; UvrC remains at 10 per cell), but
is more likely due to other SOS dependent responses, such as the
induction of the umuDC genes, as discussed in the text. This is
especially the case for the singly modified genomes. It is difficult to
imagine a single cis-DDP DNA adduct overwhelming the constitutive levels
of the UvrABC proteins such that an increase in these proteins would
have a significant increase in survival such as seen in Figure SSS.
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which are 1,3-intrastrand crosslinks (i.e. G*NG*) are repaired in E.
coli, possibly by UvrABC.1 It should be noted that G*NG* cis- and
trans-DDP are structurally dissimilar (see below), a factor that could
explain the discrimination against the recognition of cis-DDP G*NG*
adducts by UvrABC. A structural analysis of the various cis-DDP adducts
compared to the entire spectrum of UvrABC recognized DNA damage,
however, reveals that G*NG* cis-DDP are similar to other damages
recognized by this repair apparatus. The thymine-thymine cyclobutane
dimer is the prototype of a large group of bulky DNA adducts formed by a
diverse group of DNA damaging agents that are repaired by UvrABC
(Grossman et al., 1988). Distortion of duplex DNA by thymine dimers is
similar to that caused by cis-DDP DNA adducts:
Adduct Helix Unwindinq Helix Bending
T^T (uv dimer) 90 320 (major groove)
G*G* (cis-DDP) 130 32-35° (major groove)
A*G* (cis-DDP) 130 32-350 (major groove?)
G*NG* (cis-DDP) 230 30-350 ( ? )
G*NG* (trans-DDP) 9-10 ° 30-350 (hinge joint)
As can be seen, cis-DDP G*NG* adducts impose structural distortion on
DNA very similar to that of thymine dimers and the cis-DDP G*G* and A*G*
adducts with the exception of significantly greater unwinding of the DNA
'Repair of trans-DDP DNA adducts by the UvrABC complex is inferred
from experiments in which trans-DDP modified M13mp18 RF (ds) genomes
were transfected into wild-type (DL7) or uvrA (DL6) E. coli cells. The
plaque forming ability of these genomes was about an order of magnitude
greater (and similar to cis-DDP modified DNA) in the wild type cells
indicating that the trans-DDP adducts were being efficiently repaired by
UvrABC (K. Yarema, unpublished results). There have been reports to the
contrary, however, that trans-DDP adducts are not repaired, or repaired
with greatly reduced efficiency by uvrABC. There are also indications
that these adducts are repaired by systems other than UvrABC in E. coli
(Beck et al., 1985; Alazard et al., 1982; Popoff et al., 1987).
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helix (230 vs. 90 or 130). UvrABC, however, recognizes a spectrum of DNA
lesions that unwind the DNA helix anywhere from 6 to 880 (van Houten,
1990). Another structural determinant of UvrABC recognition is the
bending of the DNA helix. A model of damage recognition involves uvrABC
detection of lesions that direct DNA bending toward the major groovel
(van Houten, 1990). The direction of DNA bending imposed by the cis-DDP
G*NG* adducts has not yet been determined, if the bend is toward the
minor groove, the ability of this lesion to be repaired could be
compromised. A recent model requires that the structure of the minor
groove proximal to the lesion closely mimics normal DNA to facilitate
UvrA assisted binding of UvrB into the minor groove (Visse et al., 1991;
Williams & Gao, 1992). Considering the precedent of the [Pt(dach)C12]
G*NG* adduct (Page et al., 1990), it is most probable, however, that the
cis-DDP G*NG* adduct is bent toward the major groove and is recognized
by UvrABC. Based on this structural analysis, the cis-G*TG* adduct
should have been a substrate for UvrABC excision repair and shown a
survival increase similar to the cis-DDP G*G* and A*G* adducts if
excision repair was a factor.
b. Alternate mechanisms for repair of cis-DDP adducts
Repair of cis-DDP DNA adducts by mechanisms other than the primary
system of UvrABC excision repair has been reported (Germanier et al.,
1984). As mentioned above, both mismatch repair (Fram et al., 1985) and
post replication recombinational repair (Husain et al., 1985) have been
implicated as secondary repair systems for cis-DDP modified DNA.
'The thymine cyclobutane dimer lesion and the G*G* and A*G* cis-DDP
adducts all have bends directed toward the major groove, as is the
situation for most DNA lesions recognized by the UvrABC repair complex
for which this information has been determined. In addition, several
compounds, such as G*NG* trans-DDP adducts are recognized that have
hinge joints in which the bend is flexible, being directed toward the
major groove at least part of the time (van Houten, 1990).
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Neither of these repair systems has been reported to be SOS-dependent,
suggesting that the SOS-dependent increase in survival for G*G* and A*G*
adduct containing genomes replicated in E. coli DL7 is not due to repair
by any known mechanism. SOS-dependent bypass of the replication
blocking cis-DDP lesions, therefore, is the probable explanation for the
SOS dependent survival experienced by the cis-DDP G*G* and A*G* adducts.
c. SOS-dependent bypass of cis-DDP adducts.
The SOS inducible proteins umuC and umuD' act in concert with DNA
polymerase III and recA* (and possibly other proteins) to allow the
polymerase to bypass lesions that block DNA replication in E. coli
(Bridges & Woodgate, 1984). The exact mechanism of translesion
synthesis remains elusive (Woodgate & Sedgwick, 1992). UmuD' and UmuC,
however, are known to associate with a polymerase stalled at the site of
DNA damage, unlike UvrA2B which tracks along ds DNA until a damaged site
is reached (Grossman & Thiagalingam, 1993). UmuDC-mediated translesion
synthesis, therefore, is equally effective regardless whether the
original DNA substrate was ss or ds. It appears likely that the SOS-
dependent increase in survival for M13-derived ss genomes containing the
cis-DDP G*G* and A*G* adducts is related to UmuDC mediated bypass of the
lesions. If this hypothesis is correct, the lack of a survival increase
for the G*TG* adduct would suggest that this lesion should not be
mutagenic. This prediction is based on the lack of participation of the
umuDC gene products in translesion synthesis past the cis-DDP G*TG*
adduct (and their implied participation in bypass of the cis-DDP G*G*
and A*G* adducts). Since UmuDC mediated bypass is required for cis-DDP
mutagenesis, this model predicts that the cis-DDP G*TG* adduct would not
be mutagenic. This prediction was experimentally tested and verified,
as discussed in the next section of this dissertation.
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B. Mutagenicities of the G*G*, A*G*, and G*TG* Adducts
1. SOS-Dependence of Mutagenesis
The mutability of cis-DDP DNA adducts in E. coli is absolutely
dependent on the induction of the SOS response. Accordingly, no adduct-
specific mutations were observed for genomes containing any of the cis-
DDP G*G*, A*G*, or G*TG* adducts replicated in non-SOS induced E. coli
DL7 cells. Unlike some SOS-dependent functions, such as UvrABC excision
repair, UmuDC activity, which includes error prone bypass of DNA
lesions, is not detected in non-SOS induced cells. This lack of
activity is expected considering that UmuC is not present (or present at
undetectably low levels) in non-SOS induced cells. Furthermore,
although UmuD is present at moderate levels (-180 molecules/cell,
Woodgate & Ennis, 1991), it only becomes active upon cleavage to its
truncated UmuD' form by RecA*' (Burckhardt et al., 1988; Nohmi et al.,
1988). RecA* is also hypothesized to play a direct role in the
mutagenic bypass of bulky lesions such as cis-DDP adducts (Sweasy et
al., 1990) and is only present in SOS induced cells. Considering that
these several proteins are all required for the mutagenicity of cis-DDP
adducts, it is not surprising that cis-DDP induced mutations were not
observed in non-SOS induced E. coli DL7 cells.
By contrast to the results for the non-SOS induced E. coli DL7
cells, highly targeted cis-DDP induced mutations were observed for the
G*G* and A*G* adducts in SOS induced cells. The occurrence of drug
induced mutations associated with the cis-DDP G*G* and A*G* adducts
correlated with the enhanced survival of the genomes containing these
'The cellular regulation and intermolecular interactions required
for UmuDC mediated mutagenicity are reviewed in depth in the Literature
Survey.
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adducts in the plaque forming assay, as discussed above. Conversely,
genomes containing the G*TG* adduct did not experience an increase in
survival, neither did they give rise to adduct-induced mutations. These
results are consistent with the hypothesis that the UmuD' and UmuC
proteins are responsible for both the survival increase and mutagenicity
experienced by the cis-DDP G*G* and A*G* adducts in the SOS-induced E.
coli DL7 cells.
2. Mutational Specificity of cis-DDP Adducts
a. Comparison to previous results
The mutational specificities of the cis-DDP G*G* and A*G* adducts
have both been determined, albeit in different systems employing site-
specifically modified vectors. Each adduct, when incorporated into
genomes and replicated in SOS induced E. coli, produced highly targeted
mutations at the 5' base of the cis-DDP modified dinucleotide sequence.
Furthermore, the nature of the mutations was similar for each adduct.
About 75% of G*G* mutations were G - T transversions (Bradley et al.,
1993) and about 80% of A*G* mutations were comparable A T
transversions (Burnouf et al., 1990). In both cases tandem mutations
affecting the 5' modified base as well as the nucleotide 5' to the
adduct site were observed at low frequencies. The mutational
specificities of the G*G* and A*G* adducts located in the M13-derived ss
genomes used in the present work are remarkably similar to these
previous results, both with regard to the actual G - T and A T
transversions observed at the 5' nucleotide of the G*G* and A*G*
adducts, respectively, but also with regard to the relative abundance of
each of these predominant mutations. Even minor mutations, such as the
tandem mutants, and the A G transition experienced by the A*G* adduct
mirrored previous results (Burnouf et al., 1990).
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b. The cis-DDP G*TG* adduct is not mutagenic
The mutagenicity of the cis-DDP G*NG* adduct has not been
previously determined, although, assays utilizing randomly modified DNA
have suggested that this lesion is mutagenic (Brouwer et al., 1981;
1982). In contrast to the reported putative mutagenicity of the G*NG*
adduct, and unlike the G*G* and A*G* adducts, the G*TG* adduct was not
mutagenic in this study. Several lines of evidence indicate that this
lack of mutagenicity is a real result and not an unfortunate byproduct
of suboptimal experimental routines. First, M13 ss genomes containing
the cis-DDP G*TG* adduct were replicated in SOS induced E. coli DL7
cells under the same conditions that resulted in the mutagenic
processing of the cis-DDP G*G* and A*G* adducts. The mutagenicity of
the 1,2 adducts implied that the host cells were adequately SOS induced
to elicit a mutagenic response from cis-DDP DNA adducts. Furthermore,
the lack of mutability of G*TG* corresponded to the lack of a SOS-
dependent increase in survival for this adduct in the plaque forming
assay. These results are consistent with the mechanistic explanation
that the G*TG* is not a substrate for UmuDC-mediated translesional
synthesis, an event that is required both for the induction of mutations
and a SOS dependent survival increase, as previously discussed.
There are several possible explanations for the discrepancies
between the current lack of mutability of the G*TG* adduct and
previously observed mutations induced at d(GpNpG) sequences by cis-DDP.
Many of the putative G*NG* induced mutations observed by Brouwer et al.
(1981; 1982) occurred at d(GpApG) sequences. Considering that the A*G*
adduct is expected to form more readily than the G*AG* lesion, mutations
arising at these latter sequences might be a consequence of a 1,2 A*G*
crosslink rather than the 1,3 G*AG* crosslink. This explanation,
however, is likely not valid because most mutations occurred at the 5' G
180
in the d(GpNpG) sequence; if these mutations had resulted from a A*G*
adduct, the site specific experiments indicate that A, not the 5' G,
should be the site of mutation. The lacZ' mutational assay used in this
thesis work provides additional evidence that G*NG* adducts are
mutagenic. As will be discussed later, G*NG* adducts were implicated as
premutagenic lesions.
Another explanation for the apparent discrepancies in the
mutability of the G*NG* adducts may be that, while the cis-DDP G*TG*
adduct may not be mutable, G*AG* and G*CG* adducts are able to produce
mutations, implying that the cis-DDP G*TG* adduct is a poor model for
the study of platinum G*NG* adducts in general. While this hypothesis
cannot be ruled out at present, it remains unclear why the G*AG* and
G*CG* adducts would be mutable and the cis-DDP G*TG* adduct not. As
previously discussed, the three cis-DDP 1,3 intrastrand crosslinks are
structurally similar and, from this perspective, might be considered to
have equivalent mutagenic potentials. Finally, these adducts may or may
not be premutagenic lesions dependent on their local sequence contexts.
Again, this is unlikely. The flanking region for both the G*G* and A*G*
adducts was similar to that of the G*TG* adduct, and both of the former
adducts were mutagenic. Furthermore, as will be discussed in an
upcoming section regarding the comparative mutagenicities of cis-DDP and
ACDP, platinum induced mutagenesis does not appear to be sequence
dependent in the lacZ' region of the M13 genome.
c. Mutational frequencies of the cis-DDP G*G* and A*G* adducts
Early indications that the cis-DDP A*G* adduct was more mutagenic
(approximately 5 fold) than its G*G* counterpart (Burnouf et al., 1987)
were supported by the site specific studies which reported a mutation
frequency of 0.2% for the cis-DDP G*G* adduct (Bradley et al., 1993) and
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-2% for the cis-DDP A*G* adduct (Burnouf et al., 1990). There were two
important caveats regarding the hypothesis that the A*G* adduct is the
more mutagenic lesion. First, the work by Burnouf et al. (1987)
involved randomly modified DNA. The sites of platinum binding to the
DNA were not determined which made it impossible to know if apparent
mutational hotspots were the result of a sequence being more mutagenic
or simply a consequence of more platinum binding to sites that produced
more mutations. These limitations were overcome by the site-specific
studies. Nevertheless important differences in experimental techniques
remained that made comparison of results difficult. The A*G* adduct was
studied in a plasmid (Burnouf et al., 1990) while the G*G* adduct was
incorporated into a viral (M13) genome (Bradley et al., 1993).
Differences in the replication and cellular processing of these
constructs limited the comparative analysis of the mutagenicity of these
adducts. Furthermore, the cis-DDP G*NG* adduct had not been studied
site specifically so its contribution to the overall mutagenicity of
cis-DDP remained unknown. Accordingly, a major focus of this thesis
work was to determine the mutagenicity of all three adducts under
identical conditions in the same biological system.
The cis-DDP A*G* adduct was slightly more than fourfold more
mutagenic than the cis-DDP G*G* adduct (6.0% vs 1.4%) in singly modified
M13-derived ss genomes replicated in SOS induced E. coli DL7 cells.
Interestingly, this result is in good agreement, albeit at the low end,
of the prediction that the A*G* adduct would be 5-10 fold more mutagenic
than the G*G* adduct. Despite the agreement in the relative
mutagenicities of the G*G* and A*G* determined in previous studies, a
comparison of the various studies illustrate that these adducts, when
replicated under different conditions, do have different mutagenic
potentials. For example, the absolute mutation frequencies observed for
adducts located in ss genomes in this study were much (4-10 fold) higher
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than the mutation frequencies observed in the previous studies (Burnouf
et al., 1990; Bradley et al., 1993). A plausible explanation for the
different mutability of the cis-DDP adducts in different systems is
differential repair of the lesions. Adducts located in ds genomes
(Burnouf et al., 1990; Bradley et al., 1993) uniformly experienced lower
mutagenicities than when located in ss genomes (this work). These
results suggest that DNA repair systems remove the adducts from the ds
substrates, thus ameliorating their mutagenic potential. In ss genomes,
however, the major repair mechanism, UvrABC, for cis-DDP adducts is
inoperative, allowing the damage to persist and give rise to a higher
level of mutations.
d. Structural determinants of mutagenicity
The specificity of mutagenesis induced by a mutagen is a
consequence of the structure of the premutagenic lesion. To give an
example, the prototypic replication blocking, SOS dependent,
premutagenic lesion, the thymine-thymine cyclobutane dimer, is most
severly distorted at the 3' base (Hruska et al., 1975). Selective
distortion of the 3' base is suggested as the explanation that the
mutations arising from thymine dimers are highly targeted to the 3'
modified base, with 90% of all induced mutations occurring at this site
(Banerjee et al., 1988; LeClerc et al., 1991). Therefore the result
that the mutations induced by the cis-DDP G*G* and A*G* adducts were
targeted to the 5' base of the adduct site with a high specificity is
consistent with the structural data, depicted in Figure 20 as well as
discussed in detail in the Literature Survey and briefly below, that the
5' base of a cis-DDP modified dinucleotide suffers the greatest
distortion upon platinum binding.
The cis-DDP chelated d(GpG) sequence has been extensively
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characterized as a dinucleotide (den Hartog et al., 1982; Sherman et
al., 1985), in longer DNA sequences (Caradonna & Lippard, 1982; den
Hartog et al., 1983; 1985b), as well as in duplex DNA (van Hemelryck et
al., 1984; Bellon et al., 1991). The 3' modified G is relatively
unperturbed from its normal B-DNA conformation. Conversely, the 5'
modified G is distorted, experiencing an altered orientation that
induces a bend between the planes of the two modified nucleotides.
Based on this structural information, the result that mutations were
targeted to the 5' G was anticipated. The structural perturbation
imposed on the DNA duplex by 1,2 intrastrand binding is localized, with
distortion restricted to the sequence in close proximity to the lesion.
The DNA is more perturbed 5' to the adduct than it is in the 3'
direction. Once again, it is not surprising that while cis-DDP induced
mutations were overwhelming located at the 5' position of the adduct
site, the only other induced mutations were tandem mutations involving
the same 5' modified base as well at its neighboring 5' nucleotide.
The mutations induced by the cis-DDP A*G* adduct were
qualitatively almost identical to those from the comparable G*G* adduct.
A*G* induced mutations were highly specific to the 5' modified base with
A - T transversions comprising the predominant mutation. In addition,
tandem mutations involving the modified adenine residue and its 5'
neighboring base were also observed for the A*G* adduct. The only
difference in the mutational specificity of the A*G* adduct compared to
the G*G* adduct was the occurrence of A G transitions at the 5'
modified base (of course, comparable, i.e. G G, mutations are not
possible for G*G* adducts). The A G transitions occurred less
frequently than the predominant A T transversions, results that are
consistent with previous observations (Burnouf et al., 1990; Bradley et
al., 1993). The structure of the cis-DDP A*G* adduct has not been as
well characterized as the cis-DDP G*G* adduct has been. From what is
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known, however, the nature of the structural perturbations imposed on
DNA by both adducts is similar (van Hemelryck et al., 1984; Dijt et al.,
1989; Urata et al., 1992) accounting for the comparable mutational
specificities exhibited by each lesion. The extent of structural
distortion caused by binding at d(ApG) sites, however, is greater than
that caused by binding to d(GpG) sites (Marrot & Leng, 1989; Schwartz et
al., 1989; Anin & Leng, 1990). The greater structural distortion
imposed by cis-DDP binding at d(ApG) sites compared to d(G*G) sites,
could account for the former lesion's fourfold higher mutagenicity as
compared to the cis-DDP G*G* adduct.
The A G transitions derived from A*G* adducts notwithstanding,
cis-DDP induced purine - thymine transversions with a high specificity.
This pattern of mutability is consistent with an SOS dependent
premutagenic lesion exhibiting its effects by a noninformational, rather
than a misinformational, mechanism. Misinformational lesions mediate
their mutagenicity by incorrect base pairing during DNA replication and
are generally independent of the SOS response. By contrast, for
replication blocking lesions such as apurinic/apyrimidinic (AP) sites,
the structure of the DNA lesion precludes base pairing, rendering the
lesion "noninformational." Such lesions are only mutagenic when a
stalled polymerase is rescued by UmuDC facilitated translesion
synthesis. Most often during UmuDC mediated translesion synthesis, an
adenine residue is inserted opposite a noninformational lesion,l
resulting in the insertion of thymine in the place of the original
lesion upon subsequent rounds of DNA replication, thus fixing the N - T
'Adenines are preferentially inserted opposite noninformational
lesions. The basis for this preference is hypothesized to be that the
primary DNA damage suffered by prokaryotes would be from ultraviolet
radiation producing thymine-thymine cyclobutane dimers in the genome.
An adenine residue inserted opposite such a lesion would result in
accurate DNA replication, since a thymine would be incorporated in
subsequent rounds of DNA replication, correctly replacing the dimerized
thymime residues.
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mutation. It is hypothesized that the structural perturbation suffered
by the 5' base of the cis-DDP G*G* or A*G* adducts render the 5' base
noninformational, leading to the observed A T or G T transversion
mutations, respectively. It should be noted that, although cis-DDP DNA
adducts do act as noninformational lesions as evidenced by the
occurrence of drug induced mutations, in the vast majority of bypass
events (98.6% and 94.0% for the G*G* and A*G* adducts, respectively)
correct base pairing does occur, resulting in nonmutagenic DNA
synthesis. This relatively high rate of fidelity' is likely possible
because the base pairing region of cis-DDP modified nucleotides is not
affected by platinum binding. Interestingly, even the G*TG* adduct,
despite the more severe disruption of the DNA duplex effected by the
destacking of its central nucleotide, was also replicated
nonmutagenically. Indeed, mutagenic replication of the cis-DDP G*TG*
adduct was not observed at all (presumably because the structure of this
lesion prevented its recognition by UmuDC).
'The extent of fidelity for DNA synthesis past DNA lesions in E.
coli varies greatly. Very low fidelity occurs during SOS dependent
bypass of the thymine-thymine pyrimidine-pyrimidone (6-4) uv
photoproduct. This process is only 9% accurate (MF = 91%, LeClerc et
al., 1991). Bypass of the uv thymine-thymine cyclobutane dimer occurs
with higher fidelity, being 93% accurate (MF = 7%) (Banerjee et al.,
1989). The latter example is comparable to the 94% accuracy observed
for the bypass of the cis-DDP A*G* adduct in the present work
(incidently studied in the same M13-derived ss genome as the cyclobutane
dimer). Nevertheless these rates, or even that of the less mutagenic
G*G* adduct (98.6% accuracy in translesion bypass) must be considered to
be very low in fidelity compared to normal replication of DNA, a process
in which unmodified nucleotides are replicated more accurately by 7-9
orders of magnitude.
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Figure 20. Molecular basis for the targeting of mutations to the 5'
base of a bifunctional cis-DDP adduct. As discussed in the text, the 3'
modified base is relatively unperturbed from normal B-DNA structure and
consequently suffers few, if any, induced mutations. The 5' modified
base, however, is significantly distorted and is believed to be able to
function as a noninformational lesion. Adenosine residues are
preferentially inserted opposite the 5' modified base. In subsequent
rounds of replication, T's are inserted opposite the A's, thereby fixing
the G T transversion mutations for the G*G* adduct as shown (similar
rationale explains A - T transversions targeted to the 5' base of the
A*G* adduct).
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C. Comparison of the Genotoxicities and Mutagenicities of
cis-DDP and ACDP DNA Adducts
1. Survival
The plaque-forming ability of M13mp18 RF DNA modified with either
cis-DDP or ACDP was reduced in a dose dependent manner, suggesting that
the DNA adducts formed by both compounds are capable of blocking DNA
synthesis in E. coli. Genotoxicities, 3.3 and 5.2 adducts per lethal
hit for cis-DDP and ACDP, respectively, are comparable to the lethality
of DNA damage formed by benzo(a)pyrene-7,8-dihydrodiol-9.10-oxide
(BPDE), uv irradiation, or cis-1,2-diaminocyclohexyldichloroplatinum(II)
([Pt(DACH)C12], Figure 1). The DNA lesions of these compounds, all
processed by the SOS system in E. coli, had genotoxicities of 3, 5.54,
or 5.5 adducts per lethal hit, respectively (Mizusawa et al., 1981;
Strike & Roberts, 1981; Husain et al., 1985) in a variety of plasmid
systems. Furthermore, the in vivo results obtained in the present study
are in agreement with previous work employing in vitro primer extension
methodology that revealed cis-DDP and ACDP adducts block DNA replication
to a similar extent, with cis-DDP slightly more inhibitory (Hartwig &
Lippard, 1992).
Pretreatment of the host E. coli cells with uv irradiation to
induce the SOS response increased the survival of M13mp18 genomes
modified with either drug approximately threefold in the plaque forming
assay. An SOS-dependent increase in survival for ds DNA modified with
cis-DDP is attributable to repair of the lesions by UvrABC (Beck et al.,
1985; Husain et al., 1985) or to increased bypass of the adduct,
mediated by the umuDC and recA protein complexes (Elledge & Walker,
1983; Bridges & Woodgate, 1984; Rajagopalan et al., 1992). The SOS
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dependent survival increase for ACDP closely paralleled that seen for
cis-DDP indicating that E. coli processes both types of DNA adducts in a
similar manner. Furthermore, since the processitivity of eukaryotic, as
well as prokaryotic, polymerases is decreased by platinum DNA adducts
(Villani et al., 1988; Corda et al., 1991; Comess et al., 1992) the
similar genotoxicities of cis-DDP and ACDP in this bacterial system
might predict their relative lethalities in eukaryotic cells. This
hypothesis is supported by the recent finding that ACDP1 is about as
cytotoxic as cis-DDP and in human ovarian carcinoma cell lines (Kelland
et al., 1992b).
2. Comparative mutation frequencies of cis-DDP and ACDP
a. Comparison to other mutational assays
Since cis-DDP is an established mutagen in several bacterial and
mammalian systems, its mutagenicity in the lacZ' mutational assay was
anticipated. Other platinum compounds are also mutagens; carboplatin,
for example, produces mutations similar to those induced by cis-DDP in
the APRT gene of Chinese hamster ovary cells (de Boer & Glickman, 1992).
Although other platinum drugs are mutagenic, many are quantitatively
less mutagenic than cis-DDP. Carboplatin and cis,trans,cis-dichlorobis-
dihydroxy(isopropylamine)platinum(IV) (iproplatin, Figure 1), to give
two examples, are considerably less mutagenic than cis-DDP at equitoxic
doses in V79 lung fibroblasts and BHK21/C13 cells (Chibber & Ord, 1992).
The mutagenicity of ACDP falls into this latter category, being lower
than cis-DDP in the present lacZ' mutational assay. ACDP, like cis-DDP,
was found to be an SOS-dependent mutagen in E. coli; mutagenesis by such
'It should be noted that ACDDP, and not its DNA-reactive metabolite
ACDP, that has significant therapeutic advantages over cis-DDP owing to
the former compound's pharmacological properties.
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agents is not a passive process but requires specific processing by a
cellular system. As discussed, the SOS system consists of a family of
inducible proteins including at least three (umuD', umuC, and recA*)
that, along with PolIII, form a "mutasome" at the site of a DNA adduct
to aid in error prone, and thus mutagenic, bypass of the lesion (Bagg et
al., 1981; Bridges & Woodgate, 1985; Bailone et al., 1991b). Compounds
forming DNA adducts in E. coli requiring the specific intervention of
these proteins to induce mutations are often mutagenic in eukaryotes
(Walker, 1984; Ho et al., 1993). It is reasonable, therefore, to expect
that ACDP will also be less mutagenic in human cells, a feature that, if
realized, would be especially attractive in supporting the clinical
potential of ACDDP, its parent compound, as an anticancer drug.
b. Mechanistic rationale for differences in the mutation frequencies of
cis-DDP and ACDP
The spectra of adducts formed by cis-DDP and ACDP suggest a
molecular mechanism responsible for their relative mutagenicities. The
major adduct formed by both compounds occurs at d(GpG) sites;
approximately 65% of the total adducts for cis-DDP and 54% for ACDP
occur at these sites. The A*G* adduct, however, is about 3 times more
prevalent in cis-DDP adduct spectrum than for ACDP (25% vs 8%; Hartwig &
Lippard, 1992). A molecular rationale has been developed to explain the
diminished ability of ACDP to form the A*G* adduct. The asymmetry of
the ACDP complex gives rise to an orientational isomerism when the
complex forms 1,2 intrastrand crosslinks with DNA (Hartwig & Lippard,
1992). As illustrated in Figure 3, with d(GpG) adducts, the cyclohexyl
ligand can point either toward the 5' or 3' guanine residue and hence
both orientational isomers form upon binding to DNA. It is noteworthy
that one of the isomers (II) potentially forms a favorable hydrogen bond
between the cyclohexylamine moiety of the drug and the 6 of guanine.
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Formation of the analogous isomer (IV, Figure 3) does not occur,
apparently because the cyclohexylamine moiety sterically clashes with
the exocyclic amino group of the 5' adenine. As a consequence, the ACDP
drug forms fewer adducts at d(ApG) sites (Hartwig & Lippard, 1992).
Site specific mutagenic studies have suggested that the A*G*
adduct is 5-10 times more mutagenic than the G*G* adduct (Burnouf et
al., 1990; Bradley et al., 1993). Work done for this thesis confirmed
that the A*G* adduct was four to five fold more mutagenic than the G*G*
adduct. When formed, the A*G* adduct appears to be a dominant
contributor to the mutational spectra of platinum compounds. Therefore,
because the highly mutagenic A*G* adduct is more abundant in the cis-DDP
adduct spectrum, the finding that the overall mutagenicity of cis-DDP
would be higher than for ACDP is understandable. Also in agreement with
the observed lower mutagenicity effected by ACDP was the finding that
the G*TG* adduct was not mutagenic. Therefore even though G*NG* adducts
are twice as abundant in the ACDP spectrum compared to the cis-DDP
adduct spectrum (18% vs 8-10%), these adducts are incapable of
contributing to the potential mutagenicity of ACDP.
There are two caveats, however, to this mechanistic rationale used
to account for the relative mutability of the DNA lesions formed by cis-
DDP and ACDP. First, it is not clear that the cis-DDP G*TG* adduct is
representative of all platinum 1,3 intrastrand crosslinks. As discussed
previously, some mutational assays, including the present one, suggest
that 1,3 adducts might be mutagenic. Such studies, however, employed
randomly modified DNA and are not as definitive as the site specific
evaluation of the cis-DDP G*TG* adduct, which showed that this lesion
was not mutagenic in the context evaluated. The G*CG* and G*AG* adducts
have not been studied site specifically, and could be mutable, thereby
accounting for the apparent mutagenicity of G*NG* adducts. Since the
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G*TG*, G*CG*, and G*AG* adducts appear to be structurally similar, it is
difficult to understand from a structural perspective how the G*CG* and
G*AG* adducts could engender a different level of mutagenicity than the
G*TG* adduct. Nevertheless, if the G*CG* and G*AG* adducts, unlike the
G*TG* adduct, are mutagenic and comprise a significant proportion of the
18% of the G*NG* adducts formed by ACDP, the mutagenicity of this
compound would be higher than otherwise anticipated.
Second, the mutagenic potentials of the cis-DDP G*G*, A*G*, and
G*TG* adducts have been assumed to reflect the mutagenic potential of
the equivalent adducts formed by ACDP. The accuracy of this assumption
is dependent on two factors that could influence the genetic effects of
the DNA adducts formed by cis-DDP and ACDP. First, the structural
distortion imposed on the DNA architecture by platination (Bellon et
al., 1991) could be the primary influence affecting the molecular
processing of DNA modified by these compounds. Many platinum(II)
compounds bind DNA at similar nucleotide sequences, forming mainly 1,2-
and 1,3- intrastrand crosslinks, which effect similar bending and
unwinding of the DNA duplex (Lippard et al., 1983; Page et al., 1990;
Hartwig & Lippard, 1992). If structural deformation of the DNA helix is
the major factor contributing to the genotoxicities and mutagenicities
of platinum DNA adducts, the effects of cis-DDP and ACDP would be
expected to be very similar. Conversely, if the genetic effects of cis-
DDP and ACDP DNA adducts are a consequence of the ligands attached to
the platinum adduct, the cyclohexyl ring of ACDP, a moiety lacking in
cis-DDP, the two compounds should elicit different biological effects.
The results of this study suggest that both of the aforementioned
factors play a role in the mutagenic activity of platinum-DNA adducts.
The levels of genotoxicity and types of mutations arising from both cis-
DDP and ACDP were very similar indicating the importance of the
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structural deformation of DNA on these processes. On the other hand,
the influence of the cyclohexyl ring of ACDP was manifest through its
ability to direct the formation of potentially less mutagenic adducts
resulting in a lower mutation frequency as compared to that of cis-DDP.
c. Comparison of mutation frequencies determined from the lacZ' and the
site specific studies
A practical application of the site specific determination of the
mutagenicities of the cis-DDP G*G*, A*G*, and G*TG* adducts is the
evaluation of new platinum drugs. As discussed above, it appears
possible that the overall mutagenic potential of a platinum compound can
be extrapolated from the site specific analysis of individual DNA
adducts. To reinforce the validity of this approach further, a
quantitative evaluation of the results from the site specific and random
mutagenesis assays was done. From the results of the site specific
experiments, an "average" cis-DDP DNA adduct would be predicted to have
a mutagenicity of 2.41%:
Adduct Relative abundance x MF Normalized MF
G*G* (0.65) x (1.4%) 0.91%
A*G* (0.25) x (6.0%) 1.50%
G*NG* (0.10) x (0.0%) 0.00%
Total 2.41%
Assuming that ACDP adducts have similar mutagenicities as the comparable
adducts formed by cis-DDP, an "average" ACDP DNA adduct should have a
mutagenicity of 1.29%:
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Adduct Relative abundance x MF Normalized MF
G*G* (0.58) x (1.4%) 0.81%
A*G* (0.08) x (6.0%) 0.48%
G*NG* (0.18) x (0.0%) 0.00%
Total 1.29%
Based on these data, cis-DDP should be 1.87 fold (2.41% vs 1.29%) more
mutagenic than ACDP. From Figure 17, at an average of 1 adduct in the
370 bp fragment of M13mp18 genomes in which mutations are detectable in
the lacZ' mutational assay, cis-DDP had a mutagenicity of 0.27%, the
comparable value for ACPD was 0.16%. cis-DDP was 1.7 fold (0.27%/0.16%)
more mutagenic than ACDP, a value that closely agrees with the value of
1.89 fold predicted from the site specific results. Clearly, the site
specific approach to the evaluation of the different DNA adducts formed
by a mutagen has validity in predicting the overall mutability of the
compound. Accordingly, as the mechanism for platinum binding to DNA is
understood in increasing detail (Bloemink et al., 1992; Hartwig &
Lippard, 1992; Bernges & Holler, 1992; Green et al., 1992), an important
factor in the design of new platinum drugs should be the selection of
substituents that direct the formation of the less mutagenic, and hence
safer, DNA adducts.
d. The absolute mutation frequency differs between singly and randomly
cis-DDP modified genomes
The mutation frequencies for both cis-DDP and ACDP are much lower
in the work utilizing randomly modified DNA than was observed in the
site specific studies. As discussed elsewhere, this apparent difference
in mutability could be a consequence of utilizing ds DNA in the random
study. The randomly modified ds DNA was replicated in repair proficient
E. coli known to repair platinum DNA lesions efficiently. By contrast,
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the site specific results were obtained by using ss DNA for which repair
would not be expected. The platinum DNA adducts, therefore, could
persist in the genome and give rise to a much higher level of
mutagenicity.
An alternate explanation for the different mutation frequencies is
that different methods were used to detect mutations. The selection of
mutants occurring in the singly cis-DDP modified M13 ss genomes was
based on the ability of a mutation to block cutting at a restriction
site. This method, in theory, should allow 100% of the mutations that
occurred within the six base restriction site to be detected. By
contrast, the selection of mutants occurring from randomly cis-DDP or
ACDP modified M13mp18 RF DNA was indirect. Mutations observed in the
lacZ' mutational assay rely on amino acid changes that functionally
alter -galactosidase activity which, in turn is phenotypically
detected. Considering that the genetic code is degenerate, some
mutations do not result in amino acid substitutions and remain silent.
Other mutations, although effecting amino acid changes, do not alter f-
galactosidase activity sufficiently to be phenotypically observed. A
large number of mutants, therefore, can go undetected in the lacZ'
mutational assay. Interestingly, by accounting for these factors, as
discussed below, the results of the two studies agree fairly well.
The mutation frequency varied from about 0.3 to 0.5% for the
randomly modified genomes (1.85 or 2.36 adducts per 370 nucleotide
mutation target sequence for cis-DDP and ACDP, respectively) used in the
lacZ' mutational assay. Four mutations not giving rise to amino acid
changes were found in samples that had mutations elsewhere that enabled
their detection in the lacZ' mutational assay (see Table 12, and further
discussion in the next section). Assuming that a similar level of
mutations occurred in all platinum modified genomes, but remained
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undetected for the reasons discussed above, the actual mutation
frequency of these genomes would be increased by 1.32% (i.e. 4 neutral
mutations/303 total samples sequenced) to give a total frequency between
1.62 and 1.82% implying that only 19 to 27% of all mutations that
actually occurred were detected. This range of detection is close to
the 35% of base substitution mutations predicted to be observed based on
theoretical considerations of the degeneracy of the genetic code and the
phenotypic consequences of amino acid substitutions in protein function
(Stark et al., 1979). Of greater relevance, these adjusted mutation
frequencies are comparable to the values of 1.29% and 2.41% for ACDP and
cis-DDP, respectively, predicted above.
3. Features of the LacZ' Forward Mutational Assay
The mutational spectra of cis-DDP and ACDP obtained in the present
study confirms the utility of the lacZ' mutational assay to detect a
wide range of mutations as discussed in the literature survey section.
One hundred and eleven different single-base substitutions occurring at
85 sites were detected. Fifty-eight of these mutations were unique to
this study. Combined with the data from the other studies previously
surveyed, the lacZ' mutation assay now has the capacity to detect at
least 199 different single-base substitutions at 130 sites as well as
single base frameshifts and large deletions. The extreme sensitivity of
the lacZ' mutational assay enables it to avoid biases inherent in other
mutational assays.
Approximately 80% of the observed mutations were in the DNA
sequence coding for the lacZ' peptide fragment (Figure 18). Missense
mutations comprised about 80% of this group along with about 15%
nonsense mutations (Table 12). Interestingly, five neutral mutations,
at the wobble (3rd) position of serine, proline, leucine, threonine, and
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alanine codons were found. Four of the five samples had second,
apparently unrelated, missense mutations at other sites that probably
were responsible for the serendipitous detection of the neutral
mutations. No other mutation was found in the sample with the neutral
change in the proline codon, however, despite sequencing the lacZ' DNA
sequence from positions 6010 to 6695 (a range considerably larger than
the 370 bp sequence in which all of the other mutations were observed).
Neutral mutations that affect a-complementation previously have been
described for valine (Decuyper-Debergh et al., 1987), proline and
alanine (Sambamurti et al., 1988), and leucine (Hoebee et al., 1991)
codons. The latter group speculates that these mutations interfere with
correct transcription or translation.
4. Dark Blue plaques
Approximately 98% of mutants identified in the lacZ' mutational
assay had reduced or abolished -galactosidase activity. An
infrequently occurring class of mutations, however, had significantly
enhanced enzymatic activity as described in Table 8. An interesting
feature of this group is that they all, with one exception,1 have
mutations that form a stop codon in the C-terminal overlap region.
Furthermore, every stop codon detected in the C-terminal overlap region
gave rise to a mutated genome that produced the phenotypically observed
dark blue plaques (Figure 18).
'The one exception is a mutant that had the initiating methione
residue changed to an isoleucine. Despite lacking the initial methione,
the lacZ' polypeptide was nevertheless synthesized as evidenced by -
galactosidase activity. Peptide synthesis could been have initiated at
the third residue, which is also a methionine, or possibly further
downstream. Either way, a truncated N-terminal overlapping region would
be generated and the same mechanistic explanation given for enhanced -
galactosidase activity (in the text and Figure 21) in the mutants with
truncated C-terminal polypeptides would apply.
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Presumably, the peptide encoded by the C-terminal overlap region
interferes with the association of the subunits of the M15 a-acceptor
protein and lacZ' polypeptide a-donor during complementation. Optimal
tetramerization of the polypeptide subunits is prevented, resulting in
reduced -galactosidase activity (Figure 21 (a)). "Wild-type" 3-
galactosidase activity in the M13 system, therefore, is lower than the
activity theoretically possible from the molar equivalents of enzyme
present during the plaque forming assay. In mutants with enhanced -
galactosidase activity, the truncated peptide in the C-terminal overlap
region is hypothesized to allow more efficient tetramer formation with a
resultant increase in enzymatic activity (Figure 21 (b)), perhaps
approaching the level of activity of the natural form of -galactosidase
(Figure 21 (c)). The M112 a-complementation system provides a
precendent for this hypothesis. M112 is an inactive -galactosidase
mutant, similar to M15 in that it forms dimers but not tetramers, but
only lacks nine residues from the amino acid sequence 23-31. Under a-
complementation conditions, M112 can reach a level of activity many
times higher than is possible with the M15 protein, as a result of more
efficient tetramer formation of the M112 polypeptide subunits during a-
complementation (Welpy et al., 1981a; Zabin, 1982).
5. Mutational Spectra of cis-DDP and ACDP Modified DNA
The mutagenicity of cis-DDP DNA adducts has been investigated in a
number of assays, with varying results. The most definitive mutagenesis
studies have employed site specifically modified genomes containing the
two major cis-DDP DNA adducts. About 80% of the mutations caused by an
A*G* adduct in pEMBL8 plasmid replicated in E. coli were A - T mutations
at the 5' A of the d(ApG) pair (Burnouf et al., 1990). The cis-DDP G*G*
adduct located in an M13mp18 RF genome and replicated in E. coli
produced remarkably similar mutations, with greater than 80% G T
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mutations at the 5' G (Bradley et al., 1993). The site specific studies
previously described in this dissertation confirm the results of Burnouf
et al. (1990) and Bradley et al. (1993) and provide the additional
result that the cis-DDP G*TG* adduct is not mutagenic under conditions
that rendered the cis-DDP G*G* and G*G* adducts mutable. As might be
expected from the site specific mutagenesis studies, G T or A T
mutations occurring at the 5' position of d(GpG) or d(ApG) sites,
respectively, were observed in several studies using randomly platinated
DNA in the tetracycline-resistance gene of pBR322 in E. coli (Burnouf et
al., 1987), in exon 3 of the human hypoxanthine guanine phosphoribosyl
transferase gene in B-lymphoblasts (Cariello et al., 1992), in the
SUP4-o gene of Saccharomyces cerevisiae (Mis & Kunz, 1990) and in the
supF gene of pZ189 in normal human fibroblasts or XP12BE cells (Bubley
et al., 1991). In addition to these expected mutations, the studies by
Mis & Kunz (1990) and Cariello et al. (1992) also detected significant
numbers of G A and G C mutations at d(GpG) sites. In two other
studies, utilizing the lacI gene of E. coli (Brouwer et al., 1981; 1982)
or the adenine phosphoribosyl-transferase gene of Chinese hamster ovary
cells (de Boer & Glickman, 1989) as the mutational target, G T, G - A,
or G C mutations at the 5' position of d(GpApG) or d(GpCpG) sequences
predominated.
Most platinum induced mutations detected in the present study
occurred at d(ApG) or d(GpG) sites; furthermore many of these mutations
were A - T or G T transversions at the 5' base, consistent with the
results of the site-specific and several of the random mutagenesis
studies. Features of other cis-DDP mutational assays, such as the
significant number of G A transitions observed as well as mutations
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that could have arisen only from d(GpNpG) sites' were also represented
in the cis-DDP mutational spectrum; indeed, essentially all of the
mutations described for cis-DDP in the several mutational assays listed
above also were observed in the present lacZ' mutational assay. The
differences in the mutagencity previously observed for cis-DDP are more
a reflection of the biases inherent in the mutational assays used,
rather than an indication of different mutagenic processing of cis-DDP
in the various systems. It is reasonable, therefore, to expect that the
mutation spectrum obtained for ACDP in this study also would be
indicative of its mutagenic potential in a range of prokaryotic and
eukaryotic systems.
cis-DDP and ACDP induce similar types of mutations but there are
some significant differences in their distribution (Table 11). The
predominant type of mutation for both drugs was the single base
substitution: 93% of cis-DDP mutations and 87% of ACDP mutations. The
major mutation observed for both drugs was the G T transversion
arising from either the (+) or (-) DNA strands at almost identical
rates. In addition, G A and A - T mutations were well represented in
each mutational spectrum (Figure 18). There were some differences for
infrequently occurring mutations, but there were too few of these from
which to draw meaningful conclusions. Even though the types of
mutations were comparable for each platinum compound, the locations at
which the mutations occurred varied. Of the 257 induced mutations, 86
(43 for each drug) were identical mutations that occurred at the same
sites for both drugs; the remaining 72 cis-DDP and 99 ACDP mutations
were similar in nature but occurred at different sites. The disparity
'Unlike the occurrence of mutations expected from G*G* and A*G*
adducts in the assays using randomly modified DNA, site specific results
from the G*TG* adduct indicated that this lesion should not be
mutagenic. The discrepancy in these results was previously addressed
(in section V.B.3) and will not be discussed further at this juncture.
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in the distribution of the mutations arising from each drug may be less
a reflection of the mutagenic potential of these compounds than an
inadequate sample size.l
Regardless of sample size, however, it is unlikely that the
mutational spectra of the two drugs would become completely identical.
Differences exist in the mutational spectra of cis-DDP and ACDP for two
reasons. First, the molecular processing of cis-DDP and ACDP DNA
adducts is affected, at least to some degree, by the cyclohexyl
substituent of ACDP. For example, Hartwig and Lippard (1992) report
different stop site preferences for polymerases encountering site-
specifically prepared cis-DDP and ACDP G*G* adducts although,
quantitatively, the replication blockage effected by each adduct is
similar (92% for the cis-DDP G*G* adduct compared to 85-90% for the ACDP
G*G* adduct (Hartig & Lippard, 1992)). The results of the present study
suggest similar behavior in the mutagenicities of these adducts; the
overall mutational spectra are very similar but the individual mutations
sites vary. A second factor contributing to the differences in the
mutational spectra are differences in the distribution of DNA adducts
formed by cis-DDP and ACDP. The sequence specificity of DNA binding
sites is determined by a combination of steric and hydrogen bonding
effects influenced by the substituents attached to the platinum atom
(Green et al., 1992). As indicated earlier, the ability of ACDP to form
orientational isomers (Figure 3) could contribute to the observed
diminution in highly mutagenic A*G* intrastrand crosslinks.
1As more mutants of each drug were sequenced, the proportion of
identical mutations increased. For example, after sequencing about half
the mutants analyzed in this study (53 cis-DDP and 61 ACDP) only 7
(12%) mutations were identical but increased to 43 (33%) by the end of
the study. It is reasonable to expect that if the sample size was large
enough the distribution of the mutations would be as similar as the type
of mutations given in Table 11.
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As discussed, an analysis of the types of mutations induced by
cis-DDP adducts in the site specific studies suggested that these
adducts functioned as noninformational premutagenic lesions. This mode
of mutagenesis is consistent with the mutational results observed for
the platinum-modified M13mp18 genomes utilized in the lacZ' mutational
assay. The similarities in the mutational spectra of cis-DDP and ACDP
provides additional support for the hypothesis that platinum DNA adducts
are noninformational, rather than misinformational, lesions. The
mutagenicity of both platinum compounds is similar to AP sites. A
mutational spectrum determined for AP sites in an M13mp2 lacZ'
mutational assay showed a pattern of mutagenesis similar to that seen
for both platinum drugs in the present study (Kunkel, 1984). In
Kunkel's study, 79% of spontaneous single base changes were transitions;
a value that dropped to 28% for mutations induced by AP sites.
Similarly, in the present study, the number of transitions decreased
from 73% of single base changes in unmodified DNA to 33% in platinated
DNA. The similarities between mutations caused by cis-DDP and ACDP
observed here, as well as the similarities of mutational spectra for
cis-DDP and carboplatin in the APRT gene of mammalian cells (de Boer &
Glickman, 1992) suggest that mutations induced by platinum(II) compounds
are primarily a consequence of adduct-induced bending and unwinding of
the DNA helix and are not greatly influenced by any misinformational
effects exerted by substituents attached to the platinum atom.
6. Correlation of Sites of Adduct Formation with Mutational Spectra
The spontaneous mutational spectrum generated from unmodified DNA
was significantly different than the cis-DDP and ACDP induced spectra,
indicating that specific platinum adducts, not random DNA damage, were
responsible for the mutagenicity associated with the modified DNA
samples. Replication mapping of adducts was done to demonstrate that
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platinum adducts were present at the sites where mutations occurred to
reinforce further the mechanistic link between these DNA lesions and the
induced mutational events. As can be seen in Figure 18, most of the
observed mutations do occur at sites of platinated nucleotides. A
fraction of the mutants, (23 cis-DDP and 25 ACDP), however, occur at
nucleotides that apparently are not modified; these mutants result from
one of two causes. First, at many potential sites of modification, the
level of platination, although detectable, was too weak to quantitate
and therefore was not included in Figure 18. Such sites include the
cis-DDP induced mutants at position 6147 of the (-) strand. Seven cis-
DDP and 12 ACDP induced mutants fit into this category. Second, as
mentioned in the Results section, approximately 12-20% of the mutants in
the drug induced spectra are spontaneous in origin, and would not be
expected to occur at drug modified sites. An example of this class of
mutants can be observed near 6310 where similar mutations are seen in
the cis-DDP, ACDP, and spontaneous mutational spectra. Considering
these factors, the correlation between the sites of adduct formation and
the actual the location of mutations is excellent.
The adduct mapping experiments also revealed that platinum binding
in the M13mpl8 lacZ' DNA sequence is stochastically determined for the
major G*G* adduct. The empirically derived adduct distribution matched
the distribution predicted from the known binding preferences of these
drugs (Figure 22, white and gray bars). Ideally, the adduct mapping
experiments would have had sufficient sensitivity to compare the
relative number and sites of minor DNA adducts (e.g. A*G* and G*NG*)
formed by cis-DDP and ACDP. Unfortunately, the adduct distribution
experiments did not have sufficient sensitivity to allow a rigorous
comparison of the relative number and sites of these adducts. Such
information would afford further insight into the hypothesis that ACDP
is less mutagenic because it forms fewer of the highly mutagenic A*G*
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adducts. Unfortunately the difficulty in quantifying infrequently
occurring adducts coupled with the inability to determine which adduct
occurred at a site capable of giving rise to more than one adduct,
prevented a rigorous comparison of the relative mutagenic potentials of
the A*G*, G*G*, G*NG* or other DNA adducts formed by cis-DDP and ACDP.
This point notwithstanding, it is reasonable to predict that, as for the
G*G* adducts, the infrequently occurring adducts also would be
stochastically distributed in the lacZ' DNA sequence of the M13mp18 RF
genomes. Accordingly, the threefold higher level of A*G* adducts in the
cis-DDP adduct spectrum compared to the ACDP adduct spectrum (Hartwig &
Lippard, 1992) would offer as attractive explanation for the higher
mutagenicity of cis-DDP. An analysis of the specific adducts that
produce mutations is consistent with this hypothesis. The data in Table
13 suggest that over three times as many mutations occur at d(ApG) sites
in the cis-DDP mutational spectrum as in the ACDP spectrum.
The data in Table 13 includes a relatively small subset of the
entire mutational spectra that only includes mutations of unambiguous
origin. Mutations of ambiguous origin also can be assigned to
particular nucleotide sequences assuming that the mutational spectral
data obtained in this study reflect the results of previous site
specific mutagenesis studies showing that mutations predominantly occur
at the 5' nucleotide of either an d(ApG) or d(GpG) site (Burnouf et al.,
1990; Bradley et al, 1993) as well as the work by Brouwer et al. (1981),
which indicated that mutations also preferentially occur at the 5'
position of d(GpNpG) sites. Primarily by using this criterion to assign
mutations to particular DNA adducts (Table 14), A*G* adducts once again
were shown to induce significantly fewer mutations in the ACDP spectrum
than in the cis-DDP spectrum. Another interesting finding is the
relatively high proportion of mutations at d(GpNpG) sites, suggesting
that the G*NG* adduct, like the A*G* adduct, is more mutagenic that the
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G*G* adduct (as mentioned, this observation conflicts with the
nonmutability of the cis-DDP G*TG* adduct in the site specific
experiments). The tentative nature of these conclusions should be
emphasized, considering that the data in Table 14 are based on several
assumptions. Nevertheless, it is of note that the conclusions reached
from Table 14 are in agreement with the smaller, but more precise, set
of data presented in Table 13.
7. Sequence Dependence of Mutagenesis
Another goal of the adduct mapping experiments was to determine
whether mutations arising from cis-DDP or ACDP adducts were sequence-
dependent; that is, are mutation hotspots observed in the lacZ' DNA
sequence of M13mp18 RF genomes modified with the platinum drugs?
Apparent mutation hotspots are commonly detected in lacZ' -
galactosidase a-complementation mutation assays (Kunkel, 1984; LeClerc
et al., 1984; Decuyper-Debergh et al., 1987; Sambamurti et al., 1988;
Hoebee et al., 1989; Gupta et al., 1991; McBride et al., 1991). A
limitation of these previous studies, however, is that the exact sites
of DNA damage were not determined. It is therefore unclear whether
multiple mutations at a particular site comprise a sequence-dependent
hotspot or are simply a consequence of a higher level of DNA damage at
that site. In contrast, the adduct mapping data obtained in the present
study allow a direct comparison between the sites of platination and
sites of mutagenesis.
a. Sensitivity to mutation is related to the local function of the
lacZ' sequence
The data in Figure 18 clearly show that some sites experience
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significantly more mutations than other sites with similar levels of
platinum binding. By contrast, several highly modified sites have few,
if any, mutations. The sites of enhanced, or diminished, mutagenicity,
however, are more closely correlated with the functional specificity of
the lacZ' DNA sequence than with the local nucleotide composition of the
DNA. As shown (Figure 21), some regions of the lacZ' DNA sequence of
the M13mp18 genome, such as the CAP binding site, -35 promoter, ribosome
binding site, and 93 nucleotide sequence corresponding to the deletion
in the M15 a-acceptor protein are hypersensitive to mutations.
Mutations occurring in these functionally critical areas are expected to
have a greater chance of disrupting the a-complementation process. Such
mutations are more easily detected than mutations in less crucial
regions of the lacZ' sequence of M13mp18 such as the sequences between
the regulatory elements in the promoter/operator region and the sequence
encoding the N- and C-terminal overlapping regions of the lacZ'
polypeptide. The peptide overlapping regions are duplicated in the M15
a-acceptor protein and are not critical for -galactosidase activity
(Figure 7). It is expected that most mutations in the latter segments
of the lacZ' DNA sequence would have minimal, if any, impact on a-
complementation and would probably go undetected, as appears to be the
case in this study.
b. Distribution of missense mutations
The hypothesis that mutations occur randomly with respect to
sequence context (but are correlated with site of drug modification)
gains additional support from the relative distribution of missense and
nonsense mutations. The level of missense mutations was closely linked
to the functional importance of the lacZ' polypeptide. Only three
mutations giving rise to amino acid substitutions were detected in the
29 residue N-terminal overlapping region (Figure 7, Table 12). This
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region has been shown to be relatively insensitive to changes in amino
acid composition (LeClerc et al., 1984; Bernges & Holler, 1992); and it
is not surprising that few missense mutations were detected. The C-
terminal region of the lacZ' peptide, like the N-terminal region, has a
structural overlap with the M15 a-acceptor protein and, similarly, would
be expected to be relatively insensitive to mutations because the
functional peptide chain can be supplied by either the a-donor or a-
acceptor (Welpy et al., 1981b). Although the C-terminal overlapping
region is composed of 54 amino acids, detectable mutations typically
have been confined to the portion of this region immediately adjacent to
lacZ' DNA sequence coding for the 31 amino acid residues deleted from
the M15 a-acceptor protein. In this study, no mutations were detected
further than 30 residues from the sequence representing the deletion in
the M15 protein. Somewhat surprisingly, missense mutations were
detected at a significantly higher rate than in the N-terminal
overlapping region, affecting 13 of these 30 residues. No mutations
were detected in the 24 amino acid residues comprising the C-terminal
end of the lacZ' peptide fragment. In contrast to the overlapping
regions, the DNA sequence coding for the portion of the lacZ'
polypeptide deleted from the M15 a-acceptor protein was extremely
sensitive to amino acid substitutions. Fifty one different missense
mutations were detected affecting 21 of the 31 amino acid residues
encoded by this DNA sequence (Figure 18, Table 12).
c. Distribution of nonsense mutations
Unlike the region specific distribution of missense mutations,
discussed above, approximately the same number of nonsense mutations
were detected in the lacZ' DNA sequences corresponding to the 29 amino
acid residue N-terminal overlapping region, the 31 amino acid region
deleted from the M15 a-acceptor protein, and the 30 residue C-terminal
208
overlapping region of the lacZ' polypeptide fragment. These three
similarly sized DNA segments, suffered six, six, and five nonsense
mutations, respectively. Each of the resulting truncated lacZ'
polypeptide fragments resulting from nonsense mutations in the C-
terminal overlapping region gave rise to enhanced -galactosidase
activity (as described previously and explained in Table 8 and Figure
20).
Every nonsense mutation, because of its disruption of polypeptide
synthesis, is expected to be detected in the lacZ' mutational assay. If
these mutations occurred randomly, an equal distribution would be
expected in the 3 regions of the lacZ' polypeptide; such a distribution
was experimentally observed. By contrast, missense mutations, by only
affecting the composition of a single amino acid, could be expected to
go undetected in nonessential regions of the lacZ' polypeptide.
Therefore, even if missense mutations were randomly distributed, more
would be expected to be observed in the M15 deletion region than in the
overlapping regions of the lacZ' sequence. Once again, this prediction
was verified experimentally.
d. Mutations are correlated to a position within a codon
Further analysis of the lacZ' peptide coding region indicates that
observed mutations also reflect the position of the codon. More
specifically, 36 mutations occurred at the first base of the codon, 47
at the second base, and only 15 at the third base (of these 15, only 10
gave rise to amino acid changes; see Table 12). The low number of
mutations seen at the third, or wobble, position was expected because of
the degeneracy of the genetic code. This result suggests mutations
could be occurring at roughly comparable rates at all three positions
but are detected more readily at the first and second positions.
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The region-specific distribution of missense mutations, the
constant distribution of nonsense mutations throughout the entire DNA
sequence coding lacZ' polypeptide fragment, and the observation that the
first and second positions of codons were subject to enhanced
mutagenicity compared with the wobble position implies that mutations
reflect the functional sensitivity of the regions of the M13mp18 lacZ'
DNA sequence. It is concluded, therefore, that cis-DDP and ACDP are not
sequence-dependent mutagens in this system. Taking into account the
adduct spectra (Figure 18), mutations occur at a similar rate throughout
the entire lacZ' DNA sequence of the M13mp18 genome. Although sequence
dependent mutation hotspots were not found for platinum(II) adducts in
the lacZ' mutation assay, such hotspots may exist for other DNA lesions
in this system. Furthermore, a study in a human cells indicates that
sequence dependent hotspots exist for platinum induced mutations in an
eukaryotic system (Bubley et al., 1991). More study is required to
determine what factors contribute to whether or not a DNA adduct will
experience sequence specific mutagenesis.
e. The lack of mutational hotspots reinforces the validity of the site
specific results
A major focus of the work described in this dissertation was the
comparison of the relative mutagenicities of the various cis-DDP DNA
adducts. The validity of comparing the relative mutation frequencies of
the cis-DDP G*G*, A*G*, and G*TG* adducts in different sequence
contexts1 is uncertain. Because the local sequence context could render
one adduct more mutable than another, the relative mutation frequencies,
1The site specific cis-DDP G*G*, A*G*, and G*TG* adducts were
incorporated into similar, but not identical sequences. Each adduct was
flanked by identical d(TpCpT)3 sequences, but were directly located in
different restriction endonuclease restriction sites, resulting in
variability in the nearest neighbor nucleotides.
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in theory, could reflect the local sequence context, and not the
inherent mutability, of each adduct. This argument is undermined by the
multiple lines of evidence, discussed above, that indicate that cis-DDP
is not a sequence dependent mutagen in the lacZ' DNA sequence of M13
genomes replicated in E. coli DL7 cells.
8. Technical Features of the Adduct Mapping Experiments
Adduct mapping experiments of the type used in this work and in
many other studies are based on the premise that the DNA lesion under
study is capable of efficiently blocking DNA synthesis. When primer
extension reactions are performed on DNA templates containing such
adducts, each lesion encountered by a polymerase will block further
replication, thereby generating a set of DNA fragments corresponding to
sites of platinum binding. DNA adducts formed by either cis-DDP (Comess
et al., 1992) or ACDP (Hartwig & Lippard, 1992) efficiently inhibit DNA
polymerases, allowing the location of these adducts to be determined in
the lacZ' region of the M13mp18 RF genome. Despite the success of these
experiments in locating the sites of platinum adducts and determining
their relative abundance, some technical difficulties were encountered
that are worthy of discussion.
Success in locating DNA binding sites of DNA adducts in adduct
mapping experiments depends on the ability of the polymerase to be
blocked only at sites of DNA adducts. Unfortunately, the lacZ' region
of ds M13mp18 DNA has numerous restriction sites that form stable
secondary structures that also serve as termination sites for
polymerases. Termination sites attributable to secondary structure were
of sufficient intensity to obscure termination sites arising from
platinum DNA adducts when the mapping experiments were performed with
Sequenase T7 DNA polymerase or T4 DNA polymerase at 370C. Addition of
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E. coli or T4 single-strand binding proteins ameliorated secondary
structure termination to a degree, but did not reduce the background
sufficiently to detect adduct stop sites unambiguously. Since high
temperatures were expected to lessen secondary structure effects, adduct
mapping was attempted by using thermal cycling methodology described
recently (Bubley et al., 1991; Murray et al., 1992). This technique
involves the linear amplification of modified DNA by performing primer
extension reactions at high temperatures repeatedly on the same template
population with a single primer. Adduct mapping by this method was
attempted with unmodified, cis-DDP and ACDP modified M13mp18 RF genomes
by performing high temperature linear amplification with Taq or
VentRTM(exo) DNA polymerases over 15 to 20 cycles. Despite expectations
of lessened secondary structure at high temperatures, the same
termination sites, similar to those seen with Sequenase or T4 DNA
polymerase at 370°C, were observed for platinated and unmodified DNA
samples despite varying the primer concentration from a 5 to 20 fold
excess and the extension temperature from 55 to 820C. When a single
cycle was carried out, however, only faint secondary structure
termination sites were observed for the unmodified DNA whereas strong
adduct induced termination sites were observed for both the cis-DDP and
ACDP modified samples.
The discrepancy in the results obtained in the single cycle and 20
cycle adduct mapping results can be explained by considering that the
two populations of DNA fragments produced in each amplification cycle.
One population of DNA fragments is from the secondary structure
termination events. A second population results from adduct pecific
termination events. In successive cycles, fragments produced in
previous cycles can reanneal to the M13mp18 template DNA, serve as
primers, and be further extended. A fragment terminated at the site of
a DNA lesion is unlikely to reanneal to another template with an adduct
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at the same site; further extension of this fragment results in the loss
of the adduct termination site information generated in the previous
cycle(s). Conversely, all template molecules have the same secondary
structure, allowing these termination sites to accumulate during each
cycle. The net effect of this process is that fragments generated by
secondary structure termination sites accumulate over 15 to 20 cycles,
obscuring the fragments produced at adduct termination sites in the last
cycle (and the few that have persisted from previous cycles). Although
this methodology may be adequate for vectors free of secondary structure
or other extraneous termination sites, caution is necessary when
performing adduct mapping experiments by thermal cycling to ensure that
the results accurately reflect the actual adduct distribution. We
therefore conclude that previous studies performed by using the thermal
cycling methodology should be viewed with caution.
213
Table 13. Assignment of mutations of unambiguous origin to specific
cis-DDP or ACDP DNA adductsa
cis-DDP ACDP
Adduct Number Percent Number Percent
A*G* 5 17 2 5
G*G* 4 14 8 18
G*NG* 16 55 19 43
other 4 14 15 34
Totalb 29 100 44 100
a. Only mutations of unabiguous origin are included on this table.
Many mutations could not be definitively assigned to a particular
adduct. For example, a d(GpApGpG) sequence could accomodate a G*NG*,
A*G*, or G*G* adduct, making it difficult to assign a mutation to a
specific adduct.
b. The total number of mutations included in this table is a small
subset of the entire number of drug induced mutations that were
determined (i.e. 29 of 115 cis-DDP and 44 of 142 ACDP induced
mutations). A similar analysis can be applied to the entire set of
mutants by making a number of assumptions; such an analysis is presented
in Table 14. It should be noted that the same conclusion that ACDP
induced about 3 fewer more mutations at A*G* sites than cis-DDP did is
reached from both tables despite the differences in data sets.
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Table 14. Assignment of all mutations, of both ambiguous and
unambiguous origin, to specific cis-DDP or ACDP DNA adducts
Adduct cis-DDP ACDP
Mutations of unambiguous origina
A*G* 5 2
G*G* 4 8
G*NG* 16 19
other 4 15
Mutations for which the site of origin is ambiguous
A*G* or G*G*b 16 23
(A*G*)c (4) (3)
(G*G*) (12) (20)
G*G* or G*NG* 32 27
(G*G*) (28) (20)
(G*NG*) (4) (7)
A*G* or G*NG* 18 10
(A*G*) (13) (3)
(G*NG*) (5) (7)
A*G*, G*G*, or G*NG* 13 20
(A*G*) (3) (2)
(G*G*) (9) (14)
(G*NG*) (1) (4)
Total of all mutationsd
A*G* 23 8
G*G* 49 50
G*NG* 24 30
other 4 12
a. Mutations assigned to these adducts are unambiguous (the data in this
category is the same as depicted in Table 13.
b. Mutations that could be a consequence of more than one type of
lesion because of the overlap of potential binding sites are assigned to
a particular adduct based on the preferential site of mutation induction
determined in site specific (Burnouf et al., 1990; Bradley et al., 1993)
or random (Brouwer et al., 1982) studies of cis-DDP mutagenicity. When
the lesion causing a mutation could not be determined by using the above
criteria, the mutation was assigned to a particular adduct based on the
binding preferences of the platinum compound; for example, if there were
three ACDP induced mutations resulting from either an A*G* or G*NG*
adduct, one was assigned to the A*G* adduct and two to the G*NG* adduct
based on the 1:2 ratio of A*G* to G*NG* adducts (8% vs 18%) (Hartwig &
Lippard, 1992).
c. The adducts to which mutations are assigned based on the above
criteria are enumerated in parentheses.
d. Total mutations attributable to each adduct are given as percentages
and are the sum of the unambiguous and assigned mutations.
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Figure 21. Speculative model to account for enhanced -galactosidase
activity of phenotypically "dark blue" plaques. a. The lacZ'
polypeptide encoded by M13mp18 is about 3 times larger than required for
a-complementation. The excess peptide comprises the N- and C- terminal
overlapping regions (Figure 7). These overlapping regions are
hypothesized to interfere with the a-complementation process by
sterically preventing optimal association of the -galactosidase
subunits. b. Mutants that have a truncated C-terminal overlapping
region may be able to associate more efficiently during the a-
complementation process, perhaps attaining a conformation similar to the
natural form of -galactosidase (c), resulting in greatly enhanced
enzymatic activity (Table 8).
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Figure 22. Comparison of the predicted and actual adduct distributions
with the distributions of mutations in the various segments of the lacZ'
DNA sequence of M13mp18 RF DNA. The predicted adduct distributions
(data were pooled for both drugs for this analysis as no significant
differences were discernable at the level of this analysis) were
determined based on the known binding preferences of cis-DDP (65% at GpG
sites, -25% at ApG sites, -10% at GpNpG sites and -1% at other sites)
and ACDP (54% at GpG sites, 8% at ApG sites and 10-18% at GpNpG sites)
to DNA. The region referred to as "other" represents the DNA sequence
between the various regulatory elements upstream of the lacZ'
polypeptide coding region.
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D. Application of Results to Drug Design and Evaluation
1. Relevance results from prokaryotes in the analysis of human drugs
The experiments performed for this thesis were done in a bacterial
system with viral DNA but nevertheless have relevance in the design of
drugs intended for use in humans. The mechanism(s) by which platinum
drugs kill tumor cells are only beginning to be elucidated at the
molecular level. Likewise, the induction of potentially tumorigenic
mutations by platinum DNA adducts in mammalian systems is not well
understood. Nevertheless, there are indications that prokaryotic and
eukaryotic DNA and RNA polymerases process platinum DNA adducts in a
similar manner (Villani et al., 1988; Corda et al., 1991; Comess et al.,
1992). Indeed, evidence is emerging that both prokaryotes and
eukaryotes have functional homologues to the E. coli umuDC genes which
are required for the mutagenic processing of replication blocking DNA
lesions (Woodgate & Sedgewick, 1992; and discussed in the Literature
Survey). Therefore a comparison of the DNA lesions formed by cis-DDP
and ACDP in a bacterial system, in which the processing of cis-DDP DNA
adducts has been extensively studied and is understood at a molecular
level, may yield clues to predict the eukaryotic response to DNA adducts
formed by these platinum compounds.
DNA adducts formed by cis-DDP and ACDP are both processed by the
SOS system of E. coli. It is reasonable, therefore, to expect that
their relative mutagenicities described in this dissertation will
reflect their relative mutagenicities in eukaryotic systems as well.
The assumption that platinum compounds will elicit similar genetic
respones in prokaryotes and eukaryotes has already been demonstrated for
cis-DDP. As discussed, the mutagenicity of cis-DDP has been studied and
shown to be similar in a variety of systems. It is anticipated that the
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mutability of ACDP determined in this work will also be reflected in
eukaryotes.
2. Implications of replication blockage, mutagenic and genotoxic
studies for platinum-based drug design
The work done in this investigation has implications for the
design of human anticancer drugs. A significant concern of platinum
based therapeutic regimens is the occurrence of secondary tumors,
possibly as a consequence of drug induced mutations. A major focus of
the present study was to address to determine the comparative
mutagenicities of DNA adducts formed by cis-DDP and ACDP. Two factors
indicate that these results have validity in predicting the mutagenic
potential of these compounds in humans. First, one aspect of this work,
the comparative genotoxicities of cis-DDP and ACDP in the bacteriophage
plaque-forming assay, is consistent with recent results in human
carcinoma cell lines (Kelland et al., 1992b). Second, the mutational
spectrum determined for cis-DDP encompasses mutations seen in a variety
of mutational assays, including eukaryotic systems, suggesting that the
spectrum for ACDP will also predict its mutagenic potential in a variety
of systems, including human cells. The immediate consequence of the
lower mutagenicity of ACDP compared with cis-DDP is that the parent
compound of ACDP, ACDDP, may be less carcinogenic than current platinum
drugs.
An analysis of the molecular characteristics shared by
chemotherapeutically effective platinum agents suggests additional
implications that this study may have for drug design. Platinum
compounds bind to DNA to form a variety of adducts, but only those that
form intrastrand crosslinks at d(ApG) or d(GpG) sites are believed to be
effective anticancer drugs. A*G* and G*G* adducts induce specific
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bending and unwinding of the DNA helix that is recognized by a set of
HMG box-containing proteins that may, at least in part, mediate the
cytotoxicity of cis-DDP in mammalian cells (Toney et al., 1989; Donahue
et al., 1990; Bruhn et al., 1992; Pil & Lippard, 1992; Brown et al.,
1993). This study further supports the role of structural distortion of
the DNA helix, rather than the nature of the ligands attached to the
platinum atom, as the critical element that mediates the molecular
effects of platinum drugs. More specifically, ACDP showed comparable
lethality to cis-DDP in the plaque-forming assay and elicited similar
types of mutations,, suggesting that these genetic events were a
consequence of similar DNA distortions induced by both drugs, not the
presence or absence of the cyclohexyl moiety of ACDP. Despite the
obvious importance of structural distortion of the DNA in mediating
cytotoxicity and genotoxicity, the ligands attached to the platinum atom
also have a crucial role in determining the biological effects of these
compounds. The influence of the ligands, however, is exerted before DNA
binding by influencing the composition of the adduct spectrum. The
cyclohexyl ring of ACDP, for example, directed a dramatic reduction of
the highly mutagenic A*G* adduct compared to the number of the
comparable A*G* adducts formed by cis-DDP, a compound lacking the
cyclohexyl group. At the same time ACDP formed almost an equivalent
level of G*G* adducts as cis-DDP, an important result considering that
G*G* adducts are high toxic (Bradley et al., 1993; this work) and are
refractory to repair in human cell extracts (Szymkowski et al., 1992)
and may be the primary agent of cytotoxicity for these platinum
compounds in eukaryotic cells. These findings demonstrate a molecular
rationale for lowering the mutagenicity, and therefore the potential
carcinogenicity, of platinum anticancer drugs.
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VI. SUGGESTIONS FOR FUTURE RESEARCH
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The objectives of the work outlined in this dissertation were
twofold. The first aspect dealt with the site specific determination of
the genotoxicities and mutagenicities of the cis-DDP G*G*, A*G*, and
G*TG* adducts in wild type E. coli cells. Several experiments will be
outlined below that both expand the range of platinum adducts worth
examining by use of site specific techniques and extend the genetic
contexts of the cells in which the adducts were replicated. The second
aspect of this work addressed the practical aspects of engineering new
platinum drugs. This dissertation describes the relative mutagenicities
of the various DNA adducts formed by platinum compounds and demonstrates
a strategy to design drugs with lower mutagenic potentials. Experiments
will be mentioned that continue to elucidate principles designed to
facillitate the design of future generations of platinum anticancer
drugs.
A. Site Specific Experiments
1. cis- and trans-DDP G*NG* Adducts
The site specific studies of the cis-DDP G*G* and A*G* adducts,
both previously (Burnouf et al., 1990; Bradley et al., 1993) and in this
work have yielded consistent, well defined results regarding the
genotoxicities and mutagenicities of these adducts. Results for the
cis-DDP 1,3 intrastrand crosslinks are less definitive, however. The
cis-DDP G*TG* adduct, based on its structural similarities to the cis-
DDP G*AG* and G*CG* adducts, is expected to be a good model for all
three lesions. Nevertheless, a disparity exists in the results obtained
for the various cis-DDP 1,3-intrastrand crosslinks. cis-DDP G*TG* was
shown to not be mutagenic in the site specific part of this work,
however the random mutagenesis section of this thesis as well as similar
studies (Brouwer et al., 1981; 1982) have implicated cis-G*NG* adducts
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as premutagenic lesions. The possibility exists that the mutations
observed in the lacZ' mutational assay did come from G*AG* or G*CG*
adducts. A site specific evaluation of these adducts is required to
determine if they, unlike cis-DDP, are mutagenic. If the cis-DDP G*AG*
and G*CG* adducts are mutagenic, a more detailed structural analysis of
the three 1,3 intrastrand crosslinks would be beneficial in order to
reveal the subtle differences between these adducts that predicate their
relative mutagenic potentials.
Additional information on the mutability of 1,3 intrastrand
crosslinks could be derived from a site specific evaluation of trans-DDP
G*AG*, G*CG*, and G*TG* adducts. The 1,3 intrastrand crosslinks formed
by trans-DDP have structural similarities to the comparable adducts
formed by cis-DDP adducts such as the destacking of the central
nucleotide. Conversely, structural dissimilarities also exist between
the 1,3 DNA adducts formed by cis- and trans-DDP. For example, the
degree of unwinding of the DNA duplex and the directed bend of the helix
by cis-DDP are different than the comparable properties shown by trans-
DDP. A comparison of the respective cis- and trans-DDP G*AG*, G*CG*,
and G*TG* adducts would define exactly which of these structural
characteristics are important in the genotoxic and mutagenic processing
of these adducts.
2. Interstrand Crosslinks
Interstrand crosslinks compose a minor fraction of the DNA binding
spectrum of cis-DDP and similar platinum(II) compounds. These adducts,
however, remain inadequately studied, and their genetic effects are
largely uncharacterized. Despite their relative inabundance,
interstrand crosslinks could play an important role in the cellular
response to cis-DDP if they are disproportionately genotoxic or
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mutagenic. The study of interstrand crosslinks is technically more
challenging than the study of the intrastrand crosslinks. An
interstrand crosslink, of course, would require placement in a ds
genome, and therefore could not be incorporated into the type of singly
modified genomes described in this work. As of yet, modified
methodology, describing the high yield, efficient synthesis, and
subsequent incorporation into genomes, of such adducts has not been
reported but, if developed, could be used to determine the genetic
effects of cis-DDP interstrand crosslinks.
3. Site Specific ACDP Adducts
The second part of this dissertation described the testing and
confirmation of the prediction that ACDP had a lower mutagenicity than
cis-DDP because it formed fewer of the highly mutagenic A*G* adducts.
This prediction was based on the assumption that the DNA adducts formed
by different platinum compound have similar biological consequences, for
example an ACDP G*G* adduct and a cis-DDP adduct are equally mutable.
This assumption is reasonable and furthermore, was suppported by the
experimental observation that ACDP was less mutagenic than cis-DDP in
the lacZ' mutational assay. Nevertheless, a site specific comparison of
cis-DDP and ACDP adducts would conclusively verify, or discount, this
assumption.
The structural isomerism exhibited by ACDP upon DNA binding is
another justification for a site specific study of ACDP DNA adducts.
The cyclohexyl ring of ACDP can be oriented in either the 5' or 3'
direction when bound to DNA (Figure 3); it would be interesting to
determine if these isomers elicited different biological responses. If
so, this result would indicate that the cyclohexyl ring, and possibly
other ligands of platinum(II) compounds, are important in mediating
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genotoxic and mutagenic effects. Alternatively, if the biological
effects experienced by both isomers are similar, it would indicate that
the bending and unwinding of the DNA duplex are more important in
effecting the cellular responses to platinum adducts. The latter
outcome would further support the assumption that the site specific
results obtained from cis-DDP DNA adducts are applicable to adducts
formed by other platinum compounds.
B. Genetic Experiments
The different genotoxicities and mutagenicities experienced by
cis-DDP DNA adducts (or not, in the case of cis-DDP G*TG*) in SOS
competent, compared to non-SOS induced, E. coli cells were, in large
part, attributed to UmuDC mediated translesion synthesis past these
adducts. As discussed, several lines of evidence indicate that umuDC
gene products do play a major role in this process but do not rule out
the intervention of other systems as well. For example, post
replication mismatch repair and recombinational repair could both have
been involved in the cellular processing of the singly modified ss
genomes containing the cis-DDP DNA adducts. E. coli mutants deficient
in recombinational repair and in the various aspects of mismatch repair
could be used to determine what, if any, role these systems have in
eliciting the genetic effects of cis-DDP DNA adducts. In any event, the
roLe of UmuDC could be more closely scrutinized by the use of various E.
coli umuD and umuC mutants.
The study of cis-DDP could be extended to mammalian systems by
using either site specifically or randomly modified shuttle vectors.
The processing of cis-DDP adducts is not as well characterized in
eukaryotic cells as it is in prokaryotes. Fortunately, however, many
mammalian cell lines with different repair deficiencies are becoming
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available, and should aid in the elucidation of the mechanisms of DNA
repair in eukaryotes. More specifically, the study of cis-DDP modified
DNA in these systems may yield clues that improve the therapeutic
efficacy of platinum compounds.
C. Drug Design
Research devoted to the design of novel platinum drugs has been
oriented toward reducing toxic side effects to the patient and
overcoming drug resistance that renders platinum therapy ineffective
against most tumors. This dissertation has demonstrated the feasibility
of another objective that deserves to be incorporated into the design of
new drugs.
Current platinum drugs are suspected human carcinogens; therefore
novel drugs are also potential carcinogens. Given the strong
mechanistic link between mutagenesis and carcinogenesis, it follows that
new drugs should be designed to have as low mutagenicity as possible to
reduce their potential carcinogenicity. This thesis has demonstrated
that one way to achieve this worthy goal is to direct against the
formation of highly mutagenic DNA adducts, such as A*G*. The underlying
principles governing the binding of platinum compounds to DNA are
beginning to be understood mechanistically (Bernges & Holler, 1992;
Bloemink et al., 1992; Green et al., 1992; Hartwig & Lippard, 1992)
making it possible to rationally design compounds that avoid the
formation of the highly mutagenic A*G* adduct. Accordingly, such
compounds should be designed and evaluated in mutational assays, either
comprehensively as done for cis-DDP and ACDP in this work, or perhaps,
at: least initially, in quick screening assays, ideally in eukaryotic
systems.
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